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ABSTRACT
Lung cancer continues to be the leading cause of cancer related mortality worldwide. Lung
cancer is not a single disease but an umbrella that encompasses two major classifications, nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC). SCLC represents about 1520% of all lung cancer cases and is almost exclusively diagnosed in smokers. Typically, patients
will respond very well to first line treatment, but face inevitable relapse. The fact that SCLC still
carries a grim 5-year survival rate of less than 5% highlights the lack of advancement in
treatment options to effectively improve patient response and survival. Capsaicinoids, in
particular Capsaicin (the spicy compound in chili peppers), have previously been reported to be
an advantageous adjunct treatment with traditional chemotherapeutic options in several cancer
types. One challenge to the use of capsaicin is the variety of side effects, such as gastrointestinal
pain, sweating and ulcers that are frequently reported with clinical administration. Synthetic nonpungent capsaicinoids, which show many of the same bioactive properties as capsaicin may,
however, be a promising alternative. The studies in this dissertation investigated the use of
capsaicin and several non-pungent analogs as chemotoxic or adjuvant therapy for SCLC.
Utilizing various in vitro and in vivo models we investigated the synergistic effects of capsaicin
and camptothecin. We provide new evidence that capsaicin synergistically sensitizes SCLC to
the effects of camptothecin, inducing a rise in intracellular calcium levels and activating the
calpain pathway to induce apoptosis. Analysis of the antineoplastic capacity of various
capsaicinoid analogs found arvanil to be the most potent capsaicinoid at inducing apoptosis in
SCLC cell lines. Similar to capsaicin, arvanil also induced apoptosis in SCLC cell lines by
raising intracellular calcium levels leading to increased calpain activity. The chemotoxic potency
and non-pungent character of arvanil supports the future investigation of the adjuvant use of

xvi

arvanil with camptothecin or other chemotherapeutic agents to find a combination therapy that
provides the same synergistic effects as capsaicin, while lacking the adverse side effect profile.
Taken together, these studies demonstrate that capsaicin and arvanil have the potential to
successfully treat SCLC in combination with conventional chemotherapeutics, as well as
possibly treating other cancer types.
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CHAPTER 1: INTRODUCTION
LUNG CANCER AND CAPSAICIN
Lung cancer
In 2018 cancer was the second leading cause of death worldwide. The incidence of
cancer in men has gone down slightly from 2008 to 2014, while the incidence of cancer in
women has stayed consistent since 1999 ("Cancer," 2018; Cronin et al., 2018). The mortality
associated with cancer, however, has decreased in both sexes (Cronin et al., 2018). Lung cancer
is the second most common form of cancer in both men and women, second to prostate and
breast cancer respectively. Lung cancer is the leading cause of cancer related death regardless of
sex. The mortality rate for lung cancer is about 53 per 100,000 for men; approximately 2.8 times
higher than for prostate cancer (Cronin et al., 2018). For women, the mortality rate is about 35
per 100,000, which is about 1.8 times higher than for breast cancer. Smoking has been identified
as a leading risk factor for lung cancer. It is estimated that tobacco use causes between 80 and
90% of all lung cancers (Latimer & Mott, 2015). While higher smoking rates among men likely
contribute to the apparent gender difference in lung cancer mortality rates, other risk factors for
lung cancer including first- or second-hand smoke, as well as environmental exposures, such as
asbestos and radon affect both genders equally.
Lung cancer is comprised of two major groups based on tissue histology, non-small cell
lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC, which accounts for
approximately 80-85% of lung cancers, is further divided into subtypes; lung adenocarcinoma
(LAC), squamous cell carcinoma (SCC), large cell carcinoma (LCC) and neuroendocrine
carcinoid tumors (Friedman et al., 2019). Classification of each subtype of NSCLC is based on
the tissue of origin of the tumor. LAC, which is the most common form of lung cancer,
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originates from the mucus-secreting glands in the lungs and is typically found in the outer
regions of the lung. SCC develops in the central air passages of a patient’s lungs and is the most
common type of NSCLC found in smokers. LCC is found anywhere in the lung and is
characterized by rapid growth and spread. Each subtype is then further characterized by defined
stages of progression (Latimer & Mott, 2015). NSCLC has a staging system ranging from stage 0
to stage 4, being the most critical. Treatment for NSCLC includes surgical removal for early
stage disease. Later stages of NSCLC are treated with chemotherapy, radiation, and targeted
immunotherapies. Generally speaking, NSCLC has a better survival rate, especially for those
diagnosed in early stages (Latimer & Mott, 2015). In recent years, new treatment options have
become available for NSCLC and have led to improved therapeutic outcomes and survival rates.
SCLC differs in a variety of ways from NSCLC. SCLC represents about 15-20% of all
lung cancer cases. While NSCLC can occur in patients who are never-smokers, SCLC is found
almost exclusively in smokers. SCLC arises from neuroendocrine cells of the lung (AlvaradoLuna & Morales-Espinosa, 2016). SCLC also generally spreads much quicker and more
aggressively than NSCLC. There are no subtypes of SCLC, it is simply divided into two stages;
limited where the cancer is confined to one lung or extensive when the cancer has spread to
secondary locations outside of the single hemithorax region. About two-thirds of those diagnosed
with SCLC are already in the extensive stage. Initial treatment consists of a platinum-based
chemotherapy (cisplatin or carboplatin) combined with etoposide (Pietanza, Byers, Minna, &
Rudin, 2015). Despite high initial response rates of 60-80%, SCLC commonly develops
chemotherapeutic resistance, which leaves patients with no viable treatment options (AlvaradoLuna & Morales-Espinosa, 2016; Bunn et al., 2016; Pietanza et al., 2015). Irinotecan is used as a
second-line agent in the treatment of refractory SCLC, however, it also induces frequent tumor
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resistance in patients within 14-26 weeks (S. L. Wood, Pernemalm, Crosbie, & Whetton, 2015).
Radiotherapy is utilized in patients whose cancer is confined to the chest, and prophylactic
cranial irradiation is also used in some cases due to the common feature of secondary brain
metastases in SCLC (Pietanza et al., 2015). When diagnosed in the limited stage, the 5-year
survival rate for SCLC is about 25%. Extensive stage SCLC has a 5-year survival rate of almost
zero (Latimer & Mott, 2015). Despite the urgent need for more effective therapy, treatment
options for SCLC have not seen any significant progress in decades (Pietanza et al., 2015; Qiu et
al., 2017). Current therapeutic modalities only extend patient survival by 4 to 8 months,
compared to non-treatment. SCLC has been described as a “graveyard” for drug development
research. Given the grim outlook for those diagnosed with SCLC, identifying effective, novel
adjuvant or secondary treatment options is imperative.
Capsaicin
Natural compounds have been associated with medicinal benefits for hundreds of years
(Basith, Cui, Hong, & Choi, 2016). Capsaicin is the main pungent ingredient isolated from chili
peppers. It has commonly been utilized for its analgesic activity, and ability to treat pain and
inflammation associated with a variety of diseases (Chapa-Oliver & Mejia-Teniente, 2016; X. F.
Huang, Xue, Jiang, & Zhu, 2013). Capsaicin is considered to be the prototypical agonist of the
transient receptor potential vanilloid (TRPV) 1 receptor (Elokely et al., 2016; Hazan, Kumar,
Matzner, & Priel, 2015). The TRPV receptors are a family of cation channels and are responsible
for our sense of temperature. The analgesic activity of capsaicin is believed to involve TRPV1
signaling (Jara-Oseguera, Simon, & Rosenbaum, 2008). Diabetic neuropathy, arthritis, and skin
disorders are just a few of the maladies in which capsaicin has been shown to have potent
therapeutic pain-relieving properties (Janusz et al., 1993; Luo, Peng, & Li, 2011; Rollyson et al.,
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2014). Capsaicin has also been shown to have potent antineoplastic activity against several
cancer types, including prostate, lung, and bladder (Basith et al., 2016; Chapa-Oliver & MejiaTeniente, 2016; Pramanik, Boreddy, & Srivastava, 2011; Srinivasan, 2016). There has also been
evidence that capsaicin has the ability to enhance the cytotoxic effect of FDA approved
chemotherapeutic agents, suggesting a potential role for capsaicin as an effective adjuvant
therapy to improve chemotherapeutic response- and survival-rates in SCLC (Dai et al., 2018;
Vendrely et al., 2017; N. Wang, Chaoran, Zhang, Zhai, & Lu, 2018; Zheng et al., 2016).
A potential hindrance to the use of capsaicin as a therapeutic agent, particularly following
oral administration, is the spectrum of unpleasant side effects associated with its pungent nature.
These side effects, which often include gastric pain, sweating, ulcers, and tearing of the eyes,
frequently cause patients to discontinue use, rendering any clinical trials useless or inconclusive
(Fuhrer, Vogelsang, & Hammer, 2011; Hammer, 2006; Hammer, Fuhrer, Pipal, & Matiasek,
2008; Hammer & Vogelsang, 2007). One potential way to circumvent this issue is to explore the
use of natural or synthetic derivatives of capsaicin (capsaicinoids), which may lack many of
these adverse effects. Various capsaicinoids have been extensively evaluated in order to
determine if they are able to maintain their anti-cancer activity, while minimizing their side
effect profile. Many of these compounds show much promise as viable treatment options for
lung cancer, as well as, other types of cancer (Luo et al., 2011; Macho et al., 2003).
Statement of hypothesis
There continues to be a lack of treatment options for those diagnosed with SCLC. The
studies in this dissertation focus on evaluating two major aspects of the use of capsaicin as an
adjuvant antineoplastic agent against SCLC to improve therapeutic response. The combinatorial
effects of capsaicin with a current chemotherapeutic agent is assessed first based on the
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hypothesis that capsaicin is able to sensitize human SCLC cells to the chemotherapeutic effects
of camptothecin. These studies evaluate the possible synergy that occurs when these agents are
used concurrently both in vitro and in vivo. Signaling mechanisms controlling these effects are
also examined. Second, a study of a panel of synthetic capsaicin analogs was conducted to
identify potentially potent anti-cancer agents with equal or greater antineoplastic activity than
capsaicin, but without the adverse side effect profile. The signaling pathways activated by these
analogs are also examined and compared to capsaicin. Taken together, these studies have laid the
foundation for the use of capsaicin and capsaicinoids as potential adjuvant SCLC treatment
options. The long-term implications of this study will hopefully lead a way to increasing the
dismal survival rate of SCLC patients, as well as potentially utilizing the knowledge found to
treat additional types of cancers.
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CHAPTER 2: CAPSAICINOIDS ENHANCE CHEMOSENSITIVITY TO
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ABSTRACT
Cytotoxic chemotherapy is the mainstay of cancer treatment. Conventional
chemotherapeutic agents do not distinguish between normal and neoplastic cells. This leads to
severe toxic side effects, which may necessitate the discontinuation of treatment in some
patients. Recent research has identified key molecular events in the initiation and progression of
cancer, promoting the design of targeted therapies to selectively kill tumor cells while sparing
normal cells. Although the side effects of such drugs are typically milder than conventional
chemotherapies, some off-target effects still occur. Another serious challenge with all
chemotherapies is the acquisition of chemoresistance upon prolonged exposure to the drug.
Therefore, identifying supplementary agents that sensitize tumor cells to chemotherapy-induced
apoptosis and help minimize drug resistance would be valuable for improving patient tolerance
and response to chemotherapy. The use of effective supplementary agents provides a two-fold
advantage in combination with standard chemotherapy. Firstly, by augmenting the activity of the
chemotherapeutic drug it can lower the dose needed to kill tumor cells and decrease the
incidence and severity of treatment-limiting side effects. Secondly, adjuvant therapies that lower
the effective dose of chemotherapy may delay/prevent the development of chemoresistance in
tumors. Capsaicinoids, a major class of phytochemical compounds isolated from chili peppers,
have been shown to improve the efficacy of several anti-cancer drugs in cell culture and animal
models. The present chapter summarizes the current knowledge about the chemosensistizing
activity of capsaicinoids with conventional and targeted chemotherapeutic drugs, highlighting
the potential use of capsaicinoids in novel combination therapies to improve the therapeutic
indices of conventional and targeted chemotherapeutic drugs in human cancers.
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INTRODUCTION
The term capsaicinoid refers to the class of compounds found in the capsicum family
(also known as chili peppers) (Luo et al., 2011). The most common capsaicinoid is capsaicin,
responsible for the spicy characteristics of chili peppers. Other natural capsaicinoids isolated
from peppers include: capsiate, found in Japanese CH-19 sweet peppers; capsiconiate, found in
Capsicum baccatum L.; and resiniferatoxin (RTX), isolated from the cactus plant Euphorbia
resinifera and the Nigerian plant Euphorbia poissonii (Friedman et al., 2018; Luo et al., 2011).
All capsaicinoids display potent analgesic activity (Basith et al., 2016; Chapa-Oliver & MejiaTeniente, 2016; Evangelista, 2015; Srinivasan, 2016). Capsaicin is a common ingredient in overthe-counter pain-relieving lotions and creams (Basith et al., 2016; Evangelista, 2015). The
analgesic activity of capsaicinoids is mediated by the transient receptor potential vanilloid
(TRPV) family of receptors, which is comprised of six members (TRPV1-TRPV6) (Satheesh et
al., 2016). All capsaicinoids are high affinity agonists of the TRPV1 receptor (Satheesh et al.,
2016). However, several lines of evidence have shown that capsaicinoids exert biological
functions that are independent of TRPV1 receptor activation or are mediated by other TRPV
receptors (Chapa-Oliver & Mejia-Teniente, 2016; Chow, Norng, Zhang, & Chai, 2007; Clark &
Lee, 2016; Diaz-Laviada & Rodriguez-Henche, 2014; Friedman et al., 2018; Lau et al., 2014;
Shintaku et al., 2012).
Early studies found that capsaicinoids exert potent chemopreventive activities in a variety
of human cancers including lung, prostate, pancreatic, cholangiocarcinoma and skin cancer.
Subsequent research demonstrated that capsaicinoids display anti-neoplastic activity in human
breast, lung, prostate, gastric, renal, oral and hepatocellular carcinoma (Basith et al., 2016;
Chapa-Oliver & Mejia-Teniente, 2016; Srinivasan, 2016). However, conflicting evidence also
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exists on the anti-cancer activity of capsaicin. The long-term dietary administration of chili
peppers was found to produce neoplastic changes in the liver and cecum (Hoch-Ligeti, 1951).
More recent published reports indicated that capsaicin promoted the survival and growth of
bladder, colon and skin cancers (Bode & Dong, 2011; Hoch-Ligeti, 1951; Toth & Gannett,
1992). Similarly, studies by Erin et al., (2004 and 2006) showed that the administration of
capsaicin at high doses (125 mg capsaicin/kg body weight) increased breast cancer
aggressiveness and promoted mammary tumor metastasis to the lung and heart (Erin, Boyer,
Bonneau, Clawson, & Welch, 2004; Erin, Zhao, Bylander, Chase, & Clawson, 2006). The aim of
their studies was to demonstrate that capsaicin caused denervation of sensory neurons in breast
carcinomas and such denervation promoted breast cancer metastasis (Erin et al., 2004; Erin et al.,
2006). Apart from these few published reports, the majority of studies have confirmed that low
doses of capsaicin suppress the growth and progression of human cancers (Figure 1).
While capsaicinoids are accepted to be high affinity agonists of the TRPV1 receptor, the
anti-tumor activity of capsaicinoids appears to be predominantly independent of TRPV1 and
involves multiple molecular mechanisms, including activation of cell death mechanisms,
inhibition of mitogenic pathways and blockage of mitochondrial respiration, tumor angiogenesis
and metastasis (reviewed in (Chapa-Oliver & Mejia-Teniente, 2016; Clark & Lee, 2016; DiazLaviada & Rodriguez-Henche, 2014; Friedman et al., 2018; Srinivasan, 2016). Recent studies
have indicated that capsaicinoids sensitize human cancer cells to the apoptotic effects of anticancer drugs and compounds. These include phytochemicals, synthetic small molecules,
conventional chemotherapeutic drugs, as well as novel targeted signal-transduction inhibitors.
The present chapter will focus on the chemosensitization activity of capsaicinoids on
classifications of FDA-approved chemotherapeutic drugs that are used clinically for the
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treatment of cancer patients. We will discuss the signaling pathways underlying the
combinatorial growth-inhibitory activity of capsaicinoids and the anti-cancer drugs in vitro and
in vivo. Finally, we will discuss the pharmacokinetic nature of the interaction between
capsaicinoids and the chemotherapeutic drug, whether it is additive, synergistic or antagonistic
and the statistical methods used to determine such drug-drug interactions.

Figure 1. A schematic of the various anticancer and chemopreventive mechanisms
triggered by capsaicin in experimental models of carcinogenesis and metastasis.
ANTIMETABOLITES
Antimetabolites are a class of chemotherapeutic drugs which function by mimicking
endogenous molecules required for cell cycle progression (Chabner et al., 2011; Peters, 2014).
By mimicking these compounds, antimetabolites become incorporated into the DNA or RNA of
replicating cells, causing errors in these essential molecules. These errors lead to DNA/RNA
damage and subsequently cause cell death (Longley, Harkin, & Johnston, 2003; Longley &
Johnston, 2005). Knowledge of nucleic acid biosynthetic processes allowed for the development
of various antimetabolites, the earliest with clinical utility included methotrexate, 6mercaptopurine (6-MP) and 5-fluorouracil (5-FU; Figure 2A) (Burchenal et al., 1953; Farber &
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Diamond, 1948; Heidelberger et al., 1957; Jolivet, Cowan, Curt, Clendeninn, & Chabner, 1983;
Rutman, Cantarow, & Paschkis, 1954). Two shortcomings of antimetabolites are the dosedependent toxicities and development of drug resistance (Longley & Johnston, 2005; N. Zhang,
Yin, Xu, & Chen, 2008). One strategy to overcome these problems is to combine these potent
antimetabolite drugs with a bioactive nutritional compound that will act synergistically to reduce
the IC50 of the main chemotherapeutic treatment (Cheung-Ong, Giaever, & Nislow, 2013). The
exploration of capsaicin in combination with antimetabolite agents is ongoing and has provided
some promising results.
Several studies have examined the combinatorial anti-cancer activity of 5-FU and
capsaicin. 5-FU is an integral part of the treatment regimens for a variety of malignancies,
including skin, colorectal, breast, pancreatic and gastrointestinal cancer (Sorrentino, Kim,
Foderaro, & Truesdell, 2012). Side effects of 5-FU include cardiotoxicity, along with diarrhea,
mucositis, myelosuppression, and thrombophlebitis (Sorrentino et al., 2012). Combination
chemotherapy involving 5-FU is the cornerstone of gastrointestinal tract adenocarcinomas
(Chabner et al., 2011; Tang, Feng, Liang, & Cai, 2016). The combination of capsaicin and 5-FU
was investigated in HGC-27 metastatic gastric cancer cells. Meral et al., (2014) showed that
various concentration combinations of 5-FU and capsaicin effectively inhibited the growth of
HGC-27 cells. Treatment with 50 µM 5-FU along with 12, 25, 50 or 100 µM capsaicin showed
significant decrease in cell viability when compared to the control at 24 and 48 hours (Meral et
al., 2014). The authors inferred that capsaicin at high concentrations ranging from 25-100 µM
sensitized HGC-27 human gastric cancer cells to 5-FU-induced apoptosis at 48 hours (Meral et
al., 2014). This group also assessed cell injury and found that 25-200 µM of capsaicin
significantly altered both LDH and glucose concentrations, while low concentrations of capsaicin
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(12 µM) caused no elevation of LDH or glucose levels. Such observations suggest that the
combinatorial growth-inhibitory activity of 5-FU and capsaicin is maximal at 50 µM 5-FU and
12 µM capsaicin, while capsaicin (as a single agent) displays marginal growth-inhibitory activity
and no cell injury (Meral et al., 2014). Although the authors claimed the interaction between 5FU and capsaicin to be synergistic, statistical analysis such as the Chou-Talalay isobologram
method to confirm synergy between the two drugs was not performed. The isobologram analysis
yields a factor known as combination index (CI). A value of CI lower than 1 indicates synergy
between the drugs. The CI equals 1 for additive drug interactions. If the CI is greater than 1, the
drugs are antagonistic to one another (Chou, 2008, 2010).
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Figure 2. Antimetabolites
(A) 5-Fluorouracil. (5-FU). (B) Gemcitabine. (C) Resiniferatoxin (RTX). (D) Signaling
mechanisms underlying 5-FU induced drug resistance in human CCA cells. The presence of
capsaicin along with 5-FU downregulates autophagy and triggers downstream apoptosis in
human CCA cells.
Human cholangiocarcinoma (CCA) is a diverse group of hepatobiliary cancers, which
originate from the biliary tree (Banales et al., 2016). CCAs are classified into intrahepatic
(iCCA), perihilar (pCCA) and distal (dCCA) based on their anatomical location. The main
challenge of CCA therapy is its aggressive clinical course and chemotherapy-refractory nature
(Banales et al., 2016). Hong et al., (2015) analyzed the cytotoxicity of 5-FU in a panel of human
CCA cell lines, namely QBC939, MZ-ChA-1 and SK-ChA-1 (Z. F. Hong et al., 2015). They
observed that all three cell lines were relatively resistant to 5-FU and displayed growthinhibitory activity only at high concentrations above 100 µM. A similar trend was observed with
25-150 µM capsaicin at 48 hours, with IC50 values approximately 100 µM in all the three cell
lines. Subsequently, the authors used varying concentrations of capsaicin (0, 20, 40 and 80 µM)
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in the presence or absence of varying 5-FU concentrations (0, 20, 40 and 80 µM). Capsaicin
sensitized QBC939 human CCA cells to 5-FU-induced apoptosis at multiple concentrations (Z.
F. Hong et al., 2015). Chou-Talalay isobologram analysis was performed and the interaction
between 5-FU and capsaicin was found to be synergistic at two combinations. The presence of
40 µM capsaicin along with 40 µM 5-FU lowered the IC50 of 5-FU from 126 µM to 35 µM
(CI=0.69). Maximal synergy was observed at 40 µM capsaicin and 80 µM 5-FU (CI=0.48) in
QBC939 cells. When stained for Annexin-V the combination of 40 µM capsaicin along with 40
µM 5-FU showed significantly more Annexin-V-positive cells than that of either drug alone (Z.
F. Hong et al., 2015). The authors also showed capsaicin sensitized human CCA to the apoptotic
activity of 5-FU in athymic mouse models, lending strength to the study. The CCA-tumorbearing mice were administered 60 mg 5-FU/kg body weight/day, 150 mg capsaicin/kg body
weight/day or a combination of both. Notably, 5-FU and capsaicin alone did not have any impact
on tumor volumes, while the combination of the two drugs showed significantly greater antitumor activity (Z. F. Hong et al., 2015). Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining on the CCA tumors (isolated from athymic mice) showed significant
increase in apoptosis in tumor-bearing mice treated with the combination of 5-FU and capsaicin
than either drug administered as single agents (Z. F. Hong et al., 2015).
Autophagy is one of the mechanisms underlying 5-FU-induced resistance of
gastrointestinal cancers (Tang et al., 2016). Established tumors need autophagy to protect
themselves from hostile microenvironments like hypoxia, nutrient deprivation and
chemotherapeutic drugs (Levy, Towers, & Thorburn, 2017; White, Mehnert, & Chan, 2015). The
synergistic anti-cancer activity of 5-FU and capsaicin was due to the ability of capsaicin to
inhibit 5-FU-induced autophagy of QBC939 human CCA cells. The treatment of QBC939 with
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40 µM 5-FU upregulated the expression of autophagic genes beclin1, atg5 and the autophagic
biomarker protein LC3II. The presence of 40 µM capsaicin along with 5-FU decreased the levels
of beclin1, atg and LC3II comparable to untreated cells. When the autophagy inhibitor 3methyladenine (3-MA) was incorporated along with 5-FU the above-mentioned 5-FU induced
alterations in beclin1, atg5 and LC3II were also reversed supporting that capsaicin has the ability
to chemosensitize resistant cells by inhibiting drug-induced autophagy (Z. F. Hong et al., 2015).
The mechanistic target of rapamycin (mTOR) pathway is a vital controller of cellular autophagy
(Levy et al., 2017; Paquette, El-Houjeiri, & Pause, 2018). mTOR is a serine/threonine protein
kinase comprised of two distinct complexes called mTORC1 and mTORC2. The mTORC1
complex plays a crucial role in autophagic signaling processes. The activity of mTORC1 is
regulated by a diverse range of upstream signals such as growth and stress signals, as well as
cytoplasmic kinases like extracellular related kinase (ERK), phosphoinositol-3 kinase (PI3K)/Akt and ribosomal S6 kinase (RSK) (Paquette et al., 2018). Hong et al., (2015) observed that
5-FU inhibited the phosphorylation of Akt (Ser473) and pS6 (Ser235/236), while the presence of
capsaicin reversed 5-FU inhibition of Akt and pS6 phosphorylation (Z. F. Hong et al., 2015).
These findings suggest that capsaicin reduces chemoresistance to 5-FU by inhibiting 5-FUinduced autophagy via the Akt/mTOR pathway to induce cell death (Figure 2D).
Gemcitabine (Figure 2B), an antimetabolite pyrimidine analog, is the first-line
monotherapy treatment for pancreatic cancer (Chabner et al., 2011). Vendrely et al., (2017)
examined the effect of three nutritional compounds namely, capsaicin, resveratrol and
sulforaphane on the anti-tumor activity of gemcitabine. Chou-Talalay isobologram analysis
showed that capsaicin and gemcitabine displayed synergistic growth-inhibitory activity in
CAPAN-2 human pancreatic cancer cells (CI=0.5). The maximal synergistic activity was
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observed with a combination of resveratrol, capsaicin and gemcitabine (CI=0.05). Subsequently,
the authors tested the anti-tumor activity of these drug combinations in athymic mice (Vendrely
et al., 2017). CAPAN-2 human pancreatic tumor-bearing mice were treated with 12.5 mg
gemcitabine/kg body weight three times a week by intraperitoneal (i.p.) injection. Resveratrol
(50 mg/kg body weight) and capsaicin (5 mg/kg body weight) were administered by oral gavage
three times a week. Treatment with resveratrol and capsaicin did not sensitize CAPAN-2 tumors
to the growth-suppressive effects of gemcitabine at the standard dose. Interestingly, when the
dose of gemcitabine was reduced by 33% (8.3 mg/kg body weight) such that gemcitabine alone
did not have any impact on the growth rate of CAPAN-2 tumors in athymic mice, the
combination with capsaicin and resveratrol to the low-dose gemcitabine fully restored the antitumor response to gemcitabine equivalent to the full dose (12.5 mg/kg body weight).
Histological examination of the tumors showed increased therapeutic response in tumors treated
with low dose gemcitabine (8.3 mg/kg body weight), resveratrol and capsaicin (hereafter referred
as C+R+GL) compared to the other treatment groups. The anti-tumor activity of C+R+GL
correlated with increased Bax/Bcl2 ratio and decreased phospho-Akt/total Akt ratio, suggesting
that C+R+GL selectively stimulated pro-apoptotic pathways with concomitant downregulation of
cell survival mechanisms (Vendrely et al., 2017).
Resiniferatoxin (RTX; Figure 2C) is a naturally occurring capsaicinoid isolated from the
latex of the cactus Euphorbia resinifera (Friedman et al., 2018). Hartel et al., (2006) examined
the combinatorial apoptotic activity of RTX with gemcitabine or 5-FU. Although RTX alone
displayed robust apoptotic activity in MIA-PaCa-2 and CAPAN-1 human pancreatic cancer cells,
it showed no synergistic interaction with gemcitabine or 5-FU in these studies. Statistical
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analysis could not confirm whether the interaction between RTX and 5-FU (or gemcitabine) was
additive (Hartel et al., 2006).
PLATINUM-BASED DRUGS
Platinum-based drugs are the standard of care for the treatment of many solid tumors and
are a vital component in both curative-intent and palliative combination chemotherapy regimens
(Chabner et al., 2011; Dasari & Tchounwou, 2014; Dilruba & Kalayda, 2016; Fuertes, Alonso, &
Perez, 2003). Combination chemotherapy involving cisplatin has been used for cancers of the
lung, ovaries, testes, solid head and neck tumors, and sarcomas (Chabner et al., 2011). The first
platinum drug, Cisplatin (cis-diamminedichloroplatinum; Figure 3A), was originally described in
the late 1900s for its ability to block binary fission in bacteria (Oun, Moussa, & Wheate, 2018).
Cisplatin directly binds to DNA causing intra/interstrand crosslinking, resulting in DNA damage
and subsequent apoptosis (Chabner et al., 2011).
A major drawback to the clinical use of platinum-based drugs is the dose-limiting
toxicities, including nephrotoxicity, which can lead to acute, and often-irreversible kidney injury
(Bai et al., 2017; Dilruba & Kalayda, 2016; Manohar & Leung, 2018; Oun et al., 2018).
Ototoxicity resulting in damage to cochlear hair follicles can cause permanent hearing loss
(Dilruba & Kalayda, 2016; Paken, Govender, Pillay, & Sewram, 2016). Neurotoxicity leading to
pain, weakness or numbness in the extremities, especially the hands and feet, has been reported
in patients. Hepatotoxicity, evidenced by increased hepatic enzymes in the serum, as well as
gastrointestinal and hematological toxicities have also been reported (Dasari & Tchounwou,
2014; Manohar & Leung, 2018; Oun et al., 2018). With toxicities affecting almost every major
organ system, one can see why dose monitoring and using the lowest dose possible is crucial
when treating patients. Newer drugs of this class, including carboplatin and oxaliplatin, have
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similar mechanisms of action as cisplatin, but display divergent dose-limiting toxicity profiles
(Kilari, Guancial, & Kim, 2016). The administration of carboplatin is associated with a lower
incidence of nausea and vomiting (relative to cisplatin) and a lower risk of nephrotoxicity and
ototoxicity in cancer patients (Dilruba & Kalayda, 2016; Oun et al., 2018). However, carboplatin
possesses greater myelosuppressive activity, while oxaliplatin has the lowest risk of
nephrotoxicity and ototoxicity amongst these drugs (Oun et al., 2018).

Figure 3. Platinum-based drugs
(A) Cisplatin. (B) LH4. (C) LH5. (D) Stomach cancer cells acquire resistance to cisplatin by
increased expression of Aurora Kinase A. When capsaicin is added it stimulates the degradation
of Aurora Kinase thereby circumventing cisplatin induced drug resistance.
The clinical efficacy of platinum-based drugs is further limited by the development of
chemoresistance in tumor cells (Dasari & Tchounwou, 2014; Kilari et al., 2016). Almost all solid
tumors eventually develop resistance to cisplatin and its related compounds. Cisplatin-based
combination therapy frequently gives excellent initial outcomes in lung cancer patients.
However, the disease often relapses, and the tumor is unresponsive to cisplatin (Fennell et al.,
2016). The mechanisms underlying cisplatin resistance involve multiple pathways, including the
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elevation and conjugation by glutathione (GSH) and binding by metallothionein, which minimize
DNA binding by active forms of platinum-based drugs (Amable, 2016; Galluzzi et al., 2012;
Oun et al., 2018). Cisplatin resistance also involves the activation of DNA repair pathways,
dysregulation of p53 tumor suppressor gene function, amplification of the pro-survival
Ras/MAPK signaling pathway, and upregulation of heat shock proteins (HSP) in neoplastic cells
(Amable, 2016; Dasari & Tchounwou, 2014). Furthermore, the acquisition of cisplatin resistance
also involves down-regulation of drug uptake transporters and upregulation of the functional
activity of efflux transporters (Kilari et al., 2016). Despite these limitations, cisplatin-based
chemotherapy remains a standard of care for a variety of solid tumors (Dasari & Tchounwou,
2014; Dilruba & Kalayda, 2016). All of these observations have led to intense research to
identify potential compounds that can improve the therapeutic index of cisplatin, improve its
toxicity profile, circumvent drug resistance mechanisms, and augment its cytotoxic activity in
human cancers.
Recent interest has increased focus on natural fruit- and vegetable-derived compounds as
potential agents to reduce cisplatin nephrotoxicity and increase tumor sensitivity to
chemotherapy (Athira, Madhana, & Lahkar, 2016; Gomez-Sierra, Eugenio-Perez, SanchezChinchillas, & Pedraza-Chaverri, 2018). Garufi et al., (2016) investigated the growth-inhibitory
activity of cisplatin with capsaicin in human p53 mutant glioblastoma cells (Garufi, Pistritto,
Cirone, & D'Orazi, 2016). The authors treated U373 human glioblastoma cells with 100 µM
capsaicin, 2.5 µg/ml cisplatin or a combination of both drugs over 24 hours and observed that the
combination of capsaicin with cisplatin induced 3-fold higher cell death relative to either
capsaicin or cisplatin alone (Garufi et al., 2016). This study further showed that capsaicin
reactivated p53 function in U373 cells, using over-expression and siRNA techniques to confirm
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the role of the p53 wild type pathway in the growth-suppressive activity of capsaicin as a single
agent. The authors speculated that capsaicin was sensitizing U373 cells to cisplatin by restoration
of p53 wild type activity. The caveat of the study is the authors did not present direct
experimental evidence (by p53-siRNA and p53 plasmid vectors) showing that the enhanced
growth-inhibitory activity of cisplatin-capsaicin combination was mediated by the p53 pathway.
Notably, cell authentication experiments have shown that the U373 MG cell line (available at
ATCC and EACC) is genetically distinct from the original U373 MG cell line isolated by
Westmark et al., (1973) in Uppsala, Sweden (Ishii et al., 1999; "Misidentified Cell Lines," ;
Westermark, 1973). The U373 MG cell line obtained by ATCC and EACC was identical to
another human glioma cell line U251. Subsequently, both ATCC and EACC have discontinued
this cell line from their inventory.
Huh et al., (2011) analyzed the cooperative growth-suppressive activity of cisplatin and
capsaicin in human stomach cancers using a panel of Korean human stomach cancer cell lines
(Huh, Lee, Lee, Park, & Han, 2011). They treated SNU01, SNU-5, SNU-16, SNU-601, SNU638 and SNU-668 cells with 100-500 µM cisplatin for 6 hours. The authors observed that out of
all the cell lines tested, SNU-668 was the most resistant to cisplatin, with an IC50 value of over
500 µM (Huh et al., 2011). Subsequently, they tested whether 300 µM capsaicin could sensitize
SNU-668 cells to cisplatin-induced apoptosis. The combination of 20 µM cisplatin with 300 µM
capsaicin decreased viability of SNU-668 cells approximately 7-fold, relative to vehicle treated
or cisplatin only treated cells (Huh et al., 2011). Similarly, the combination of cisplatin and
capsaicin displayed 5-fold lower cell viability, compared to SNU-668 cells treated with capsaicin
alone. By using flow cytometry, Huh and colleagues were able to detect that the treatment of
SNU-668 cells with both capsaicin (300 µM) and cisplatin (20 µM) resulted in an accumulation
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of G1- and S-phase cells. When SNU688 cells were treated with cisplatin alone, the cells
accumulated in the G2/M-phase, which led to the conclusion that capsaicin overcame cisplatininduced G2/M-phase arrest in SNU-688 cells and caused accumulation in G1 (Huh et al., 2011).
TUNEL apoptosis assays revealed the treatment with 20 µM cisplatin alone caused apoptosis in
5.16% of SNU-668 cells; 300 µM capsaicin alone in 22.4% of cells; however, the combination
induced apoptotic cell death in 48.5% of cells. Capsaicin induced a greater magnitude of
apoptosis in SNU-668 cells than cisplatin probably due to the fact that SNU-688 cells are
cisplatin resistant and therefore have a low apoptotic response towards cisplatin. The
combination of cisplatin and capsaicin abolished the expression of both Bcl-2 and Bcl-xL.
Notably, cisplatin increased the expression of Bcl-2 in SNU-688, implying that Bcl-2 may be one
of the mechanisms underlying a cisplatin resistant phenotype.
Several lines of evidence show that overexpression of Aurora kinase A (Aurora A) leads
to tumor-acquired chemotherapeutic resistance, especially to cisplatin (Figure 3D) (Kuang et al.,
2017; Polacchini et al., 2016; L. Wang, Arras, et al., 2017; Xu et al., 2014). Aurora A is a serine
threonine kinase involved in several steps of mitosis, such as centrosome function, spindle
assembly, chromosome alignment and mitotic entry (Borisa & Bhatt, 2017). Treatment with
cisplatin was found to increase the expression of Aurora A levels in SNU-668 cells (Huh et al.,
2011). In contrast, the treatment of SNU-668 with 300 µM capsaicin almost abolished the levels
of Aurora A in these cells. The combination of cisplatin and capsaicin also decreased expression
of Aurora A below detectable levels, effectively inhibiting cisplatin-induced increase in Aurora
A. Experiments using the proteasome inhibitor MG132 revealed that capsaicin suppressed the
levels of cellular Aurora A via enhancement of proteasomal degradation (Huh et al., 2011). Such
capsaicin-induced degradation of Aurora A prevents cisplatin-induced nuclear factor kappa-B
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(NF-kB) activation and survival of drug resistant SNU-338 cells (Huh et al., 2011). Therefore,
the inclusion of capsaicin along with cisplatin may provide a valuable strategy for overcoming
cisplatin resistance in human stomach cancer cells.
In other studies, the combination of cisplatin and capsaicin robustly decreased viability of
the human neuroblastoma cell line KELLY (Altun, Altun, Olgun, Pamukoglu, & Olgun, 2016).
KELLY cells were treated with 5 µM capsaicin, 100 µM cisplatin or a combination of both for
24 hours. WST-1 assays revealed that 5 µM capsaicin had no effect on the viability of these
cells. In contrast, 100 µM cisplatin decreased the viability by approximately 25% (Altun et al.,
2016). When 5 µM capsaicin was combined with 100 µM cisplatin there was a dramatic decrease
in the viability (by about 88%). Annexin-V/PI flow cytometric analysis revealed that the
combination of cisplatin and capsaicin induced greater magnitudes of apoptosis than either drug
alone (Altun et al., 2016).
Arzuman et al., (2014) synthesized a new platinum-based compound
tris(benzimidazole)chloroplatinum(II) or LH4 (Figure 3B) (Arzuman, Beale, Chan, Yu, & Huq,
2014) and examined the combinatorial activity of LH4 with various phytochemicals including
capsaicin. MTT assays were used to determine the concentration-dependent growth-inhibitory
activity of LH4 and cisplatin at concentrations ranging from 0.16-20 µM in three variants of the
human ovarian cancer cell line A2780 at 72 hours. These three variant ovarian cancer cell lines
are characterized by their chemoresistant behavior; A2780 is cisplatin sensitive, A2780cisR is
cisplatin resistant, and A2780ZDO473R is picoplatin resistant (Arzuman et al., 2014). They
observed that capsaicin decreased the viability of all three lines. Using Chou-Talalay
isobologram, the authors found that the combination of LH4 and capsaicin was synergistic in
A2780 (CI=0.41), A2780cisR (CI=0.48) and A2780ZDO473R (CI=0.36) cells (Arzuman et al., 2014).
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They also investigated whether pretreatment with one of the drugs could enhance synergistic
growth suppressive activity. They pretreated all the cell lines with LH4 and then treated the cells
with capsaicin four hours later and revealed that the interaction remained synergistic in A2780
(CI=0.52), A2780cisR (CI=0.94) and A2780ZDO473R (CI=0.84) cells. A noteworthy observation is
the magnitude of synergy between LH4 and capsaicin was maximal when both drugs were added
simultaneously to the cells, especially in the platinum resistant A2780 cell lines (Arzuman et al.,
2014). The combination of capsaicin and LH4 added together to A2780 and A2780cisR showed
higher intracellular platinum levels than when LH4 was given alone (Arzuman et al., 2014). The
combination of LH4 and capsaicin induced a higher magnitude of intracellular platinum
accumulation in A2780cisR cells (6-7 fold higher than LH4 alone) than in the parent line A2780
(1.5 fold higher than LH4 alone). The combination of LH4 and capsaicin showed no changes in
platinum-DNA binding in A2780 and A2780cisR cells, relative to LH4 alone. However, when the
cells were treated with capsaicin followed by LH4, there was a robust increase in the amounts of
platinum-DNA complexes in A2780cisR human ovarian cancer cells (Arzuman et al., 2014).
A monofunctional platinum (II) drug tris(quinoline)monocloroplatinum(II) or LH5
(Figure 3C) (Arzuman, Beale, Yu, & Huq, 2016) was used to evaluate the combinatorial growthsuppressive effects of LH5 and capsaicin in human ovarian cancer cells. The authors observed
that the greatest synergistic effect was seen when both LH5 and capsaicin were used to treat the
cells at the same time (the 0/0 protocol) in ED50, ED75, and ED90 measured across A2780,
A2780cisR and A2780ZDO473R human ovarian cancer cells (Arzuman et al., 2016). The picoplatin
resistant cell line A2780ZDO473R showed the lowest degree of synergy, when compared to the
other two cell lines. Although the authors have not performed any experiments to investigate the
signaling pathways underlying the synergistic growth-suppressive activity of LH5 and capsaicin,
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they speculate that capsaicin induces an accumulation of cells in the G1-phase, while LH5 causes
cell cycle arrest in the G2-phase and subsequent apoptosis via the p53 pathway. Experiments
involving pretreatment of LH5 followed by capsaicin 4 hours after (0/4 protocol) showed greater
magnitude of synergy and lower CI values than the 4/0 protocol, when LH5 was added 4 hours
after capsaicin (Arzuman et al., 2016). Further studies are warranted to investigate why the 0/0
protocol showed a greater synergistic interaction than pretreatment of either drug.
Wang et al., (2018) have demonstrated that capsaicin synergizes with cisplatin in
osteosarcoma cells xenografted in athymic mice (Y. Wang et al., 2018). As a proof of concept,
they investigated the combinatorial activity of cisplatin and capsaicin in three human
osteosarcoma cell lines, namely MG63, 143B and HOS. The combination of 50 µM or 100 μM
capsaicin synergistically decreased cell viability of MG63 and 143B cells across a range of
cisplatin concentrations (16.7-66.7 µM). Furthermore, the combination of 100 μM capsaicin with
16.7 μM cisplatin induced a greater magnitude of apoptosis and cell cycle arrest in all
osteosarcoma cell lines than either drug administered alone (Y. Wang et al., 2018). This
correlated with enhanced upregulation of pro-apoptotic and cell cycle inhibitory proteins (Bax,
caspase-3, cytochrome C, p21, p18) and decreased expression of pro-survival biomarkers (Bcl-2,
survivin, cyclins D1, D3 and cdk4/6). Most interestingly, the presence of 100 μM capsaicin
increased the anti-invasive activity of cisplatin (Y. Wang et al., 2018). The functional activity of
matrix metalloproteinase-2 and -9 (MMP2 and MMP9) was suppressed to a greater extent when
cisplatin and capsaicin were added together than either drug alone. Finally, the administration of
20 mg capsaicin/kg body weight along with 4 mg cisplatin/kg body weight decreased the growth
rate of 143B human osteosarcoma tumors xenotransplanted in athymic mice more potently than
either drug administered alone (Y. Wang et al., 2018).
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Innovative studies have also examined the ability of capsaicin to diminish/minimize the
toxic side effects of cisplatin. A major toxic side effect of cisplatin is ototoxicity, which is
defined as hearing loss due to temporary or permanent damage to the sensory hair cells in the
cochlea (Oun et al., 2018; Paken et al., 2016). Altun et al., (2016) evaluated the possibility of
using capsaicin as a preventative agent to combat cisplatin-induced ototoxicity in murine mouse
ear organ corti cells (HEI-OC1) (Altun et al., 2016). The treatment of HEI-OC1 with 100 µM
cisplatin caused a 64% decrease in cell viability. Notably, 5 µM capsaicin did not impact the
viability of HEI-OC1 cells (Altun et al., 2016). The combination of capsaicin and cisplatin
displayed lower growth-inhibitory activity (20% decrease in cell viability) relative to cisplatin
alone (64% decrease in cell viability). Gene expression analysis revealed that the combination of
cisplatin and capsaicin upregulated mitosis-related cell cycle genes (cdc25c), DNA repair genes
(Fancg, Mif, M1H3), and downregulated apoptosis-related genes (Bax, PARP2, p53), leading to
survival of HEI-OC1 ear organ corti cells (Altun et al., 2016).
Capsaicin was also shown to protect against cisplatin-induced nephrotoxicity. Shimeda et
al., (2005) induced nephrotoxicity in Sprague-Dawley rats by i.p. injection of 5 mg cisplatin/kg
body weight followed by 10 mg capsaicin/kg body weight by oral gavage twice daily for six days
after cisplatin administration. Cisplatin-induced nephrotoxicity was characterized by decreased
body weight, kidney GSH content and kidney superoxide dismutase (SOD) activity, an increase
in kidney weight, kidney malondialdehyde levels, serum creatinine, and blood urea nitrogen
(BUN) levels. The administration of capsaicin along with cisplatin significantly decreased BUN,
serum creatinine and kidney malondialdehyde levels and increased kidney SOD activity
(Shimeda et al., 2005). Capsaicin administration also reversed the cisplatin-induced increase in
kidney weight, returning kidneys to normal weights. The authors went on to show that capsaicin
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mitigated cisplatin-induced nephrotoxicity by scavenging free radicals (generated by cisplatintreatment) via the SOD pathway.
Jung et al., (2014) observed that capsaicin abrogated the growth-suppressive effect of
cisplatin in HK2 human renal proximal tubule cells. Subsequently, they extended their studies to
a mouse model to confirm the protective activity of capsaicin in cisplatin-induced nephrotoxicity
in C57BL6 mice (Jung et al., 2014; Shimeda et al., 2005). Their study design was slightly
different from Shimeda et al., (2005). The differences in cisplatin treatment regimens was most
likely due to rats being more susceptible to cisplatin nephrotoxicity than mice (Katayama et al.,
2011; Perse & Veceric-Haler, 2018). They orally administered three doses of capsaicin (2.5, 5, or
10 mg/kg body weight) once a day for five consecutive days. A single dose of cisplatin (5 mg/kg
body weight) was i.p. injected on day 4 (twelve hours after the administration of capsaicin). The
administration of cisplatin induced an 8-fold increase in serum creatinine and a 4-fold increase in
BUN. The pretreatment of mice with capsaicin at doses of 5 mg/kg body weight or 10 mg/kg
body weight decreased cisplatin-induced increases in serum creatinine and BUN levels. Notably,
the dose of 10 mg/kg body weight capsaicin, completely normalized creatinine and BUN levels
in mice. The kidneys of mice treated with cisplatin showed tubular and glomerular injury,
namely tubular dilation, vacuole formation and necrosis. However, when the mice were preadministered capsaicin, their kidney reverted to near normal morphology, with only slight
changes in glomeruli and minor edema of the tubular cells (Jung et al., 2014).
Several convergent studies have shown that oxidative stress, inflammation,
proinflammatory cytokines and toll-like receptors (TLR) contribute to tubular toxicity and
vascular injury observed in cisplatin-induced renal injury (Cenedeze et al., 2007; Kuhad,
Pilkhwal, Sharma, Tirkey, & Chopra, 2007; Mitazaki et al., 2013; Mukhopadhyay et al., 2010;
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Ramesh & Reeves, 2002; Sahu, Kuncha, Sindhura, & Sistla, 2013; Valles, Lorenzo, Bocanegra,
& Valles, 2014). Jung et al., (2014) observed that cisplatin induced the upregulation of
proinflammatory cytokines (TNF-α, IL-1b and IL-6), TLR4 and its ligands (high mobility group
box 1, HMB1; advanced glycation end product, AGE) in the kidney. The pre-administration of
capsaicin (10 mg/kg body weight) abolished cisplatin-induced alterations in TNF-α, IL-1b, IL-6,
TLR, HMB1 and AGE in the kidneys of mice (Jung et al., 2014). Next, the authors examined the
effect of capsaicin on cisplatin-induced production of ROS in the kidney. The enzymes of the
NADPH oxidase family (NOX) play a vital role in ROS generation by catalyzing the transfer of
electrons from NADPH to molecular oxygen (Bedard & Krause, 2007). Out of seven NOX
isoforms, NOX4 (and to a lesser extent NOX2) have been implicated in cisplatin-induced
nephrotoxicity (Sedeek, Nasrallah, Touyz, & Hebert, 2013). Jung et al., (2014) measured ROS
levels in HK2 immortalized human proximal tubule cells (Jung et al., 2014). They observed that
the treatment of HK2 cells with 30 μM cisplatin induced robust ROS activity. The presence of
100 μM capsaicin along with cisplatin decreased the ROS levels close to those observed in
vehicle-only treated cells. Similarly, the combination of 30 μM cisplatin and 100 μM capsaicin
reversed cisplatin-induced NOX4 expression in HK2 cells over 24 hours. IHC of kidney tissues
from cisplatin-treated mice showed vigorous expression of NOX-4 and 4-hydroxynonenal (4HNE; a biomarker for lipid peroxidation), which was reduced by pre-treatment with 10 mg
capsaicin/kg body weight (Jung et al., 2014). These findings suggest that capsaicin reduced
oxidative stress and ROS formation mediated by cisplatin treatment.
A previous study showed that increased expression of heme oxygenase-1 (HO-1) via
overexpression or pharmacological induction confers protection from cisplatin-induced
ototoxicity in both cell culture and in vivo mouse models (So et al., 2008). Traditionally, the
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principal function of HO-1 is to catalyze the breakdown of heme into biliverdin, carbon
monoxide and iron (Loboda, Damulewicz, Pyza, Jozkowicz, & Dulak, 2016). Several congruent
studies have indicated that the induction of HO-1 functions as a defense mechanism, shielding
cells from the damaging effects of oxidative stress (Bolisetty, Zarjou, & Agarwal, 2017). The
disruption of HO-1 activity in rats or deletion of the HO-1 gene in mice results in exacerbation of
cisplatin-induced renal injury, emphasizing the protective role of this enzyme in cisplatininduced nephrotoxicity (Bolisetty et al., 2017). Jung et al., (2014) found that HO-1 was
substantially decreased in the kidneys of cisplatin-treated mice. When the mice were pretreated
with 2.5, 5.0 and 10 mg capsaicin/kg body weight (before the administration of cisplatin), there
was an induction of HO-1 protein levels in kidney homogenates (Jung et al., 2014). The
protective effect of capsaicin on the growth-suppressive activity of cisplatin (in HK2 cells) was
reversed in the presence of pharmacological inhibitors of the HO-1 pathway (namely ZnPP 1X)
or HO-1 siRNA. Notably, the treatment of HK2 cells with 100 μM capsaicin caused robust
upregulation of HO-1 levels starting at 6 to 24 hours. Taken together, the data of Jung et al.,
(2014) indicate a pivotal role of the HO-1 pathway in the cytoprotective activity of capsaicin
against cisplatin-induced nephrotoxicity (Jung et al., 2014). We believe that the protective
activity of capsaicin against cisplatin-induced nephrotoxicity is extremely clinically relevant.
Such observations may facilitate the design and application of novel capsaicin-cisplatin based
combination therapies that will improve the therapeutic index of cisplatin in cancer patients.
Furthermore, the synergistic cytotoxic activity of cisplatin and capsaicin suggests that lower
doses of cisplatin (along with capsaicin) may be required to achieve optimal therapeutic response
in patients. The ability to lower the dose of cisplatin administered to a patient, while maintaining
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or increasing potential cancer cell kill would be predicted to minimize the adverse effects and
toxicity profile of cisplatin, while improving health outcomes for cancer patients.
ANTHRACYCLINES
Anthracyclines are a class of chemotherapeutic drugs originally isolated from
Streptomyces peucetius bacteria (Arcamone et al., 1969; Chabner et al., 2011). Daunorubicin
(Figure 4A) is considered to be the prototypical anthracycline, being the first anthracycline
shown to have anti-cancer properties (Davis & Davis, 1979). A derivative of daunorubicin,
doxorubicin (Figure 4B), was the second anthracycline to be discovered and evaluated for its
antineoplastic activity (Baboota et al., 2014; Tacar, Sriamornsak, & Dass, 2013). Additional
derivatives and metabolites have since joined the anthracycline chemotherapy family, including
epirubucin, idarubicin and pirarubicin (Cersosimo & Hong, 1986; Hollingshead & Faulds, 1991;
Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). Anthracycline drugs have the ability to
treat a variety of cancers, including both solid tumors and hematological malignancies (Chabner
et al., 2011). Doxorubicin intercalates into the DNA and RNA and inhibits topoisomerase II
function, preventing DNA and RNA replication, and inducing cell death in both normal and
cancerous cells (Baboota et al., 2014; Tacar et al., 2013) .

Figure 4. Anthracyclines
(A) Daunorubicin. (B). Doxorubicin. (C). Pirarubicin.
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Similar to other nonspecific chemotherapeutic agents, doxorubicin has a variety of toxic
side effects associated with its use. Apart from nausea, gastrointestinal problems and
neurological disturbances, doxorubicin has been documented to cause toxicity in the liver, brain
and kidneys (Tacar et al., 2013). The dose-limiting toxicity of doxorubicin is acute and chronic
cardiotoxicity, characterized by myofibrillar loss, cytoplasmic vacuolization, apoptosis,
interstitial edema, and fibroplasia (Chatterjee, Zhang, Honbo, & Karliner, 2010; Y. Shi, Moon,
Dawood, McManus, & Liu, 2011). Due to the highly documented cardiotoxicity associated with
doxorubicin, different types of clinical restrictions have been put in place for use in patients.
Different types of drugs, such as beta-blockers or angiotensin II inhibitors, are now administered
with doxorubicin in hopes of lowering the chance of the patient experiencing cardiotoxicity
(Chatterjee et al., 2010). Due to the variety and severity of toxicities, the ability to use a lower
dose of doxorubicin while maintaining its antineoplastic qualities would be a valuable
therapeutic strategy to improve both the short-term and long-term safety of patients.
The second generation doxorubicin analog, pirarubicin (also called THP-Adriamycin or
THP-doxorubicin; Figure 4C), displays a wide spectrum of anti-tumor activity amongst solid
tumors of the urinogenital system like bladder cancer (Arakawa et al., 2011; Crijnen & De
Reijke, 2018). Almost 80% of all bladder cancers are superficial and do not invade surrounding
muscles (Crijnen & De Reijke, 2018). Intravesical chemotherapy involving pirarubicin is the
standard of care for non-invasive bladder cancer after transurethral resection of bladder tumors
(TURBT) (Arakawa et al., 2011; Crijnen & De Reijke, 2018). A drawback of this therapeutic
regimen is that the five-year recurrence rate amongst bladder cancer patients is relatively high
(greater than 30%) (Crijnen & De Reijke, 2018). The capsaicin-receptor TRPV1 functions as a
tumor suppressor in bladder cancer (Mistretta et al., 2014; Santoni et al., 2012). Capsaicin has
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been shown to induce robust apoptosis and prevent metastasis of human bladder cancers via a
TRPV1-dependent mechanism (Amantini et al., 2009; Santoni et al., 2012). Based on these
findings, Zheng et al., (2016) investigated the anti-tumor activity of the combination of the
TRPV1 agonist capsaicin in addition to the current standard of care, pirarubicin, in human
bladder cancer cell lines (Zheng et al., 2016).
The authors chose two human bladder transitional cell carcinoma cell lines (5637 and
T24) for their studies. The 5637 cells expressed robust amounts of TRPV1 (at both mRNA and
protein levels), whereas T24 cells are null for TRPV1 (Zheng et al., 2016). Their studies revealed
that capsaicin displayed growth-suppressive activity only in TPRV1 expressing 5637 cells (IC50
=150 µM) but not in the TRPV1 null T24 cells. Subsequently, they treated 5637 cells with a
range of concentrations of pirarubicin (0-800 µM) in the presence or absence of 150 µM
capsaicin for 12 hours and measured cell viability. They observed that the presence of capsaicin
along with pirarubicin decreased the IC50 value of pirarubicin from 566 nM to 335 nM (Zheng et
al., 2016).
The predominant mechanism by which anthracycline compounds like pirarubicin
suppress cell growth is intercalation between DNA strands, causing S- or G2/M-phase cell cycle
arrest (Figure 5). Flow cytometry analysis revealed that the treatment of 5637 cells with 150 µM
capsaicin caused G0/G1 arrest at 12 hours. When pirarubicin was combined with capsaicin, there
was an elevation in the number of cells arrested in G2/M- and S-phase and a concomitant
decrease in the fraction of cells in G0/G1-phase (Zheng et al., 2016). The presence of TRPV1
antagonist capsazepine partially reversed the observed elevation of G2/M- and S-phase
populations observed in the pirarubicin plus capsaicin treated 5637 cells. These findings suggest
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that the TRPV1 pathway is at least in part responsible for capsaicin-induced sensitization of 5637
cells to the anti-proliferative activity of pirarubicin.

Figure 5. A simplified schematic of the signaling mechanisms of the synergistic anticancer
activity of doxorubicin and capsaicin in human cancer cells.
One of the important proteins involved in the entry of cells into S-phase is proliferating
cell nuclear antigen (PCNA), which becomes elevated as cells progress from G1- to S-phase.
Translocation of PCNA from the cytosol to the nucleus then facilitates cell cycle progression
from S- to G2/M-phase (Zheng et al., 2016). The combination of capsaicin and pirarubicin did
not induce significant elevation of PCNA relative to each drug alone; however, it potently
blocked nuclear translocation of PCNA, thereby arresting the 5637 cells in S- and G2/M-phase
(Zheng et al., 2016).
A major factor that limits the efficacy of chemotherapy is the acquisition of multi-drug
resistance in tumors during prolonged treatment. The molecular basis of such drug resistance
(intrinsic or acquired) is multifactorial; however, drug efflux and drug metabolism mechanisms
32

play a major role in this process (Chabner et al., 2011). Drug efflux is mediated by membranebound transporters that pump many of these anticancer drugs back out of the cell. This process
decreases the bioavailability of the anti-cancer drug, and ablates their ability to kill cancer cells
(Miller, 2003). Out of the seven subfamilies of ATP-binding cassette (ABC) transporters, the
most extensively studied efflux transporter protein is the P-glycoprotein (P-gp), whose functional
activity is elevated in a diverse array of human cancers (Z. Chen et al., 2016). Li et al., (2018)
investigated the effect of capsaicin on the functional activity of P-gp in doxorubicin-resistant
Caco-2 human colon carcinoma cells (H. Li, Krstin, Wang, & Wink, 2018). The efflux of the
fluorescent dye Rho123 was used as a measure of cellular P-gp activity. The authors observed
that the treatment of Caco-2 cells with capsaicin resulted in a concentration-dependent cellular
retention of Rho123, implying that capsaicin blocked the activity of P-gp in Caco-2 cells.
Furthermore, they confirmed the inhibitory effect of capsaicin on P-gp activity in a second
resistant human leukemic cell line CEM/ADR5000 and obtained similar results (H. Li et al.,
2018). This is in contrast with the observations of Sadzuka et al., (2008) who did not see any
effect of capsaicin on doxorubicin influx or efflux in Ehlrich ascitis carcinoma (EAC) cells and
M5076 ovarian carcinoma cells (Sadzuka, Hatakeyama, Daimon, & Sonobe, 2008). Such
differences may be explained by alterations in experimental design and in the nature of the
cancer cell lines, such as differences in expression or function of P-gp, used in the two
experiments. Sadzuka et al., (2008) measured total doxorubicin influx and efflux in neoplastic
cells, whereas Li et al., (2018) specifically measured P-gp activity in human colon cancer and
leukemia cell lines (H. Li et al., 2018; Sadzuka et al., 2008). There were also species differences
of the cell lines used in the two research papers. The experiments by Sadzuka et al., (2008) were
performed in M5076 murine ovarian sarcoma and mouse ascites carcinomas whereas the studies
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by Li et al., (2018) used doxorubicin resistant human colon cancer and leukemia cell lines for
their investigations (H. Li et al., 2018; Sadzuka et al., 2008). Whereas capsaicin blocks human Pgp activity, it may have minimal impact on the functional activity of the abovementioned mouse
ABC transporters. If capsaicin does not regulate the functional activity of murine ABC
transporters, then doxorubicin transport in M5076 and EAC cells may not be sensitive to
capsaicin.
Subsequently, Li et al., (2018) explored the synergistic growth-inhibitory activity of
doxorubicin and capsaicin in Caco-2 cells (H. Li et al., 2018). They combined the serial dilution
doses of doxorubicin with fixed, non-toxic doses of capsaicin (IC10, IC20 or IC30) and determined
the effect of these combinations on the viability of Caco-2 cells (H. Li et al., 2018). All three
combinations of doxorubicin and capsaicin displayed synergistic growth inhibitory activity
(CI<1) and significantly reduced the IC50 value of doxorubicin in Caco-2 cells. The magnitude of
the CIs was very similar across all three groups. They repeated the experiments in
CEM/ADR5000 cells and obtained analogous results. The magnitude of CI was higher
(indicating less synergy) in CEM/ADR5000 cells relative to Caco-2 cells (H. Li et al., 2018).
Studies in mouse models have indicated that capsaicin minimizes the acute cardiotoxic
side effects of doxorubicin administration. Patel & Mehta, (2017) administered capsaicin at two
doses (1 mg/kg body weight and 2 mg/kg body weight) to mice via intraperitoneal injections
daily for ten days (Patel & Mehta, 2017). On day eight they injected the mice with 20 mg
doxorubicin/kg body weight via i.p. Mice that were administered vehicle only or doxorubicin
alone served as one of the control groups of the study. The authors observed that the acute
administration of doxorubicin caused a reduction in the body and heart weights of the mice.
However, doxorubicin-induced decreases of body weight and heart weights were abrogated when
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the mice were pretreated with 1 mg capsaicin/kg body weight before doxorubicin administration
(Patel & Mehta, 2017). The authors observed that the acute administration of doxorubicin caused
cardiotoxicity as evidenced by elevation in creatinine kinase-muscle/brain (CK-MB), LDH and
tissue malonaldehyde (MDA) levels. Similarly, the amounts of antioxidant enzymes like SOD,
myocardial catalase (CAT) and GSH were reduced. The pre-administration of 1 mg capsaicin/kg
body weight significantly abrogated doxorubicin-induced elevation of CK-MB, LDH and MDA
levels (Patel & Mehta, 2017). Furthermore, capsaicin elevated the levels of SOD, CAT and GSH
(which were lowered by the administration of doxorubicin). Histological analysis of heart
sections from doxorubicin treated mice showed inflammation and cardiac necrosis as evidenced
by vascular dilatation and loss of myofibrils network. In contrast, the heart sections of mice
pretreated with 1 mg capsaicin/kg body weight before administration of doxorubicin were
morphologically and histologically normal and comparable to vehicle-treated mice (Patel &
Mehta, 2017).
CAMPTOTHECIN ANALOGS
Camptothecins are natural topoisomerase-1 inhibitors isolated from the Chinese tree
Camptotheca accuminata (Chabner et al., 2011). Camptothecin (Figure 6A) and its related
analogs form a tertiary complex with single-stranded DNA (during S-phase of the cell cycle) and
topoisomerase 1, leading to DNA damage and cell death (Chabner et al., 2011). Two synthetic
analogs of camptothecin, topotecan and irinotecan (Figure 6B and 6C), are used clinically for the
treatment of ovarian, SCLC and colorectal cancer (Chabner et al., 2011). Irinotecan is a prodrug,
which is cleaved by carboxylesterases in the tumor, liver or red blood cells to generate the active
drug SN-38, which displays 10-100 fold more potent anti-tumor activity than irinotecan
(Chabner et al., 2011).
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The dose-limiting toxicities of topotecan are mainly hematological in nature, causing
neutropenia, with or without thrombocytopenia in cells (Chabner et al., 2011). The dose-limiting
toxicity of irinotecan is severe diarrhea (experienced by about 35% of patients) with or without
neutropenia. Another challenge with irinotecan is poor bioavailability in the plasma and tissues
(Chabner et al., 2011). Although the active metabolite SN-38 can be measured in the plasma
(shortly after intravenous infusion), the amount of SN-38 is only 4% of the amount of irinotecan
injected, suggesting that only a small portion of the pro-drug is converted to the active form of
the drug. In contrast, intravenous topotecan is detected at about 25-35% in the plasma (Chabner
et al., 2011).
Studies in our laboratory focus on the cell biology of small cell lung cancer (SCLC).
SCLC is characterized by rapid doubling time, aggressive clinical course and a dismal survival
rate (Gazdar, Bunn, & Minna, 2017; Ujhazy & Lindwasser, 2018). Cisplatin-based
chemotherapy is the cornerstone for SCLC therapy. Initially, SCLC patients respond very well to
therapy, with 80-100% of patients showing remission; however, the tumors typically relapse
within a year and frequently do not respond to chemotherapy or radiation (Ujhazy & Lindwasser,
2018). A significant drawback with the cisplatin-etoposide regimen is its toxicity, which
frequently renders SCLC patients more susceptible to adverse symptoms upon subsequent
treatments. Patients with recurrent SCLC have very limited treatment options. The standard
second-line chemotherapy for recurrent SCLC, camptothecin (topotecan, irinotecan), has an
objective response rate of approximately 3% and little or no survival benefit (Ardizzoni, 2004;
Horita et al., 2015). A subset of patients also presents with refractory platinum-resistant SCLC,
which does not respond to cisplatin-based combination therapy from the beginning (Lara et al.,
2015).
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Figure 6. Camptothecin analogs
(A) Camptothecin. (B) Topotecan. (C) Irinotecan. (D) SN-38.
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Figure 7. Combinatorial effects of capsaicin and camptothecin in small cell lung cancer
(A) Caspase-3 activity of DMS53 human small cell lung cancer cells when treated with various
concentrations of capsaicin (CAP). Data points denoted with a * are statistically significant
relative to control (p£0.05). (B) Caspase-3 activity of DMS53 human small cell lung cancer cells
when treated with various concentrations of camptothecin (campto) alone or in combination with
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10 𝜇M capsaicin. Data points denoted with a * are statistically significant relative to campto
alone (p£0.05). (C) Tumor volumes of DMS53 xenograft mice treated with vehicle, 10 mg
capsaicin/kg food, 0.5 camptothecin/kg body weight (administered twice weekly), capsaicin in
combination with camptothecin as above-mentioned doses. Doses denoted with * are statistically
significant relative to the vehicle, capsaicin alone and camptothecin alone (p£0.05).
Studies in our laboratory have explored the ability of capsaicin to increase the antineoplastic activity of camptothecin in human SCLC cell lines. Using a panel of three human
SCLC cell lines, namely DMS 114, NCI-H69 and NCI-H82, we performed apoptosis assays
using multiple concentrations of capsaicin (0-100 µM) and observed that 10 µM was the highest
concentration of capsaicin that did not trigger cellular apoptosis (Friedman et al., 2017). These
assays were repeated in DMS 53 human SCLC cells with similar results (Figure 7A). Apoptosis
was then evaluated following treatment with a concentration range of camptothecin (10 nM-100
µM) in the presence or absence of 10 µM capsaicin (Figure 7B). Isobologram analysis
demonstrated that capsaicin and camptothecin synergistically induce apoptosis (CI<1) in DMS
53 SCLC cells (Table 1). Signal transduction studies revealed that the combinatorial apoptotic
activity of capsaicin and camptothecin was mediated by increased intracellular calcium and
subsequent activation of the calpain family of calcium-sensitive proteases (Friedman et al.,
2017). This chemosensitizing mechanism of capsaicin on camptothecin-induced apoptosis was
further verified in H69 chicken chorioallantoic membrane (CAM) tumor models (Friedman et al.,
2017). Using a DMS 53 human SCLC xenograft mouse model, we found that the dietary
administration of capsaicin (10 mg/kg food in AIN-76A diet) along with 0.5 mg/kg
camptothecin (i.p. injection, twice/week) displayed greater anti-tumor activity relative to either
drug administered as a single agent (Figure 7C). Future studies in our laboratory aim to examine
the combinatorial activity of capsaicin with irinotecan, given its clinical use in the treatment of
lung cancer patients.
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Concentration of
Camptothecin
100 nM
10 µM
25 µM
50 µM
100 µM

Concentration of
Capsaicin
10 µM
10 µM
10 µM
10 µM
10 µM

Combination Index
(CI)
0.031
0.03
0.045
0.055
0.066

Table 1. Combination index of the growth inhibitory activity of camptothecin along with
capsaicin in DMS53 human small cell lung cancer cells
CI<1: Synergy CI=1: Additive CI>1: Antagonistic
The pharmacokinetics of irinotecan is complex and involves several transporters and drug
metabolizing enzymes (Mathijssen et al., 2001). Briefly, carboxylesterase enzymes transform
irinotecan to SN-38 (Figure 6D), which is subsequently converted by UGT1A1 to form SN-38G
(SN-38 Glucuronide), or by CYP3A4 to form APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1piperidino]-carbonyloxycamptothecin (Mathijssen et al., 2001). The OAT1B1 transporter
predominantly mediates the hepatic uptake of SN-38 (Iusuf et al., 2014). Several studies have
indicated that capsaicin regulates bioavailability of drugs metabolized by CYP3A4 and inhibits
the activity of OAT1B1 (F. Chen, Zhai, Zhu, & Lu, 2015; Duan et al., 2013; X. J. Zhai, Shi,
Chen, & Lu, 2013).
Wang et al., (2018) explored if the presence of capsaicin could increase the
bioavailability of irinotecan and SN-38 in both cell culture and rat models (N. Wang et al.,
2018). They pretreated Sprague-Dawley rats daily with 3 mg capsaicin/kg body weight (by oral
gavage) for seven days. On the seventh day, 20 mg irinotecan/kg body weight was injected
intravenously, 30 minutes after capsaicin administration. They observed that the plasma
concentration of active SN-38 was about 1.5-fold higher in the capsaicin-pretreated mice relative
to mice treated with irinotecan only. The presence of capsaicin prevented SN-38 from binding to
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plasma protein and increased the unbound fraction of SN-38 by about 2.0-2.5-fold. Similarly, the
liver/plasma ratio (L/P ratio) for SN-38 was substantially lower in capsaicin-pretreated mice
compared to mice injected with irinotecan only. Taken together, these findings suggest that the
presence of capsaicin increases the bioavailability of SN-38 in the plasma so that it can display
greater anti-cancer activity (N. Wang et al., 2018). An innovative study by L. Wang et al., (2017)
involved the synthesis of an oral self-emulsifying hydrophobic drug delivery system in which
both SN-38 and capsaicin were encapsulated (referred to as 1-SEEDS) (L. Wang, Chen, et al.,
2017). Subsequently, the authors characterized the drug release profiles, morphology, and
droplet size of these polymeric encapsulated drug systems. They measured the effect of 1SEEDS on the viability of a panel of human cancer cell lines, namely HCT-116, SW680 (colon
carcinoma), MCF-7, MDA-MB231 (breast carcinoma) and H1299 (lung carcinoma). The
growth-inhibitory activity of 1-SEEDS in colon and breast cancer cell lines was 1.5-3.0-fold
higher than SN-38 alone. Furthermore, 1-SEEDS induced almost 2-fold higher apoptosis than
SN-38 alone and 4-fold higher apoptosis than capsaicin alone in HCT-116 cells (L. Wang, Chen,
et al., 2017). Studies in an athymic mice bearing HCT-116 human colon cancer tumors showed
that 30 mg 1-SEEDS/kg body weight suppressed the growth of HCT-116 tumors to a greater
extent than SN-38 or capsaicin-alone. The administration of 1-SEEDS did not produce any toxic
side effects, like hemolysis or alteration in the body weights of mice (L. Wang, Chen, et al.,
2017). Future research in the development of targeted drug delivery systems may make delivery
of both an anti-cancer drug and a chemosensitizing agent to the site of the tumor, in a selective
efficacious manner, a clinical reality. This would greatly improve the anti-tumor activity of these
compounds in human cancers.
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TARGETED SIGNAL TRANSDUCTION INHIBITORS
The proteasome inhibitor bortezomib (also called Velcade; Figure 8A) is used for the
treatment of patients suffering from multiple myeloma (Kouroukis et al., 2014). Bhutani et al.,
(2007) analyzed the combinatorial apoptotic activity of capsaicin and bortezomib in U266 human
multiple myeloma cells in vitro (Bhutani et al., 2007). The treatment of U266 cells with 25 μM
capsaicin along with 20 nM bortezomib increased the fraction of apoptotic cells by about 4-fold
compared to 20 nM bortezomib alone and by about 8-fold relative to 25 μM capsaicin alone. The
combinatorial apoptotic effects of capsaicin and bortezomib were mediated by disruption of
STAT3 activation and phosphorylation (Bhutani et al., 2007). Notably, a recent “Editor Note”
alerted readers about certain ambiguities in the figures of this published report, involving the
apoptosis assays performed with bortezomib and capsaicin (Bhutani et al., 2018). Figure 6A of
the paper by Bhutani et al., (2007) describes the combinatorial apoptotic activity of thalidomide
and capsaicin in U266 cells. Figure 6B shows that capsaicin sensitizes U266 cells to bortezomibinduced apoptosis. The images used to represent controls and capsaicin-treated cells are identical
between Figure 6A and B. The editorial note mentions that the authors were unable to provide
the original data for these images at the time of institutional review (Bhutani et al., 2018).
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Figure 8. Targeted signal transduction inhibitors
(A) Bortezomib. (B) Sorafenib. (C). Gefitinib.
The anti-cancer drug sorafenib (Figure 8B) is an inhibitor of multiple receptor and
cytoplasmic kinases including vascular endothelial growth factor receptor 1 and 2 (VEGFR-1,
VEGFR-2), and platelet-derived growth factor-b (PDGF-b) -tyrosine kinase (Wilhelm et al.,
2008). Sorafenib is the only systemic treatment for patients with unresectable hepatocellular
carcinoma (HCC). Clinical studies indicate that it prolongs overall survival of HCC patients by
approximately 2.8 months (Daher, Massarwa, Benson, & Khoury, 2018). A challenge with
sorafenib therapy is the acquisition of drug resistance upon long-term treatment (Niu et al.,
2017). Cell culture data suggest that sorafenib resistance may be partially abrogated by the use of
PI3K/Akt inhibitors (Matter, Decaens, Andersen, & Thorgeirsson, 2014; B. Zhai et al., 2014; H.
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Zhang, Wang, Liu, & Cao, 2018). Capsaicin triggers apoptosis and autophagy in many types of
human cancers by blocking the PI3K/Akt/mTOR pathway (Clark & Lee, 2016; Diaz-Laviada &
Rodriguez-Henche, 2014; Srinivasan, 2016). With this finding in mind, Dai et al., (2018)
investigated the combinatorial growth-suppressive activity of sorafenib and capsaicin in LM3,
Hep3B and HuH7 human HCC cell lines (Dai et al., 2018). The combined treatment of capsaicin
and sorafenib decreased the viability of all HCC cell lines to a greater magnitude than either drug
alone. The authors confirmed these findings using colony formation assays in LM3 cells,
showing that multiple concentrations of capsaicin (80, 100 and 120 μM) and sorafenib (2, 3 and
4 μM) showed synergistic inhibition (CI<1) of colony formation in all possible combinations
(Dai et al., 2018). The synergistic induction of apoptosis (by capsaicin and sorafenib) was
accompanied by an increase in pro-apoptotic proteins like Bax, cleaved caspase-3, cleaved PARP
and decrease of pro-survival proteins like Bcl-2 (Dai et al., 2018). Similarly, the combination of
capsaicin and sorafenib displayed synergistic autophagic activity upregulating autophagic
biomarkers Beclin-1 and LC3A/B-II and decreasing the levels of autophagy-specific substrate
P62. Furthermore, Boyden chamber and wound healing assays revealed that the treatment with
capsaicin (80 µM) along with sorafenib (4 µM) synergistically inhibited (CI<1) the migration
and invasion of LM3 cells (Dai et al., 2018). A notable point here is that it is unclear whether this
observed anti-migratory and anti-invasive activity is due to cell death or due to inhibition of cell
motility pathways. The combination of capsaicin and sorafenib decreased the expression of proinvasive proteins like vimentin, N-cadherin, MMP2 and MMP9, and increased the expression of
the epithelial biomarker E-cadherin. The authors further confirmed the synergistic anti-tumor
activity of sorafenib and capsaicin in LM3 human HCC tumors xenografted in athymic mice.
The administration of 2.5 mg capsaicin/kg body weight together with 50 mg sorafenib/kg body
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weight showed greater decrease in tumor volumes than when the drugs were administered as
single agents (Dai et al., 2018). The combinatorial anti-neoplastic activity of sorafenib and
capsaicin correlated with inhibition of EGFR, PI3K/Akt and activation of their downstream
substrates like mTOR and p70S6 kinase.
A similar study exploring the synergistic growth inhibitory activity of sorafenib and
capsaicin was performed by Zhang et al., (2018), using PLC/PRF/5, HuH7 and HepG2 human
HCC cells (S. S. Zhang et al., 2018). Chou-Talalay isobologram analysis revealed that 100 µM
capsaicin showed synergistic growth-suppressive activity with 3, 10 and 30 µM sorafenib. The
interaction between capsaicin and lower concentrations of sorafenib (0.3 or 1 µM) showed a
moderate-to-slightly antagonistic interaction. No synergy between capsaicin and sorafenib was
observed in normal liver cells. The combination of 200 µM capsaicin and 50 mg sorafenib/kg
body weight synergistically inhibited the growth of PLC/PRF/5 tumors in athymic mouse model
(S. S. Zhang et al., 2018). Analogous to the results of Dai et al., (2018), the combination of 5 or
10 µM sorafenib with 100 µM capsaicin showed robust apoptosis with inhibition of ERK and
STAT3 activation (Dai et al., 2018; S. S. Zhang et al., 2018).
Parashar et al., (2019) synthesized folic acid functionalized nanoparticles, enabling the
co-administration of the epidermal growth factor receptor (EGFR) inhibitor gefitinib (Figure 8C)
along with capsaicin (Parashar et al., 2019). Overexpression and activating mutations in EGFR
have been reported in 10-15% of caucasian non-small cell lung cancer (NSCLC) and in about
50% of Asian NSCLC patients. The EGFR inhibitors, namely gefitinib and erlotinib, are first
line therapies for such NSCLC patients (Hirsh, 2018). The authors characterized these gefitinibcapsaicin-folic acid based nanoparticles (referred hereafter as Gnb-CAP-NP) by transmission
electron microscopy (TEM), measuring the particle size, drug loading, efficiency, drug
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entrapment efficiency and release kinetics (Parashar et al., 2019). Cell viability and cell
proliferation assays showed that Gnb-CAP-NP displayed greater growth-suppressive activity
relative to capsaicin-loaded folic acid nanoparticles (CAP-NP) or gefitinib-loaded nanoparticles
(Gnb-FA-NP) in A549 human NSCLC cells (Parashar et al., 2019). The encapsulated
formulations of gefitinib and capsaicin decreased the viability of A549 cells to a greater
magnitude than the unmodified compounds. The interaction between gefitinib and capsaicin was
synergistic (CI<1).
The enhanced growth-inhibitory effect of Gnb-CAP-NP was observed to be due to both
apoptosis and cell cycle arrest (Parashar et al., 2019). Cell cycle analysis revealed that GnbCAP-NP induced G0/G1-phase arrest in A549 cells. Gnb-CAP-NP decreased the expression of
the pro-invasive protein MMP9, and the cell cycle regulatory protein p16, as well as an increase
of pro-apoptotic proteins (caspase-3 and caspase-9) in A549 cells. The intravenous
administration of Gnb-CAP-NP (releasing 20 mg/kg gefitinib and 10 mg/kg capsaicin
simultaneously) robustly suppressed urethane-induced lung carcinogenesis in both male and
female albino Wistar rats (Parashar et al., 2019). Drug delivery systems capable of coadministration of the chemotherapeutic drug as well as the chemosensitizer may represent a
promising breakthrough for the treatment and management of human cancers.
RADIATION THERAPY
Radiation therapy is a modality of cancer therapy that involves administration of
high doses of radiation to kill cancer cells and shrink tumors. Radiotherapy induces the death of
cancer cells by causing DNA damage (Baskar, Dai, Wenlong, Yeo, & Yeoh, 2014; Eriksson &
Stigbrand, 2010). Apoptosis is the predominant mechanism of cell death in response to radiation
therapy, especially in hematopoietic cells and their malignant counterparts. However, radiation
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therapy can also initiate cell death by other mechanisms including cell cycle arrest, senescence,
and mitotic catastrophe (Eriksson & Stigbrand, 2010). As with chemotoxic therapeutics, the
predominant challenges of radiation therapy are also disease recurrence and tumor resistance.
The main reason for innate or acquired resistance to radiation therapy is still unknown, but
current evidence suggests that multiple pathways like hypoxia and DNA-repair enzymes
contribute to radiation resistance of neoplastic cells. Therefore, radiosensitizers like dietary
compounds, gold nanoparticles, and HSP inhibitors have potential to improve the efficacy of
radiation therapy for cancer.
Combined modality therapy refers to the combination of radiotherapy with drugs which
enhance the lethal effect of radiation on cancer cells (Tannock, 1989). The radiosensitizing
ability of capsaicin has been studied in human prostate cancer. Venier et al., (2013, 2015)
evaluated the effects of capsaicin and radiation therapy using three distinct human prostate cell
lines, namely LNCAP (androgen-receptor positive, wild type p53), DU145 (androgen-receptor
negative, mutant p53 P223L, and V274F) and PC3 (androgen-receptor negative, p53 null;
(Venier, Colquhoun, Klotz, Fleshner, & Venkateswaran, 2013; Venier et al., 2015). The authors
wanted to compare the radiosensitizing ability of capsaicin between prostate cancer cells and
normal prostate epithelial cells. They selected RWPE-1 as the normal prostate epithelial cell line
(undetectable androgen receptor expression, p53 null, Rb null). The authors measured the
radiosensitizing ability of capsaicin using colony formation assays. They treated LNCAP, PC-3
and RWPE-1 cells with radiation in the presence or absence of capsaicin for 5 days (Venier et
al., 2015). The capsaicin was added one hour prior to irradiation. The sensitizer enhancement
ratio (SER) was calculated by dividing the area under the curve (AUC) for vehicle (DMSO) and
the AUC for capsaicin-treated cells. The authors observed that the radiosensitizing activity of
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capsaicin was not concentration-dependent. LNCAP showed robust radiosensitizing activity of
capsaicin at all three concentrations (0.01, 1 and 10 μM; SER greater than 1). However, RWPE-1
only showed synergistic radiosensitization with capsaicin at the 10 μM dose (Venier et al., 2015).
It was found that the treatment of LNCAP and PC3 cells with radiation and capsaicin increased
the expression of the DNA damage marker phospho-H2AX and decreased the number of cells in
S-phase. The combinatorial growth-inhibitory activity of capsaicin and radiation was determined
to be independent of TRPV1 and correlated with decreased levels of phospho-NF-kB (Venier et
al., 2013; Venier et al., 2015). Previous studies by the same research group showed that the
radiosensitization of capsaicin coincided with upregulation of Bax, Bad, p21and p27 and
decrease in the levels of androgen receptor in a panel of human prostate cancer cell lines (Klotz
et al., 2011; Venier et al., 2012). Subsequently, the authors confirmed the radiosensitizing ability
of capsaicin in athymic mice xenografted with LNCAP tumors (Venier et al., 2015). Mice were
given a dose of 6 Gray (Gy) units of ionizing radiation on day 16 in the presence or absence of
capsaicin. HPLC analysis confirmed the presence of capsaicin and its metabolites in the serum of
mice. The combination of capsaicin and radiation significantly decreased the growth rate of
LNCAP tumors compared to vehicle-treated mice or mice administered each drug alone (Venier
et al., 2015). IHC analysis of the tumors revealed that radiation upregulated the expression of
NF-kB, which was decreased when capsaicin was included in the treatment regimen. Notably,
they did not observe any alteration of total NF-kB expression when they treated LNCAP cells in
vitro with radiation alone, capsaicin alone or in combination. However, they did observe that
capsaicin suppressed radiation-induced phospho-NF-kB levels in both LNCAP cells (in cell
culture) and in LNCAP tumors excised from athymic mice. The combination of radiation and
capsaicin resulted in sustained DNA damage in LNCAP tumors as evidenced by increased
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expression of the DNA damage marker g-H2AX in the sections prepared from LNCAP tumors
xenografted in athymic mice (Venier et al., 2015). Moreover, LNCAP tumor bearing mice
administered radiation in the presence of capsaicin showed significantly lower Ki-67 index (a
marker for cell proliferation) and androgen receptor expression. Conflicting data exists on the
radiosensitizing activity of capsaicin. Nishino et al., (2016) did not find any combinatorial
growth-inhibitory activity of radiation and capsaicin in A549 human lung adenocarcinoma cells
(Nishino et al., 2016). However, such divergent results can be explained by differences in
experimental design in the two studies. Whereas the studies described by Venier et al., (2015)
pretreated the cells with 10 µM capsaicin one hour prior to irradiation, Nishino et al., (2016)
treated cells with 10 µM capsaicin 5 minutes after irradiation (Nishino et al., 2016; Venier et al.,
2015). The data obtained from drug-combination studies are often dependent on the treatment
protocol (pretreatment versus adding both drugs simultaneously versus post-treatment). Also,
Nishino et al., (2016) used A549 human lung cancer cells for their studies. Other studies have
reported that capsaicin decreased the viability of A549 cells at high concentrations (above 200
µM) via inflammatory signaling and genotoxic stress mechanisms rather than apoptosis (Halme
et al., 2016; Lewinska, Jarosz, et al., 2015; Reilly et al., 2003). Such observations seem to
suggest that capsaicin may have divergent bioactivity depending on the nature of the cell line, the
concentration of capsaicin being used, or the time sequence of the experiments. The studies by
Klotz et al., (2011) and Venier et al., (2012, 2013 and 2015) used prostate cancer cells, whereas
Nishino et al., (2016) investigated the radiosensitizing activity of capsaicin in lung
adenocarcinoma and melanoma cells (Klotz et al., 2011; Nishino et al., 2016; Venier et al., 2013;
Venier et al., 2012; Venier et al., 2015). A strength of the research report by Venier et al., (2015)
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is that they validated their findings both in cell culture and athymic mouse models of prostate
cancer (Venier et al., 2015).
CONCLUSIONS AND FUTURE DIRECTIONS
The capsaicinoid family of nutritional compounds, isolated from chili peppers, can
sensitize multiple types of human cancers to the apoptotic effects of conventional, as well as
targeted anti-cancer drugs. However, only a handful of targeted therapies, namely sorafenib,
gefitinib and bortezomib, have been combined with capsaicin to investigate their combinatorial
growth inhibitory activity. It is hoped that several classes of targeted therapies like antiangiogenic agents, immunotherapies, hormonal agents and signal transduction inhibitors will
display synergistic anti-cancer activity upon combination with capsaicinoids. Recent research
has characterized novel drug delivery systems like liposomes and nanoparticles which
simultaneously release the chemosensitizer (capsaicin) and the anti-cancer drug namely SN-38 or
gefitinib.
The clinical application of capsaicin is limited by its unpleasant side effects including gut
pain, hyperalgesia, stomach cramps and nausea (Drewes et al., 2003; Hammer, 2006; O'Neill et
al., 2012). This drawback could be circumvented by natural non-pungent capsaicinoids, like the
capsiates, which retain the anti-tumor activity of capsaicin but do not produce the “heatsensation” of capsaicin and RTX (Friedman et al., 2018). Apart from natural non-pungent
capsaicinoids, structure-activity relationship studies have generated synthetic non-pungent
capsaicin analogs (Friedman et al., 2018). Future research involving the chemosensitization
activity of these non-pungent capsaicin analogs will facilitate the development of clinically
relevant combination therapies for the treatment and management of cancer.
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CHAPTER 3: CAPSAICIN SYNERGIZES WITH CAMPTOTHECIN TO INDUCE
INCREASED APOPTOSIS IN HUMAN SMALL CELL LUNG CANCERS VIA THE
CALPAIN PATHWAY
A manuscript published in Biochemical Pharmacology.
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ABSTRACT
Small cell lung cancer (SCLC) is characterized by excellent initial response to
chemotherapy and radiation therapy with a majority of the patients showing tumor shrinkage and
even remission. However, the challenge with SCLC therapy is that patients inevitably relapse
and subsequently do not respond to the first line treatment. Recent clinical studies have
investigated the possibility of camptothecin-based combination therapy as first line treatment for
SCLC patients. Conventionally, camptothecin is used for recurrent SCLC and has poor survival
outcomes. Therefore, drugs which can improve the therapeutic index of camptothecin should be
valuable for SCLC therapy. Extensive evidence shows that nutritional compounds like capsaicin
(the spicy compound of chili peppers) can improve the anticancer activity of chemotherapeutic
drugs in both cell lines and animal models. Statistical analysis shows that capsaicin synergizes
with camptothecin to enhance apoptosis of human SCLC cells. The synergistic activity of
camptothecin and capsaicin is observed in both classical and variant SCLC cell lines and in vivo,
in human SCLC tumors xenotransplanted on chicken chorioallantoic membrane (CAM) models.
The synergistic activity of capsaicin and camptothecin are mediated by elevation of intracellular
calcium and the calpain pathway. Our data foster hope for novel nutrition-based combination
therapies in SCLC.
INTRODUCTION
Small cell lung cancer (SCLC) accounts for about 15–20% of all lung cancer cases and is
the most aggressive type of lung cancers (Kahnert, Kauffmann-Guerrero, & Huber, 2016; Koinis,
Kotsakis, & Georgoulias, 2016). Cisplatin or carboplatin in combination with etoposide is the
standard of care for SCLC patients. Although this regimen initially works very well in SCLC
patients with a response rate of greater than 80%, the disease inevitably relapses within a year, at
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which point the tumor is non-responsive to cisplatin-based combination therapies (AlvaradoLuna & Morales-Espinosa, 2016). Another drawback with the cisplatin- etoposide regimen is its
toxicity, which may render SCLC patients more susceptible to adverse symptoms upon
subsequent treatments (Stewart, 2004). Patients with recurrent SCLC have very limited options,
as the only standard chemotherapy with an FDA-approved drug, camptothecin (Figure 9A), has
an objective response rate of approximately 3% and little or no survival benefit (Asai, Ohkuni,
Kaneko, Yamaguchi, & Kubo, 2014). Clinical trials have explored the possibility of
camptothecin-based combination regimens for standard of care therapy for SCLC patients
(Stewart, 2004). Therefore, agents which can increase the therapeutic efficacy of camptothecin
may improve the outcomes of SCLC therapy. Several convergent studies have shown that dietary
compounds can sensitize neoplastic cells to the apoptotic effects of chemotherapeutic drugs (Ho
& Cheung, 2014; Mohan, Narayanan, Sethuraman, & Krishnan, 2013). Our published data show
that capsaicin (the spicy compound of chili peppers; Figure 9B) can induce robust apoptosis in
human SCLC cells in cell culture and mouse models (Lau, Brown, Dom, & Dasgupta, 2012; Lau
et al., 2014). Therefore, we conjectured that low doses of capsaicin (where it does not cause cell
death) may sensitize human SCLC cells to the apoptotic activity of camptothecin and its
derivatives.
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Figure 9. Structure of (A) camptothecin and (B) capsaicin
A survey of literature shows that capsaicin increases the therapeutic index of several
anticancer treatments. The administration of capsaicin increased the therapeutic efficacy of
radiation in prostate cancer. Monofunctional platinum-based drugs, like LH5, showed increased
apoptotic activity in combination with capsaicin (Arzuman et al., 2016). Similarly, the treatment
of stomach cancer cells with a combination of cisplatin and capsaicin caused greater apoptosis
than either of these agents given singly (Huh et al., 2011; Wiwanitkit, 2012). A similar effect
was also observed when capsaicin was given in combination with the doxorubicin analog
pirarubicin (Zheng et al., 2016). The present manuscript investigates for the first time the
anticancer activity of the combination of capsaicin and camptothecin. We show that low doses of
capsaicin (where it does not cause any apoptosis) synergizes with camptothecin to induce high
levels of cellular apoptosis in human SCLCs. We confirmed the synergistic apoptotic activity of
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capsaicin and camptothecin in classical human SCLC cell lines (NCI-H69 and DMS 114), as
well as the variant human SCLC cell line NCI-H82. Another innovative feature about our study
is that we have analyzed the synergistic interaction between these two drugs by the Chou-Talalay
isobologram method (Chou, 2008, 2010).
The apoptotic activity of capsaicin-camptothecin combination was confirmed using two
independent apoptosis assays. Subsequently, we show that the combination of capsaicin and
camptothecin enhances apoptosis (compared to these agents given alone) in vivo, in human
SCLC tumors xenotransplanted on chicken chorioallantoic membranes (CAM) (NowakSliwinska, Segura, & Iruela-Arispe, 2014). We also examined the signaling pathways underlying
the combinatorial synergistic apoptotic activity of capsaicin and camptothecin. We found that the
synergistic apoptotic activity capsaicin and camptothecin was mediated by elevation of
intracellular calcium and activation of the calpain pathway both in cell culture and in chicken
CAM models. The results of our studies may lead to improved treatment regimens for SCLC.
MATERIALS AND METHODS
Reagents
Camptothecin, capsaicin, BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’tetraacetic acid tetrakis(acetoxymethyl ester) and calpeptin were purchased from Sigma-Aldrich
(St. Louis, MO, USA). All cell culture reagents, including RPMI-1640, FBS, Trypsin-EDTA,
and HEPES, were purchased from American Type Culture Collection (ATCC; Manassas, VA,
USA). Sodium pyruvate, glucose, and penicillin-streptomycin solutions were obtained from
Corning (NY, USA).
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Cell culture
The human SCLC cell lines NCI-H82, NCI-H69 (hereafter referred to as H82 and H69)
and DMS 114 were purchased from ATCC (Manassas, VA). The ATCC used Short Tandem
Repeat (STR) profiling for authentication of these cells. H69 and H82 were cultured in RPMI1640 supplemented with 2 mM glutamine, 4.5 g/L glucose, 100 units/ml penicillin, 100 units/ml
streptomycin and 10% fetal bovine serum (FBS). DMS 114 was cultured in RPMI-1640
containing 2 mM glutamine, 25 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, 100
units/ml penicillin, 100 units/ml streptomycin and 10% FBS. All cell lines were maintained in a
37°C humidified incubator with 5% carbon dioxide (NuAire Laboratory Equipment, Plymouth
MN).
Preparation of lysates
Cell lysates were made using detergent-based lysis protocol as described previously
(Hurley et al., 2017). Cells were harvested and washed three times with cold PBS. Cells were
then lysed with M2 lysis buffer (20 mM Tris, pH 7.6, 0.5% IGEPAL-CA-630, 250 mM NaCl, 3
mM EGTA, 3 mM EDTA, 4 µM DTT, 5 mM PMSF, 1 mM sodium fluoride, 1 mM sodium
orthovanadate, 25 µg/ml leupeptin, 5 µg/ml pepstatin, 5 µg/ml aprotinin, and 25 µg/ml trypsinchymotrypsin inhibitor) and the lysates were prepared as detailed elsewhere (Hurley et al., 2017).
The protein concentration of the lysate was measured using Bradford Reagent (Bio-Rad
Laboratories, Hercules, CA, USA).
Measurement of caspase-3 activity
DMS 114 human SCLC cells were cultured to 80% confluence as described above. On
the day of the experiment, the medium of the cells was changed to RPMI medium containing 1%
FBS. Subsequently, cells were treated with the indicated concentrations of the relevant drugs for
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24 hours at 37°C. A few of the drug treatments involved treating the human DMS 114 cells with
both camptothecin and capsaicin. In these cases, capsaicin was added 45 minutes before
camptothecin and then the cells were incubated for 24 hours at 37°C.
Cell lysates were made using the Caspase-3 Activity Kit (EMD Millipore Corporation,
Billerica, MA, USA). The protein concentration of the lysate was measured using Bradford
Reagent (Bio-Rad Laboratories, Hercules, CA, USA). An aliquot of the cell lysate containing
one hundred micrograms of protein was used for the measurement of caspase-3 activity,
according to the manufacturer’s protocol.
Each sample was measured in triplicate and the whole experiment was repeated three
times using independent sets of cell lysates. Caspase-3 Activity in untreated lysates was
considered to be equal to 1, and the activity observed in treated lysates was calculated as fold
increase relative to the untreated control sample. The experimental procedure was identical in
H69 and H82 cells.
Cell death ELISA
DMS 114 human SCLC cells were cultured to 80% confluence in T-75 tissue culture
flasks (Nunc, Roskilde, Denmark). On the day of the experiment, the medium of the cells was
changed to RPMI medium containing 1% FBS. The DMS 114 human SCLC cells were treated
with the indicated concentration of the appropriate drug for 24 hours at 37°C. A few experiments
involved treating the human DMS 114 SCLC cells with both camptothecin and capsaicin. In
these cases, capsaicin was added 45 minutes before camptothecin, and then the cells were
incubated for 24 hours at 37°C.
Cells were then lysed with M2 lysis buffer (described above), and the lysates were
prepared as detailed above (Hurley et al., 2017). The protein concentration of the lysate was
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measured using Bradford Reagent (Bio-Rad Laboratories, Hercules, CA, USA). Twenty
micrograms of lysate were used for each sample. Cellular apoptosis was measured by the Cell
Death ELISA Kit (Roche Life Sciences, Indianapolis, IN, USA), according to manufacturer’s
protocol. The absorbance value of control untreated cells was taken as 1, and the absorbance of
drug-treated cells were graphically represented as fold-increase relative to the control. The
protocol was identical for H69 and H82 human SCLC cells. Each sample was measured in
duplicate and the entire experiment was repeated three times with independent sets of lysates.
Chicken chorioallantoic membrane (CAM) assay
Specific pathogen-free (SPF) fertile chicken eggs (Charles River Laboratories, North
Franklin, CT) were incubated at 37.5°C with 75% relative humidity and continuously rotated
slowly by an automatic egg turner (G.Q.F. Manufacturing Company, Savannah, GA). At Day 9,
eggs were candled and windows opened on the shell to expose the CAM (Nowak-Sliwinska et
al., 2014). H69 cells (1.5 X 106) were suspended in 100 µL cold serum-free medium, mixed with
100 µL cold BD Matrigel Matrix (BD Biosciences, San Jose, CA) and treated with 10 µM
capsaicin or 1 µM camptothecin or a combination of 10 µM capsaicin and 1 µM camptothecin
(K. C. Brown et al., 2013; Lau et al., 2013). These cells were applied to the CAM of each
chicken embryo. Eggs were incubated at 37°C for seven days before tumor implants were
removed, photographed and weighed. A total of eight eggs were assayed for each group.
Preparation of tumor lysates from CAM
Chicken CAM experiments were performed as described above. After the H69 human
SCLC tumors were excised, they were snap frozen in liquid nitrogen. An aliquot of 30 mg of the
tumor was weighed and used to make tumor lysates. Tumor lysates were prepared using T-Per
lysis buffer (Pierce Biotechnology, Rockford, IL, USA), according to manufacturer’s protocol
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(K. C. Brown et al., 2013; Dasgupta et al., 2011; Lau et al., 2014; Lau et al., 2013). The caspase3 activity assay was performed with four independent sets of tumor lysates prepared from control
CAM H69 tumors, 10 µM capsaicin-treated CAM H69 tumors, 1 µM camptothecin-treated CAM
H69 tumors, and H69 CAM tumors treated with a combination of 1 µM camptothecin and 10
µM capsaicin. The cellular apoptosis in these lysates was measured by using the Caspase-3
Activity Kit (Chemicon, Temecula, CA, USA). Each sample was measured in triplicate and the
entire experiment was repeated four times with independent sets of lysates.
Measurement of calpain activity
H69 human SCLC cells were treated with 10 µM capsaicin or 1 µM camptothecin or a
combination of 10 µM capsaicin and 1 µM camptothecin (for 24 hours) in RPMI medium
containing 1% FBS. Subsequently, cells were harvested and washed twice with PBS. Cell lysates
were prepared using the assay buffer provided in the Sensolyte 520 Calpain Activity Assay Kit
(Anaspec, Freemont, CA, USA). An aliquot of the cell lysate containing two hundred
micrograms of protein was used for each replicate sample. The samples were incubated with 50
µl of calpain substrate for 60 minutes at 37°C (Guha et al., 2010; Lau et al., 2014). The rest of
the assay was performed according to manufacturer’s instructions. The fluorescence intensity
was measured using a Biotek Synergy2 spectrofluorometer (Biotek Instruments, Winooski, VT,
USA) at excitation and emission wave- lengths of 490 and 520 nm, respectively. Each sample
was measured in duplicate and the whole experiment was repeated three times with independent
sets of lysates. Calpain activity in untreated lysates was considered to be equal to 1, and the
activity observed in treated lysates was calculated as fold increase relative to the untreated
control sample.
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The calpain enzyme activity assay was also performed using the tumor lysates from H69
tumors xenografted on chicken CAM (K. C. Brown et al., 2013; Dasgupta et al., 2011; Lau et al.,
2014; Lau et al., 2013). The tumor lysates were made as described above. An aliquot of two
hundred micrograms of the protein was used in the calpain assay. The methodology and data
representation of the assay was similar to the one described for H82 and H69 cells.
Statistical analysis
All data were plotted using GraphPad Prism 5 Software, Inc (La Jolla, CA, USA), and
results were represented as the mean ± standard deviation (SD). Results from the control and
treated samples were compared using an analysis of variance (ANOVA) followed by a Tukey
posthoc multiple comparison test. All analyses were completed using a 95% confidence interval.
Data were considered significant when p£0.05.
All data involving combinatorial interactions between camptothecin and capsaicin were
evaluated by the Chou-Talalay isobologram analysis using the method of non-constant ratios
(Chou, 2008, 2010). The Chou-Talalay isobologram analysis (Calcusyn Graphing Software
Version 2.11, Biosoft Inc., Ferguson, MO, USA) is an established method to determine if two
drugs exhibit synergistic, additive or antagonistic interactions (Chou, 2008, 2010). This method
was used to examine whether camptothecin and capsaicin displayed a synergistic increase in
apoptotic activity. The Chou-Talalay isobologram analysis yields a parameter called the
combination index (CI). A CI below 1 is taken to be an indicator of synergism. The lower the
value of the CI, the stronger the synergy between the drugs.
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RESULTS
A concentration of 10 µM capsaicin does not cause significant apoptosis (p£0.05) in human
small cell lung cancer (SCLC) cell lines.
The first series of experiments analyzed the concentration dependent apoptotic activity of
capsaicin in human SCLC cell lines over 24 hours, using the caspase-3 activity assay. We
observed that the capsaicin displays little apoptotic activity until 10 µM and subsequently causes
robust apoptosis at 50 and 100 µM in DMS 114 human SCLC cells (Figure 10A). The highest
concentration at which capsaicin did not induce significant apoptosis (p£0.05) was 10 µM in
DMS 114 cells. The caspase-3 activity assay was repeated in two additional human SCLC cell
lines, H69 and H82, and similar results were obtained (Figure 10B and C). Our eventual goal
was to test if low doses of capsaicin (where it does not display apoptotic activity) could sensitize
human SCLC cells to camptothecin-induced apoptosis. Therefore, we selected the concentration
of 10 µM capsaicin for all our subsequent experiments.
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Figure 10. Concentration dependent apoptotic activity of capsaicin in human SCLC cells
over 24 hours, as measured by the caspase-3 activity kit
(A) Capsaicin displayed very little apoptotic activity until 10 µM, after which it induced robust
apoptosis at 50 µM and 100 µM in DMS 114 cells. (B) The apoptotic activity of capsaicin was
confirmed in H69 as well as H82 human SCLC cells (C) Each sample was measured in triplicate
and the whole experiment was repeated three times using independent sets of cell lysates.
Caspase-3 activity in untreated lysates was considered to be equal to 1, and the activity observed
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in treated lysates was calculated as fold increase relative to the untreated control sample.
Statistical analysis showed that 10 µM capsaicin (indicated by the box on the graph) was the
highest concentration at which capsaicin did not display significant apoptotic activity (p£0.05).
Values represented by the same letter are not statistically significantly different from each other.
The results obtained from the caspase-3 activity assay were verified using a second
apoptosis assay, the Cell Death ELISA Kit (Roche Life Science). We obtained similar results as
the caspase-3 activity assay. The treatment of DMS 114 cells with varying doses of capsaicin
caused little cell death until 10 µM, and after that the levels of cell death rose significantly over
24 hours (p£0.05) (Figure11A). The experiment was repeated in H69 and H82 cells and similar
results were obtained (Figure 11B and C). Based on the data of these two assays we selected 10
µM capsaicin for our subsequent experiments.
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Figure 11. Cell Death ELISA assays were used to confirm the apoptotic activity of
capsaicin over 24 hours
(A) The apoptotic activity of capsaicin was minimal in DMS 114 human SCLC cells until a
concentration of 10 µM, after which it caused between 1.5 and 2.0-fold apoptosis at 50 µM and
100 µM over 24 hours. (B) The pro-apoptotic activity of capsaicin was verified in a classical
human SCLC cell line H69 and as well as a variant human SCLC cell line H82 (C) and
analogous results were obtained. Each sample was measured in triplicate and the whole
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experiment was repeated three times using independent sets of cell lysates. The absorbance
obtained in untreated lysates was considered to be equal to 1, and the activity observed in treated
lysates was calculated as fold increase relative to the untreated control sample. The highest
concentration at which capsaicin did not display significant apoptotic activity was 10 µM
(p£0.05). Values represented by the same letter are not statistically significantly different from
each other.
The combinatorial apoptotic activity of camptothecin and capsaicin is greater than these
drugs treated alone in human SCLC cells
Caspase-3 activity assays were performed to test the combinatorial apoptotic activity of
capsaicin (referred as CPZ) and camptothecin (referred as CPT) in DMS 114 human SCLC cells
(Figure 12A). DMS 114 cells were treated with multiple concentrations of camptothecin (0.01–
100 µM) in the presence or absence of 10 µM capsaicin. The 10 µM capsaicin was added 45 min
before the addition of camptothecin. Figure 12A shows that the combination of camptothecin and
capsaicin (indicated by solid black line with the black round dots) possessed greater apoptotic
activity than corresponding concentrations of camptothecin alone (dotted line with black square
dots) or capsaicin alone (Figure 10 and 11). The Chou-Talalay analysis was used to determine if
capsaicin synergized with camptothecin to induce enhanced apoptotic activity (Chou, 2008,
2010). As mentioned in Materials and Methods, a combination index (CI) below 1 is an indicator
of synergism; the lower the magnitude of CI (below 1) the greater the synergy (Chou, 2008,
2010). Figure 12A shows that the maximal synergy was observed for the combination of 10 µM
capsaicin and 1 µM camptothecin (CI = 0.095). The combination of 10 µM capsaicin and 10 µM
camptothecin was also synergistic (CI = 0.15); however, the magnitude of synergy was
decreased. Figure 12B represents the normalized isobologram of the capsaicin-camptothecin
combination in DMS 114 cells (Chou, 2008, 2010). The symbols on the isobologram indicate the
CI of the two drugs namely camptothecin (CPT) and capsaicin (CPZ). The numbers 1–6 next to
the symbols on the isobologram represent the different combination regimens (described in the
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legends). The closer the CI is to the zero value the stronger is the synergy between the two drugs.
Figure 12B shows that treatment number 3 (10 µM capsaicin and 1 µM camptothecin) showed
the maximal synergistic interaction.
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Figure 12. Capsaicin (CPZ) sensitizes human SCLC cells to the apoptotic activity of
camptothecin (CPT)
(A) Concentration dependent apoptosis observed in DMS 114 cells human SCLC cells in
response to camptothecin (10 nM–100 µM; depicted by the dotted lines with square symbols).
Apoptosis was measured by Caspase-3 Activity assays. The solid black line (with circular
symbols) represents the concentrations of camptothecin (10 nM–100 µM) along with 10 µM
capsaicin. The data were evaluated by the Chou-Talalay isobologram and the combination
indices (CI) were determined. A CI value below 1 indicates synergy, the lower the CI value the
stronger is the synergy. The maximal synergy was observed for the combination of 1 µM
camptothecin and 10 µM capsaicin (CI = 0.095). The combination of 10 µM camptothecin and
10 µM capsaicin (CI = 0.15) showed lower synergy than the 1 µM camptothecin–10 µM
capsaicin combination. Each sample was measured in triplicate and the experiment was
performed three independent times. Values indicated by the same letters are not statistically
significant (p£0.05). (B) The normalized isobologram generated from the Chou-Talalay analysis
of Figure 12A. The CI of the various combination treatments are numbered 1–6 on the graph (the
details of the treatments are described in the legends). We observed that treatment # 3
(corresponding to 1 µM camptothecin and 10 µM capsaicin) has the lowest CI. (C) The results
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obtained from the caspase-3 activity assay were verified using the Cell Death ELISA assay in
DMS 114 cells and similar results were obtained. The apoptotic activities of varying
concentrations of camptothecin (CPT) are represented by the dotted lines with square symbols
over 24 hours. When 10 µM capsaicin (CPZ) was added to each of these treatments, the
magnitude of cell death was substantially increased (solid black lines with circular symbols). The
maximal synergy was obtained with a combination of 1 µM camptothecin and 10 µM capsaicin
(CI = 0.067) followed by 10 µM camptothecin–10 µM capsaicin combination (CI = 0.261) in 24
hours. (D) The normalized isobologram obtained after the Chou-Talalay analysis of Figure 12C.
The combination treatment #3 (1 µM camptothecin and 10 µM capsaicin) has the lowest CI
followed by treatment #4 (10 µM camptothecin and 10 µM capsaicin).
The synergistic apoptotic activity of capsaicin and camptothecin in DMS 114 cells was
verified by a second apoptosis assay, the Cell Death ELISA Kit (Roche BioSciences). We
observed similar results as the caspase-3 activity assay. The combination of 10 µM capsaicin
(CPZ) with varying concentrations of camptothecin (CPT) produced increased apoptosis
(indicated by solid black line with the black round dots) compared to camptothecin alone (dotted
line with black square dots) or capsaicin alone (Figure 12C) in DMS 114 cells over 24 hours.
The values for the combination indices (CI) showed that 10 µM capsaicin displayed the maximal
synergy with 1 µM camptothecin (CI = 0.067) followed by 10 µM capsaicin and 10 µM
camptothecin (CI = 0.261; Figure 12C). Figure 12D shows the corresponding normalized
isobologram in DMS 114 cells. The pattern of CI in the isobologram corresponds to the Cell
Death ELISA Kit (Figure 12C). As can be observed, the combination of 10 µM capsaicin (CPZ)
and 1 µM camptothecin (CPT) has the lowest CI out of all other combinations. The results of
these experiments were repeated in H82 human SCLC cells (Figure 13A) and H69 human SCLC
cells (Figure 14A). Capase-3 Activity assays show that the synergistic interaction between 10
µM capsaicin (CPZ) and 1 µM camptothecin (CPT) is stronger in H82 than in DMS 114 and
H69 cells. Figure 13B represents the normalized isobologram of the capsaicin-camptothecin
combination in H82 as measured by the caspase-3 activity assay. A similar isobologram was also
obtained for H69 cells (Figure 14B). These combinatorial apoptotic activities of camptothecin
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and capsaicin were proved in H82 cells (Figure 13C) and H69 cells (Figure 14C) using the Cell
Death ELISA Kit. The pattern of synergy observed in the isobologram in both cell lines closely
parallels the results obtained by the caspase-3 activity assay (Figure 13D and 14D). Taken
together, the combination of 10 µM capsaicin (CPZ) and 1 µM camptothecin (CPT) displayed
the maximum synergy in all three human SCLC cell lines, and this combination was used for the
signal transduction experiments outlined later in the manuscript.
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Figure 13. The synergistic apoptotic activity of capsaicin (CPZ) and camptothecin (CPT) is
observed in multiple SCLC cell lines
(A) Caspase-3 activity assays were used to measure the pro-apoptotic activity of a range of
camptothecin concentrations (10 nM–100 µM; dotted lines with square symbols) in H82 human
variant SCLC cells over 24 hours. When 10 µM capsaicin was added along with camptothecin
there was a significant increase in cellular apoptosis (p£0.05; depicted by solid black lines) in
H82 cells. Chou-Talalay isobologram analysis demonstrates that the greatest synergy was
observed for the combination of 1 µM camptothecin and 10 µM capsaicin (CI = 0.02).
Furthermore, the combination of 10 µM camptothecin and 10 µM capsaicin (CI = 0.133)
exhibited poorer synergy than the 1 µM camptothecin–10 µM capsaicin combination in H82
cells. Each sample was measured in triplicate and the experiment was performed three
independent times. Values indicated by the same letters are not statistically significant (p£0.05).
(B) The normalized isobologram generated from the Chou-Talalay analysis of Figure 13A. The
CI of the various combination treatments represented as points within the isobologram
(numbered 1–6 on the graph; the details of the treatments are described in the legends). (C) The
data obtained in the Cell Death ELISA assay (with H82 cells), closely match the caspase-3
activity assay; the utmost synergy was observed with a combination of 1 µM camptothecin
and10 µM capsaicin (CI = 0.014) followed by blend of 10 µM camptothecin–10 µM capsaicin
(CI = 0.058) in H82 cells over 24 hours. (D) The normalized isobologram obtained after the
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Chou-Talalay analysis of Figure 13C. The combination regimen 3 (1 µM camptothecin and 10
µM capsaicin) has the lowest CI followed by regimen #4 (10 µM camptothecin and 10 µM
capsaicin).

Figure 14. Camptothecin (CPT) and capsaicin (CPZ) induce synergistic cell death in the
classical human SCLC cell line H69
(A) Caspase-3 activity assays demonstrate that camptothecin (at concentrations ranging from 10
nM to 100 µM; dotted lines with square symbols) induce 4–5-fold apoptosis in H69 cells over 24
hours. When 10 µM capsaicin was added along with each of these concentrations of
camptothecin there was upregulation of apoptotic cell death (shown by solid black lines) in H69
cells. The highest synergy was observed 1 µM camptothecin and 10 µM capsaicin (CI = 0.023),
as measured by the Chou-Talalay analysis. We also noted that the amalgamation of 10 µM
camptothecin and 10 µM capsaicin (CI = 0.061) exhibited decreased synergy compared to the 1
µM camptothecin–10 µM capsaicin combination in H69 cells. Each sample was measured in
triplicate and the experiment was performed three independent times. Values indicated by the
same letters are not statistically significant (p£0.05). (B) The normalized isobologram generated
from the Chou-Talalay analysis of Figure 14A. The CI of the various combination modalities are
represented as points within the isobologram (these points are numbered 1–6 on the graph; the
details of the treatments are labelled in the legends) in H69 cells. (C) The outcomes obtained
from the caspase-3 activity assay were confirmed using the Cell Death ELISA assay in H69 cells
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and parallel results were obtained. (D) The normalized isobologram obtained after the ChouTalalay analysis of Figure 14C. The combination treatment # 3 (1 µM camptothecin and 10 µM
capsaicin) has the lowest CI followed by treatment condition #4 (10 µM camptothecin and 10
µM capsaicin).
Capsaicin synergizes with camptothecin to display increased apoptotic activity in vivo in
chicken chorioallantoic membrane (CAM) assay
We wanted to study whether capsaicin and camptothecin display synergistic apoptotic
activity in vivo. For this purpose, we selected the chicken CAM model (K. C. Brown et al., 2013;
Lau et al., 2013; Nowak-Sliwinska et al., 2014). The advantage of the chicken CAM model is
that the concentrations used in cell culture can be directly translated in the chicken CAM
experiments. In contrast, the doses in mice experiments are usually expressed in mg/kg body
weight, and it is difficult to correlate these doses to the concentration of the drugs used in cell
culture models (Kain et al., 2014; Lokman, Elder, Ricciardelli, & Oehler, 2012). Keeping these
considerations in mind we opted for the chicken CAM model to determine whether capsaicin
could sensitize H69 human SCLC cells to the apoptotic activity of capsaicin. An aliquot of
1.5X106 H69 cells were treated with 1 µM camptothecin in the presence or absence of 10 µM
capsaicin and then implanted on the chorioallantoic membrane of a fertilized chicken egg. The
H69 cells formed tumors on the chicken CAM. The chicken CAM was incubated at 37°C for
seven days, and then the tumors were excised and weighed. Figure 15A shows that the
combination of 10 µM capsaicin and 1 µM camptothecin displayed significantly greater antitumor activity than either of these agents alone (p£0.05). An aliquot of these tumors was snap
frozen in liquid nitrogen and lysates were made. Four independent sets of lysates were made for
every treatment. Caspase-3 activity apoptosis assays showed that the tumors treated with 10 µM
capsaicin and 1 µM camptothecin showed significantly greater apoptosis than 10 µM capsaicin
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alone or 1 µM camptothecin alone (p£0.05; Figure 15B). Each sample was measured in duplicate
and the entire experiment was repeated three independent times.

Figure 15. The combination of 1 µM camptothecin and 10 µM capsaicin inhibited the
growth of human SCLC tumors in vivo in chicken chorioallantoic membrane (CAM) model
The tumor weights in the control group were taken as 100, and the tumor volumes in the rest of
the samples were calculated as percentage of control. (A) Chicken CAM assays showed that the
treatment of 10 µM capsaicin (as a single agent) did not significantly suppress the growth of H69
tumors xenotransplanted on chicken CAM (tumor weights = 92 ± 18% relative to control;
p£0.05). The treatment of H69 tumors with 1 µM camptothecin caused a decrease in tumor
volumes (tumor volumes = 66 ± 20.6% relative to control). However, the combination of 1 µM
camptothecin and 10 µM capsaicin decreased tumor volumes down to about 36 ± 10% relative to
control. Each group was comprised of eight chicken CAMs. (B) After seven days, the tumors
were excised and snap frozen in liquid nitrogen. Four independent tumor lysates were made for
each sample. Caspase-3 apoptosis assays reveal that the control tumors (1–4) and capsaicintreated tumors (5–8) displayed very little apoptotic activity. Camptothecin-treated H69 tumors
(9–12) induced about 1.5-fold increase in caspase-3 activity. However, the H69 tumors treated
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with both 1 µM camptothecin and 10 µM capsaicin (13–16) displayed robust apoptotic activity
which was significantly higher than any of the drugs as single agents (p£0.05). Each sample was
measured in triplicate and the experiment was performed four independent times. Values
indicated by the same letters are not statistically significantly different (p£0.05).
The synergistic activity of capsaicin and camptothecin was dependent on intracellular
calcium and the calpain pathway
The signal transduction pathways underlying the combinatorial activity of capsaicin and
camptothecin was probed by using specific chemical inhibitors. Multiple convergent studies have
shown that the elevation of intracellular calcium and subsequent activation of the calpain
pathway is important in mediating camptothecin-induced apoptosis in several experimental
systems (Cao, Deng, & May, 2003; Mandic et al., 2002; D. E. Wood & Newcomb, 1999; D. E.
Wood et al., 1998). Similarly, our published data and those of others have also shown a role for
calcium signaling pathway and calpain activation in the apoptotic effects of capsaicin (Lau et al.,
2014; Oh & Lim, 2009). We conjectured that perhaps these two drugs were converging on the
calcium-calpain pathway and the amplification of this signaling network was responsible for the
synergistic apoptotic activity of capsaicin and camptothecin.
Caspase-3 Activity apoptotic assays were used to determine the role of intracellular
calcium in the apoptotic effects of capsaicin and camptothecin over 24 hours. The calcium
chelator BAPTA-AM potently abrogated the apoptotic activity of camptothecin-capsaicin
combination (Figure 16A) in H69 cells (Lau et al., 2014; Oh & Lim, 2009). The experiment was
repeated in H82 cells and similar results were obtained (Figure 16B). The role of the calpain
pathway in the synergistic apoptotic activity of capsaicin and camptothecin was analyzed by the
calpain inhibitor calpeptin. The presence of calpeptin ablated the synergistic apoptotic activity of
capsaicin and camptothecin (in H69 human SCLC cells), as measured by the caspase-3 activity

74

(Figure 16C). The experiment was repeated in a second human SCLC cell line H82, and similar
results were obtained (Figure 16D).

Figure 16. The combinatorial apoptotic activity of 1 µM camptothecin and 10 µM capsaicin
was mediated by intracellular calcium and the calpain pathway
(A) Caspase-3 activity assays indicate that the presence of 10 µM BAPTA-AM abrogated the
combinatorial apoptotic activity of capsaicin and camptothecin in both H69 and H82 (B) human
SCLC cells over 24 hours. (C) Similarly, the treatment of H69 human SCLC cells with 10 µM
calpeptin suppressed the synergistic apoptotic activity of 1 µM camptothecin and 10 µM
capsaicin (as measured by caspase-3 activity assays) in H69 cells. (D) The experiment was
repeated in H82 cells and similar results were obtained in 24 hours. Each sample was measured
in triplicate and the experiment was performed three independent times. Values indicated by the
same letters are not statistically significant (p£0.05).
The results obtained with BAPTA-AM and calpeptin were verified by using a second
apoptosis assay, the Cell Death ELISA Kit. The presence of BAPTA-AM reversed the
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combinatorial apoptotic activity of capsaicin and camptothecin in H69 human SCLC cells in 24
hours (Figure 17A). These experiments were repeated in H82 human SCLC cells and similar
results were obtained (Figure 17B). Similarly, we observed that calpeptin suppressed the
synergistic apoptotic activity of capsaicin and camptothecin in H69 human SCLC cells (Figure
17C), as measured by the Cell Death ELISA Kit. The assay was repeated in the human SCLC
cell line H82, and similar results were obtained (Figure 17D).
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Figure 17. H69 human SCLC cells were treated with 1 µM camptothecin, 10 µM capsaicin
or a combination of 1 µM camptothecin and 10 µM capsaicin in the presence or absence of
10 µM BAPTA-AM for 24 hours
(A) Cell death ELISA assays show that BAPTA-AM reversed the apoptotic activity of the
capsaicin-camptothecin combination in H69 human SCLC cells. (B) The experiment was
repeated in H82 human SCLC cells and analogous results were obtained. (C) The calpain
inhibitor calpeptin suppressed cell death induced by a combination of 1 µM camptothecin and 10
µM capsaicin in H69 cells over 24 hours. (D) The entire experiment was repeated in the H82
variant human SCLC cells and similar results were obtained. Each sample was measured in
duplicate and the experiment was performed three independent times. Values indicated by the
same letters are not statistically significant (p£0.05).
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SCLC cells treated with 10 µM capsaicin and 1 µM camptothecin show increased calpain
activity relative to each of the drugs alone
The role of the calpain pathway in the synergistic apoptotic activity of 10 µM capsaicin
and 1 µM camptothecin was confirmed by the measurement of calpain activity in H69 and H82
cells. Figure 18A shows that the treatment of H69 human SCLC cells with 10 µM capsaicin and
1 µM camptothecin produces a potent increase in calpain activity (over 24 hours), which is
significantly greater than each of these drugs as single agents. The calpain activity (induced by
capsaicin-camptothecin combination) was abrogated by the intracellular calcium chelator
BAPTA-AM (Figure 18A; white bars). The experiment was repeated in the variant human SCLC
cell line and analogous results were obtained (Figure 18B).
We also observed that the combination of 10 µM capsaicin and 1 µM camptothecin
caused a 4–5-fold increase in calpain activity in H69 human SCLC cells in 24 hours, which was
suppressed by the calpain pathway inhibitor calpeptin (Figure 18C; white bars) (Lopatniuk &
Witkowski, 2011). The experiment was repeated in H82 cells and similar results were obtained
(Figure 18D).
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Figure 18. The combination of 1 µM camptothecin and 10 µM capsaicin potently stimulates
calpain activity in human SCLC cells
(A) H69 human SCLC cells treated with 1 µM camptothecin or 10 µM capsaicin or a
combination of both for 24 hours. Cell lysates were made and calpain activity was measured.
The combination of 1 µM camptothecin and 10 µM capsaicin induced greater than 4-fold
increase in calpain activity, which was greater than either drugs used as single agents. The
elevation of calpain activity (in response to the combination of 1 µM camptothecin and 10 µM
capsaicin) was dependent on the calcium pathway, as demonstrated by its abrogation by
BAPTA-AM. (B) The results of these experiments were confirmed using H82 human SCLC
cells. (C) The combination of 1 µM camptothecin and 10 µM capsaicin elevated specifically
calpain activity in H69 cells, and such elevation of calpain activity was blocked by the calpainspecific inhibitor calpeptin over 24 hours. (D) The calpain enzyme assay was repeated in a
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second human SCLC cell line H82 and comparable results were obtained. Each sample was
measured in duplicate and the experiment was performed three independent times (p£0.05).
Finally, we tested whether calpain activity was upregulated in the H69 tumors implanted
on chicken CAM which had been treated with a combination of camptothecin and capsaicin.
Four tumor lysates were analyzed per treatment regimen. Figure 19 shows that the calpain
activity in the H69 tumors treated with 10 µM capsaicin and 1 µM camptothecin is substantially
higher than those treated with 10 µM capsaicin alone and 1 µM camptothecin alone. Our data
suggest that the synergistic apoptotic activity of capsaicin and camptothecin involves elevation
of intracellular calcium which in turn induces enhanced activation of calpain pathway, leading to
cellular apoptosis.

Figure 19. Elevation of calpain activity in H69 tumors treated with a combination of 1 µM
camptothecin and 10 µM capsaicin
Four independent tumor lysates were used for the assay for each sample. Calpain activity assays
show that 10 µM capsaicin-treated tumors (5–8) displayed very little increase of calpain activity
relative to control tumors (1– 4). Camptothecin-treated H69 tumors (9–12) induced modest
elevation increase in calpain activity. However, the H69 tumors treated with both 1 µM
camptothecin and 10 µM capsaicin (13–16) displayed a greater magnitude of increase in calpain
activity, relative of the drugs as single agents (p£0.05). Each sample was measured in duplicate
and the experiment was performed four independent times. Values indicated by the same letters
are not statistically significant (p£0.05).
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DISCUSSION
Camptothecin is primarily an inhibitor of topoisomerase 1. Topoisomerase 1 is an
enzyme which relaxes supercoiled DNA during DNA replication. During DNA replication and
repair, the enzyme topoisomerase 1 creates single strand breaks in the DNA. Camptothecin
forms a tertiary complex with topoisomerase 1 and the cleaved DNA, thereby blocking the
annealing of DNA sister strands (Nagourney, Sommers, Harper, Radecki, & Evans, 2003;
Stewart, 2004). This camptothecin-DNA-Topoisomerase 1 complex causes DNA damage and
eventually leads to cellular apoptosis. Other mechanisms of camptothecin-induced cell death
include cell cycle arrest at the G1 or G2/M phase (depending on the dose of drug used),
generation of reactive oxygen species, causing activation of apoptotic proteases of the calpain
family, and direct induction of cytosolic calcium which triggers apoptotic proteins of the Bcl-2
family, leading to cell death (Gokduman, 2016).
Camptothecin and its related compounds are used for second line therapy for a variety of
cancers including SCLC and is well tolerated (Asai et al., 2014). Patient-oriented studies show
that camptothecin is active against brain metastases in SCLC (Nagourney et al., 2003; Stewart,
2004). The clinic profile of camptothecin, its broad-spectrum anti-tumor activity, and its lack of
cross resistance with other anticancer agents has prompted clinical studies investigating the
feasibility of camptothecin being used in a first-line setting for SCLC patients (Asai et al., 2014;
Gokduman, 2016; Stewart, 2004).
A unique feature of camptothecin is its ability to induce enhanced anticancer activity with
multiple anti-neoplastic compounds (Gokduman, 2016; O'Brien, Eckardt, & Ramlau, 2007). In
many of these studies, the interactions between camptothecin and other cancer chemotherapeutic
drugs was found to be potentially synergistic (Asai et al., 2014; Gokduman, 2016; Stewart,
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2004). Although the combinatorial activity of other anticancer drugs (like cisplatin) has been
investigated with multiple dietary compounds, there are very few such studies involving
camptothecin. This study investigates for the first time the potential combinatorial apoptotic
activity of camptothecin and capsaicin in SCLC. We selected a concentration of capsaicin which
did not induce any cell death in SCLC, and when we combined it with varying concentrations of
camptothecin we found that the two agents synergistically enhance apoptosis within a range of
concentrations. A rare feature of our studies is that we used the Chou-Talalay isobologram
analysis to determine whether the interactions between capsaicin and camptothecin were truly
synergistic (Chou, 2008, 2010). Hormann et al., (2012) showed that the apoptotic efficacy of the
camptothecin analog topotecan was increased in the presence of the flavonoid genistein
(Hormann, Kumi-Diaka, Durity, & Rathinavelu, 2012). However, they did not perform any
statistical analysis to show whether the topotecan-genistein combination was additive or
synergistic. Similarly, several studies have shown that capsaicin increased the therapeutic
efficacy of cisplatin or radiation in stomach and prostate cancer, but rigorous statistical analyses
of the nature of the interaction between the two therapies were absent (Arzuman et al., 2016;
Chou, 2008; Huh et al., 2011; Wiwanitkit, 2012; Zheng et al., 2016).
The present manuscript also shows that the combination of capsaicin and camptothecin
showed increased anti-tumor activity in vivo (compared to the agents administered singly) in
chicken CAM models. Previous studies have shown that human cancer cells implanted on CAM
constitute an established model to study tumor growth in vivo (Canela et al., 2017; Dehelean et
al., 2013; Michaelis et al., 2015). The advantage of the chicken CAM model is that we can take
the optimal concentrations, found in cell culture models, and directly apply them in the in vivo
setting (Kain et al., 2014; Lokman et al., 2012). This is in contrast to athymic mouse models

82

where dosages are translated to mg/kg body weight, and it is difficult to correlate whether the
concentration of the drug in vitro is similar to the dose of the drug in the tumor
microenvironment in vivo (de Jong, Essers, & van Weerden, 2014; M. Liu et al., 2013). Our
previous publications have already shown that the administration of capsaicin does not cause any
gross discomfort in mice (K. C. Brown et al., 2010; Lau et al., 2012; Lau et al., 2014). Our
published reports reveal that capsaicin displays significant bioavailability in the lungs of mice
(Rollyson et al., 2014). Taken together, our data suggest that the combination of camptothecin
and capsaicin has the potential for being a feasible strategy for therapy and management of
human SCLCs.
Several convergent studies have shown that the calpain super-family of calcium-regulated
intracellular cysteine proteases (Ono, Saido, & Sorimachi, 2016; Potz, Abid, & Sellke, 2016) are
involved in the biological activities of camptothecin. Calpains have been shown to mediate
camptothecin-induced apoptosis and play a role in camptothecin-induced DNA damage and drug
resistance (Cao et al., 2003; Mandic et al., 2002; D. E. Wood & Newcomb, 1999; D. E. Wood et
al., 1998). Our published data and those of other research laboratories show that calpains are also
vital regulators of capsaicin-induced apoptosis (Lau et al., 2014; Oh et al., 2008). Therefore, we
conjectured that perhaps an intracellular calcium and calpain pathway was the converging point
for the two drugs. We show that the combination of camptothecin and capsaicin amplifies
cellular calpain activity leading to a large increase in cellular apoptosis.
Although, the results presented in this manuscript are unique and innovative, our study
has a few limitations. One of the limitations of the study is that the synergistic apoptotic activity
of capsaicin and camptothecin has not been investigated in athymic mouse models. It is well
established that several pro-apoptotic and pro-survival proteins are substrates of the calpain
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pathway. These include p53, Bcl-2, Bcl-xl, Bid, Bax, caspase-3, caspase-7, - 8, and -9, caspase12, and NFjB (Lopatniuk & Witkowski, 2011; Moretti, Del Bello, Allavena, & Maellaro, 2014).
Several of these proteins have been shown to be downstream targets of both camptothecin- and
capsaicin-induced apoptosis (Clark & Lee, 2016; Legarza & Yang, 2006). However, we do not
know the precise calpain substrates that are key players in the combinatorial activity of capsaicin
and camptothecin. Finally, we have yet to investigate whether capsaicin and camptothecin
display synergistic apoptotic activity in cisplatin- resistant human SCLC cells. These studies are
currently underway in the laboratory and will form the basis of a future publication.
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ABSTRACT
The nutritional compound capsaicin is the major spicy ingredient of chili peppers.
Although traditionally associated with analgesic activity, recent studies have shown that
capsaicin has profound antineoplastic effects in several types of human cancers. However, the
applications of capsaicin as a clinically viable drug are limited by its unpleasant side effects,
such as gastric irritation, stomach cramps, and burning sensation. This has led to extensive
research focused on the identification and rational design of second-generation capsaicin
analogs, which possess greater bioactivity than capsaicin. A majority of these natural
capsaicinoids and synthetic capsaicin analogs have been studied for their pain-relieving activity.
Only a few of these capsaicin analogs have been investigated for their anticancer activity in cell
culture and animal models. The present review summarizes the current knowledge of the growth-
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inhibitory activity of natural capsaicinoids and synthetic capsaicin analogs. Future studies that
examine the anticancer activity of a greater number of capsaicin analogs represent novel
strategies in the treatment of human cancers.
INTRODUCTION: CAPSAICIN
Capsaicin (trans-8-methyl-N-vanillyl-6-noneamide; Figure 20A) is the principal,
pungent ingredient of chili peppers in the plant genus Capsicum. The compound can be found
predominantly within the white pith and membrane of both cayenne and chili peppers (ChapaOliver & Mejia-Teniente, 2016). It is a potent analgesic and is used topically to treat pain and
inflammation associated with a variety of diseases (Basith et al., 2016; O'Neill et al., 2012). The
analgesic activity of capsaicin is mediated by transient receptor potential subfamily vanilloid
member 1 receptor (TRPV1), which belongs to the transient receptor potential superfamily of
cation-channel receptors (J. Chen et al., 2014). The transient receptor potential vanilloid receptor
family is comprised of six members (TRPV1-6). Capsaicin functions as the classic agonist of the
TRPV1 receptor (Caterina et al., 1997). The binding of TRPV1 to capsaicin trigger a plethora of
molecular events ultimately inducing to depletion of substance P, and desensitization of sensory
neurons leading to its analgesic activity. This paved the way for the isolation, design, and
synthesis of capsaicin-like compounds (which were TRPV1 agonists) that displayed more potent
analgesic activity than capsaicin.
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Figure 20. Structures of natural capsaicinoids
(A) Pharmacophore of capsaicin. The blue structural moiety represents Region A; the red portion
of the structure represents Region B; the green alkyl side chain represents Region C. (B)
Structures of natural capsaicinoids, which have been investigated for their growth-inhibitory
activity in cell culture or animal models.
Emerging evidence shows that capsaicin displays anticancer activity in several human
cancers, both in cell culture and mouse models (for excellent reviews please refer to (Basith et
al., 2016; Chapa-Oliver & Mejia-Teniente, 2016; Clark & Lee, 2016; Diaz-Laviada &
Rodriguez-Henche, 2014; Srinivasan, 2016)). This led researchers to conjecture that natural and
synthetic TRPV1 agonists would display growth-inhibitory effects analogous to capsaicin.
Because a large number of TRPV1 agonists (which had been tested for analgesic activity) had
already been described in literature, they were initially investigated for their anticancer activity.
However, a majority of research studies have shown that the anticancer activity of capsaicin and
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capsaicin analogs is completely independent of TRPV1 receptor. This is true of both natural
capsaicinoids and synthetic capsaicin mimetics (the reader is referred to excellent reviews and
papers (Basith et al., 2016; Chapa-Oliver & Mejia-Teniente, 2016; Clark & Lee, 2016; Ziglioli et
al., 2009). Although these natural synthetic capsaicin mimetics are TRPV1 ligands, their
anticancer activity does not involve the TRPV1 receptor (Lau et al., 2012). The anticancer
activity is mediated through the direct interaction of these compounds with key signaling
molecules of the cytoplasmic, mitochondrial, and metabolic survival pathways (Basith et al.,
2016; Chapa-Oliver & Mejia-Teniente, 2016; Clark & Lee, 2016; Diaz-Laviada & RodriguezHenche, 2014; Srinivasan, 2016). The cellular pathways underlying the anticancer activity of
capsaicin are not fully understood; however, multiple mechanisms such as increase of
intracellular calcium, induction of calpain activity, reactive oxygen species (ROS) generation,
inhibition of coenzyme Q, suppression of mitochondrial respiration, and inhibition of
transcription factors like p53, signal transducer and activator of transcription (STAT) 3, and
nuclear factor κΒ have been involved (for excellent reviews, see (Bode & Dong, 2011; Cho, Lee,
& Choi, 2017; Clark & Lee, 2016; Fernandes, Cerqueira, Soares, & Costa, 2016; Lau et al.,
2012)). In addition to suppressing the growth of human cancer cells, capsaicin promotes the
apoptotic activity of cancer chemotherapy agents by multiple mechanisms (Arzuman et al., 2016;
Clark & Lee, 2016; Friedman et al., 2017; Huh et al., 2011; Vendrely et al., 2017). For example,
capsaicin has been reported to inhibit p-glycoprotein efflux transporters in KB-C2 human
endocervical adenocarcinoma cells. The presence of capsaicin in vinblastine-treated KB-C2 cells
increases the concentration of vinblastine in the cellular microenvironment and thereby sensitizes
these cells to undergo apoptosis (Khan, Maryam, Mehmood, Zhang, & Ma, 2015). The p-
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glycoprotein is a well-characterized transmembrane ATP-binding cassette, multidrug resistance 1
transporter involved in efflux of numerous drugs and other xenobiotics (Silva et al., 2015).
The development of capsaicin as a clinically useful drug for pain relief or cancer therapy
is hindered by its adverse side effects. The topical or oral administration of capsaicin in humans
causes skin redness, hyperalgesia nausea, intense tearing in the eyes, conjunctivitis,
blepharospasm (sustained, forced, involuntary closing of the eyelids), vomiting, abdominal pain,
stomach cramps, bronchospasm, and burning diarrhea (Drewes et al., 2003; Evangelista, 2015;
Hammer, 2006). Clinical trials exploring the pain-relieving activity of capsaicin have shown that
such side effects have results in patients discontinuing use of capsaicin due to its strong
pungency and nociceptive effect (Drewes et al., 2003; Evangelista, 2015; Hammer, 2006). Such
observations have led to research focused on the discovery and design of capsaicin-like
compounds, which display greater anticancer activity than capsaicin with a gentler side effect
profile. Another incentive for the design of capsaicin-based drug candidates is to obtain
compounds endowed with improved pharmacological activity, bioavailability, biologic half-life,
selectivity, specificity, and therapeutic index relative to capsaicin (Lau et al., 2012). The
anticancer activity of capsaicin is covered in several review articles (Chapa-Oliver & MejiaTeniente, 2016; Clark & Lee, 2016; Khan, Bi, Qazi, Fan, & Gao, 2015). However, the anticancer
activity of these natural and synthetic capsaicin-like compounds has yet to be summarized. The
present review fills this void of knowledge and discusses the growth-suppressive activity of
natural and synthetic capsaicin-like compounds in human cancers. Specifically, the growthinhibitory activity of these in both tissue culture and animal models will be discussed. We
believe that this detailed discussion of the anticancer activity of capsaicin analogs is both timely
and relevant, for the potential applications of such compounds in cancer therapy.

90

STRUCTURE ACTIVITY RELATIONSHIP OF CAPSAICIN
The potential clinical application of capsaicin is restricted by its unfavorable side effect
profile. Clinical studies investigating the analgesic activity of capsaicin have shown that oral
capsaicin administration in humans leads to intense abdominal pain, hyperalgesia, stomach
cramps and nausea (Basith et al., 2016; O'Neill et al., 2012). These adverse side effects have
caused patients to abandon taking capsaicin. This has led to intense research involving capsaicin
structure activity relationship studies to isolate or develop new, less irritating analogs (Drewes et
al., 2003; Evangelista, 2015; Hammer, 2006). A second driving force behind the identification
and synthesis of capsaicin analogs is that of novel drug discovery that aims to generate new
capsaicin mimetics with better pharmacological and therapeutic profile than the parent molecule.
The structure of capsaicin can be broken down into three major areas, which are depicted in
Figure 20A. The three major regions are as follows: aromatic (Region A), amide (Region B), and
the hydrophobic (Region C) (Basith et al., 2016; Chapa-Oliver & Mejia-Teniente, 2016; Clark &
Lee, 2016; Diaz-Laviada & Rodriguez-Henche, 2014; X. F. Huang et al., 2013; Srinivasan,
2016).
ANTINEOPLASTIC ACTIVITY OF NATURAL CAPSAICIN ANALOGS
Capsiates
Data from several independent research laboratories have led to the discovery of natural
capsaicin-like compounds that resemble the structure of capsaicin but contain variations in
Regions A (aromatic), B (amide), or C (hydrophobic). There are few published reports about
natural capsaicin-like compounds (capsaicinoids) that have alterations in Region A (Gavaraskar,
Dhulap, & Hirwani, 2015; Ogasawara, Matsunaga, Takahashi, Saiki, & Suzuki, 2002). However,
several capsaicinoids having variations in Region B have been reported to suppress the growth of
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human cancer cells in cell culture. The non-pungent capsaicinoid, capsiate (Figure 20B3), is
isolated from a strain of peppers called CH-19 Sweet. Apart from capsiate, CH-19 Sweet is also
the source for two additional capsiate-like compounds, namely dihydrocapsiate and
nordihydrocapsiate (Figure 20B4 and B5) (Macho et al., 2003; Watanabe, Ohnuki, & Kobata,
2011). These three compounds differ from capsaicin in Region B; dihydrocapsiate and
nordihydrocapsiate contain an ester bond instead of an amide bond between the vanillyl motif
and the fatty acid side chain. Dihydrocapsiate and nordihydrocapsiate also differ in Region C
relative to capsaicin. Dihydrocapsiate and nordihydrocapsiate have only saturated bonds in the
alkyl chain of Region C instead of a single double bond observed in capsaicin. Macho et al.,
(2003) studied the antiapoptotic activity of capsiate, dihydrocapsiate, and nordihydrocapsiate in
Jurkat human acute T-cell leukemia cells. They observed that all three compounds induced
apoptosis in a concentration-dependent manner when incubated with Jurkat cells.
Several convergent studies have indicated that capsaicin may also function as a tumor
promotor in skin cancer, breast cancer, and colon cancer (Bode & Dong, 2011). In contrast, all
capsaicin-like compounds (natural capsaicinoids or synthetic capsaicin mimetics) have shown
only growth-inhibitory activity toward numerous cell lines (Basith et al., 2016).
Nordihydrocapsiate further showed potent chemopreventive activity in an in vivo two-stage
model of mouse skin carcinogenesis. These findings would suggest that, in this experimental
model and with application of a promotor, nordihydrocapsiate may provide protection against
skin cancer (Macho et al., 2003). The mechanism of action of these capsiates was similar to
capsaicin and was mediated by inhibition of transcription factor nuclear factor kB, elevation of
reactive oxygen species, and loss of mitochondrial membrane potential (Figure 21A) (Macho et
al., 2003; Watanabe et al., 2011). Most interestingly, nordihydrocapsiate showed better
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proapoptotic activity than capsaicin in Jurkat cells, as reflected by the IC50 values
(nordihydrocapsiate, IC50=75 mM; capsaicin, IC50=125 mM) (Macho et al., 2003). Both capsiate
and dihydrocapsiate displayed antiangiogenic activity in cell culture and mouse models (Figure
21A). These compounds suppressed vascular endothelial growth factor–induced angiogenesis in
human umbilical cord endothelial cells via direct suppression of Src kinase activity and
phosphorylation of its downstream substrates, such as p125FAK and vascular endothelial
cadherin. Most interestingly, capsiate and nordihydrocapsiate do not affect autophosphorylation
of the vascular endothelial growth factor receptor kinase insert domain/fetal liver kinase (Min et
al., 2004; Pyun et al., 2008). The antiangiogenic activities of the two compounds were
comparable to each other and to capsaicin. Such non-pungent capsaicinoids (capsiate and its
related compounds) may be more applicable in cancer therapy than capsaicin.

Figure 21. Signaling pathways underlying the anticancer activity of natural capsaicinoids
(A) Capsiate and dihydrocapsiate. (B) Evodiamine and Rutaecarpine.
Evodiamine and Rutaecarpine
Evodiamine (EVO; Figure 20B6) and rutaecarpine (RUT; Figure 20B7) are alkaloids
isolated from the fruit of the Chinese medical plant Evodia rutaecapra, otherwise known as
Evodia fruit (Wu, Chien, Chen, & Chiu, 2016; Wu, Chien, Liu, Chen, & Chiu, 2017; Yu, Jin,
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Gong, Wang, & Liang, 2013). Capsaicin and EVO share pharmacophore elements, but their
lipophilic moiety (Region C) is different, encompassing a saturated isononenyl unsaturated group
in capsaicin, and two phenyl rings in evodiamine (De Petrocellis et al., 2014; Pearce et al., 2004;
S. Wang et al., 2015; T. Wang, Wang, & Yamashita, 2009). Wang et al., (2012, 2015) have
performed docking and molecular modeling on the pharmacophore of EVO and capsaicin and
observed a remarkable similarity between the pharmacophore of the two compounds (S. Wang et
al., 2015; Z. Wang et al., 2012). EVO has been characterized as a potent, selective agonist of the
TRPV1 receptor, similar to capsaicin (Ivanova & Spiteller, 2014; S. Wang et al., 2016). Cell
culture studies show that EVO displays growth-inhibitory activity in human breast cancer,
prostate cancer, leukemia, urothelial cell carcinoma, gastric cancer, osteosarcoma, oral cancer,
non-small lung cancer, colon cancer, glioma, glioblastoma, thyroid cancer, melanoma, and
cervical cancer cells (M. C. Chen et al., 2010; Du et al., 2013; Fang et al., 2014; Gavaraskar et
al., 2015; Hu et al., 2016; J. Huang et al., 2015; Kan et al., 2007; Khan, Bi, et al., 2015; T. J. Lee
et al., 2006; Sachita, Kim, Yu, Cho, & Lee, 2015; Shen et al., 2015; C. S. Shi et al., 2017; Wu et
al., 2017; F. Yang et al., 2017). However, EVO has been shown to be an antagonist of the aryl
hydrocarbon receptor as well (Yu et al., 2010). The growth-suppressive activity of EVO is
mediated by cell cycle arrest, apoptosis, and autophagy, which involve a symphony of
mechanisms (Figure 21B), including downregulation of survivin, Akt, STAT3, Mcl-1, B-cell
lymphoma-2 (Bcl-2) and cdc-p15, and upregulation of caspase-3, phosphatase and tensin
homolog, Bcl-2 associated killer, Bax, Fas ligand, microRNA-429, matrix metalloproteinase-9,
Jun kinase, cyclin B1, cdc25c, and cdc2-p161 (T. C. Chen, Chien, Wu, & Chen, 2016; Fan et al.,
2017; Fang et al., 2014; Han et al., 2016; J. Huang et al., 2015; Khan, Bi, et al., 2015; T. J. Lee et
al., 2006; Y. L. Li et al., 2016; Liu, Huang, Wu, & Wen, 2016; Meng et al., 2015; Peng et al.,
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2015; L. Wei, Jin, Cao, & Li, 2016; Wu et al., 2017; F. Yang et al., 2017; Zhu et al., 2011; Zou
et al., 2015). EVO-induced autophagy in human glioblastoma cells is mediated by Jun kinase,
Bcl-2, and elevation of Bax, intracellular calcium, and induction of ROS/nitric oxide (A. J. Liu,
S. H. Wang, K. C. Chen, et al., 2013; A. J. Liu, S. H. Wang, S. Y. Hou, et al., 2013). The
antitumor activity of EVO has been explored in athymic mouse models of human hepatocellular
carcinoma, colon cancer, and renal carcinoma (Wu et al., 2016; J. Yang et al., 2013; C. Zhang et
al., 2010). The anticancer activity of EVO in hepatocellular cancer (Figure 21B) may be
attributed to its ability to suppress β-catenin–mediated angiogenesis (L. Shi et al., 2016). In
contrast, EVO suppressed the growth of human renal carcinoma cells in vivo by inducing
phosphorylation of Bcl-2 (Wu et al., 2016). In addition, EVO targeted breast cancer stem-like
cells by activating p53 and p21 expression (Han et al., 2016). In gastric cancer stem cells, EVO
inhibited proliferation via inhibition of the Wingless/β-catenin pathway (Wen et al., 2015).
EVO has been shown to induce apoptosis in drug-resistant human cancer cells. EVO
displays antiproliferative activity in camptothecin-resistant human leukemia cells (Pan et al.,
2012).The mechanism of EVO-induced G2/M arrest involves the inhibition of topoisomerase 1
and 2 (Y. C. Lee et al., 2015). Similarly, EVO induces cell cycle arrest in Taxol-resistant ovarian
cancer cells and in Adriamycin-resistant human breast cancer cells (Liao et al., 2005; Zhong,
Tan, Wang, Qiang, & Wang, 2015). EVO triggers apoptosis in human colon cancer cells
resistant to oxaliplatin and cisplatin (Ogasawara, Matsubara, & Suzuki, 2001; Wen et al., 2015).
EVO sensitizes human cancer cells to the apoptotic effects of chemotherapeutic agents. EVO
synergizes with doxorubicin and gemcitabine to produce increased apoptosis in breast cancer and
pancreatic cancer cells, respectively (S. Wang et al., 2014; W. T. Wei et al., 2012). Likewise,
EVO enhances the efficacy of erlotinib in human lung cancer and in human ovarian cancers (Y.
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L. Li et al., 2016). Moreover, EVO sensitizes U87MG human glioblastoma cells to the
proapoptotic effects of tumor necrosis factor–related apoptosis-inducing ligand. Hu et al., (2016)
observed that EVO sensitizes human gastric cancer cells to the growth-suppressive effects of
radiotherapy in vitro and in vivo (Hu et al., 2016). In addition to promoting apoptosis in various
cancer cells, EVO alters the ATP-binding cassette subfamily G member 2 breast cancer–resistant
protein transporter to increase chemosensitivity of colorectal cancer cells. EVO was not a
substrate inhibitor of ABCG2, as EVO diminished ABCG2 protein expression in HCT-116/LOHP cells, which increased cancer chemosensitivity to cisplatin (Sui et al., 2016). Additional
studies are needed to explore whether EVO can modify ABCG2 protein expression in other
cancer cells.
EVO displays antimigratory, anti-invasive, and anti-metastatic activity in human lung
cancer, breast cancer, and nasopharyngeal cancer cells in vitro and in mouse models. EVO exerts
anti-metastatic activity by multiple mechanisms, such as regulation of matrix metalloproteinase3 activity, p38 kinase activity, extracellular signal-regulated kinase activity, and Janus
kinase/STAT pathway, and downregulation of phosphoglucose isomerase (Du et al., 2013; Peng
et al., 2015; Zhao et al., 2015).
RUT is the second major alkaloid isolated from E. rutaecapra. It is a potent agonist of
TRPV1 (Ivanova & Spiteller, 2014). RUT displayed antiproliferative activity in threedimensional spheroid models of human breast cancer cells (Guo et al., 2016). The antineoplastic
activity of EVO and RUT has led to intense research involving design and synthesis of secondgeneration EVO-like or RUT-like analogs with improved anticancer activity (Figure 21B). The
reader is referred to some excellent reviews on this subject (Y. H. Hong et al., 2010; Li-Weber,
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2013; Song et al., 2013; Yu et al., 2013). Further studies are needed to investigate whether
TRPV1 signaling pathway plays a role in the anticancer activity of EVO and Rut.
Resiniferatoxin
The capsaicin analog resiniferatoxin (RTX; Figure 20B8) is a tricyclic diterpene isolated
from the latex of the cactus plant Euphorbia resinifera (Iadarola & Gonnella, 2013). RTX is one
of the most potent TRPV1 agonists ever described in literature (D. C. Brown, 2016). As can be
seen in the figure above, the structure of capsaicin and RTX closely resembles each other, except
that Region C is a diterpene moiety of the daphnane class (Carnevale & Rohacs, 2016).
Furthermore, pharmacophore clustering and docking studies reveal a close similarity between the
two compounds (Athanasiou et al., 2007; Carnevale & Rohacs, 2016; Elokely et al., 2016; Hartel
et al., 2006; Y. H. Lee, Im, Kim, & Lee, 2016). Based on previous studies, four sites represent
the pharmacophore of RTX, as follows: 1) 4-hydroxy-3-methoxyphenyl, 2) C20 ester, 3) C3keto, and 4) orthophenyl groups (X. F. Huang et al., 2013). The growth-inhibitory activity of
RTX has been investigated in multiple human cancer cells. Of these, RTX caused robust
apoptosis in human bladder cancer cell lines (T24, 5637) and in athymic mouse models
xenografted with T24 bladder cancer cells (Farfariello et al., 2014). However, it did not trigger
cell death in normal human urothelial cells. This observation is interesting because RTX
selectively targeted human bladder cancer cells, but not the normal urothelial cells.
RTX mimics capsaicin-producing selective apoptosis for human cancer cells while
sparing the normal cells (Lau et al., 2014). However, RTX differs by inducing prolonged cell
cycle arrest (within G0 phase) in IEC-18 rat ileal epithelial cells. Such differences can be
explained by the fact that the IEC-18 is an immature epithelial cell line derived from rat
intestinal crypt, and therefore its growth characteristics cannot be compared with normal primary
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adult epithelial cells (Frey et al., 2004). Additionally, species-specific differences between rat
and human cell lines may explain the varying response of RTX between IEC-18 and normal
urothelial cells. In agreement with other studies, the growth-suppressive effects of RTX were
found to be independent of TRPV1 receptor and involved a decrease of cyclin D1 at mRNA and
protein levels (Frey et al., 2004). The compound resiniferanol-9, 13, 14 ortho-phenylacetate
(ROPA) is a hydrolysis product of RTX (Figure 20B9). Frey et al., (2004) investigated the
growth-inhibitory activity of ROPA on IEC-18 cells (Frey et al., 2004). ROPA was found to
induce a transient protein kinase C–dependent cell cycle arrest in G1 phase. The cell cycle–
inhibitory effects of ROPA were accompanied by a decrease in cyclin D1 levels and
simultaneous upregulation of p21 expression (Figure 22A) (Frey et al., 2004). In contrast, RTX
did not have any effect on p21 levels in IEC-18 cells. A remarkable observation was that the
growth- inhibitory activity of ROPA as well was found to be independent of the TRPV1 receptor
family (Frey et al., 2004). The apoptotic activity of RTX was mediated by diverse mechanisms
(Figure 22A) such as mitochondrial depolarization, generation of reactive oxygen species,
suppression of mitochondrial respiration, blockage of protein kinase C, inhibition of cyclin D1,
and induction of p21waf1/Cip1 (Athanasiou et al., 2007; Farfariello et al., 2014; Hartel et al., 2006;
Vercelli et al., 2014; Ziglioli et al., 2009).
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Figure 22. Signal transduction pathways mediating the antitumor activity of natural
capsaicinoids
(A) RTX and ROPA. (B) DHC.
Dihydrocapsaicin
The capsaicin analog dihydrocapsaicin (DHC) differs from capsaicin in the hydrophobic
Region C. It contains a saturated bond between C6 and C7 carbon atoms of Region C (Figure
20B2). DHC is less pungent than capsaicin based on the Scoville heat unites. The anticancer
activity of DHC has been observed in several human cancer cell lines, including human breast
cancer cells, colon cancer cells, and gliomas (Oh et al., 2008; Oh & Lim, 2009). A majority of
these studies have been done in cell culture. An intriguing observation was that DHC showed
greater growth-inhibitory activity than capsaicin in these cell lines. The growth-inhibitory effects
of DHC (Figure 22B) were mediated via cell cycle arrest, apoptosis, and autophagy inhibition of
cellular metabolism (Halme et al., 2016; Oh et al., 2008). The antitumor activity of DHC was
observed in athymic mouse models of human gliomas as well (Xie et al., 2016). However, the
drawback with DHC is that it has pungent and irritant properties like capsaicin (Schneider, SeußBaum, & Schlich, 2014).
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ANTINEOPLASTIC ACTIVITY OF SYNTHETIC CAPSAICIN ANALOGS
N-Acylvanillamides
Among all synthetic analogs of capsaicin, the N-acylvanillamides (N-AVAMs) are of the
most extensively researched for their analgesic activity (X. F. Huang et al., 2013; Kobata et al.,
2010; Melck et al., 1999). There are numerous studies that have investigated their anticancer
activities in diverse human cancer cell lines (Sanchez-Sanchez et al., 2015; Sancho et al., 2003;
Stock et al., 2012). This class of compounds is modified in the hydrophobic Region C of
capsaicin (Figure 23). Early studies experimented with substituting the acyl side chain with
saturated long-chain lipophilic groups. However, these compounds were inactive (Melck et al.,
1999). The introduction of long-chain unsaturated fatty acids fully restored the analgesic activity
of these compounds. The N-AVAMs are non-pungent and do not have the unfavorable side
effects of capsaicin. Structure activity studies experimented with the magnitude of unsaturation
in these side chain and the length of the side chain to yield capsaicin analogs with improved
analgesic activity and binding profile to TRPV1 (X. F. Huang et al., 2013). Recent studies
examined the growth-inhibitory activity of these unsaturated N-AVAMs (UN-AVAMs). Tuoya
et al., (2006) demonstrated that the UN-AVAM dohevanil (Figure 23A) induced a greater
magnitude apoptosis in MCF-7 human breast cancer cells than capsaicin in vitro (Tuoya et al.,
2006). Appendino et al., (2005) synthesized a panel of UN-AVAM compounds with varying
affinity for human TRPV1 receptor (Appendino et al., 2005; Appendino, Minassi, Morello, De
Petrocellis, & Di Marzo, 2002). Of these compounds, several studies have investigated the
growth-inhibitory activity of olvanil (Figure 23B), rinvanil (Figure 23C), and
phenylacetylrinvanil (PhAR; Figure 23D). The 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assays showed that olvanil decreased the viability of C6 rat
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glioma cells and EFM-19 breast cancer cells (Figure 24) (X. F. Huang et al., 2013; Melck et al.,
1999). Apart from being a potent TRPV1 agonist, these compounds displayed weak binding and
activation of cannabinoid receptor 1 (CB1) and competitively inhibited the anandamide
membrane transporter. Luviano et al., (2014) studied the growth-inhibitory activity of rinvanil
and PhAR in J774, P388, and WEHI-3 mouse leukemic cell lines (Figure 24). PhAR showed
improved growth-inhibitory activity relative to rinvanil and capsaicin in all of the cell lines
studied (Luviano et al., 2014). Additionally, PhAR displayed some selectivity for leukemic cell
lines relative to normal mouse bone marrow cells (Luviano et al., 2014). However, contradictory
findings were found later by Sánchez-Sánchez et al., (2015), who analyzed the antiproliferative
and cytotoxic activity in a panel of human cervical cancer cell lines, namely HeLa, CaSki, and
ViBo. The growth-inhibitory activity of these compounds varied from cell line to cell line and
did not correlate with their binding profile to human TRPV1 receptor (Sanchez-Sanchez et al.,
2015). The researchers also observed that rinvanil showed selective growth-inhibitory effects on
the cervical cancer cells relative to normal lymphocytes, whereas PhAR showed no selectivity
between normal and tumor cells (Sanchez-Sanchez et al., 2015). Such variance in results may be
attributed to the nature of the cancer, species-specific differences (human cell lines versus mouse
cell lines) and the disparity in the methodology used in the two studies. Whereas the studies
performed by Luviano et al., (2014) studied the growth- inhibitory effects of PhAR and rinvanil
by the Sulforhodamine B assay, Sánchez-Sánchez et al., (2015) used the lactate dehydrogenase
assay to evaluate the effect of PhAR and rinvanil on normal lymphocytes (Luviano et al., 2014;
Sanchez-Sanchez et al., 2015).

101

Figure 23. A panel of UN-AVAMs that have been investigated for their growth-suppressive
activity in cell culture or mice models
(A) Dohevanil. The first number in the rectangular brackets indicates the chain length and the
number after the colon indicates the number of double bonds. For example: [C22:6] written next
to dohevanil means dohevanil has a chain length of 22 carbon atoms and 6 double bonds in this
alkyl side chain. (B) Olvanil [C18:1]. (C) Rinvanil [C18:1]. (D) Phenylacetylrinvanil [C18:1].
(E) Arvanil [C20:4].
Di Marzo et al., (2002) developed arvanil, an extremely powerful TRPV1 agonist (Figure
23E). Arvanil is a very potent agonist of the TRPV1 and CB1 receptor (Di Marzo et al., 2002). It
also induces robust inhibition of anandamide membrane transporter and fatty acid amide
hydroxylase (De Petrocellis, Bisogno, Davis, Pertwee, & Di Marzo, 2000; Di Marzo et al., 2002;
Glaser et al., 2003; Melck et al., 1999). Experiments in cell culture systems showed that arvanil
suppressed the growth of C6 mouse glioma cells, Jurkat human T-cell leukemia cells, human
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breast cancer cells (MCF-7, T-47D, and EFM-19 cell lines), and prostate cancer cells (DU145,
PPC-1, and TSU cell lines; Figure 24) (De Lago et al., 2006; Di Marzo, Melck, De Petrocellis, &
Bisogno, 2000; W. Li & MooreII, 2014; Melck et al., 1999; Sancho et al., 2003). A majority of
these studies showed that the growth-suppressive activity of arvanil was independent of TRPV1
and CB1 receptor (Melck et al., 1999). Stock et al., (2012) investigated the antineoplastic activity
of arvanil in HG-astrocytoma cells organotypically grown in mouse brain slices (Figure 24).
Arvanil suppressed the growth of HG-astrocytoma at a relatively low concentration of 50 nM
(Stock et al., 2012). Subsequently, Stock et al., (2012) confirmed the antineoplastic activity of
arvanil in HG-astrocytoma tumors implanted in immunocompromised severe combined
immunodeficiency mice. They observed that arvanil suppressed the tumor growth rate of HG
astrocytomas better than temozolomide (the standard of care for astrocytoma patients). The
survival time of mice administered with arvanil was greater than vehicle-treated mice (Stock et
al., 2012). This study administered a combination of arvanil and temozolomide, which showed
an increase in survival times compared with either agent administered alone or mice
administered with vehicle only (Stock et al., 2012). Stock et al., (2012) observed that the
anticancer activity of arvanil in human astrocytomas was dependent on the TRPV1 receptor only
(Stock et al., 2012). These results are divergent from those found in human breast and prostate
cancer cells (Melck et al., 1999). Such different observations may be due to differences in the
cell biology of neuronal and non-neuronal human cancer cells. Small cell lung cancer is a
neuroendocrine tumor characterized by rapid doubling time, aggressive clinical course, and a
dismal 5-year survival rate. The N-AVAMs arvanil and olvanil suppressed the invasion of
human small cell lung cancer cell lines via the 5’ AMP-activated protein kinase pathway (Hurley
et al., 2017).

103

RPF, Epoxide-Based Analogs
de-Sa-Junior et al., (2013) synthesized a capsaicin mimetic called RPF101 (Figure 25A).
The structure of RPF101 differs from capsaicin, primarily in Region B, where the amide group
has been replaced by a bioisosteric sulfonamide (de-Sa-Junior et al., 2013). The alkyl side chain
in Region C was replaced with a benzene moiety. The antiproliferative and apoptotic activity of
RPF101 in MCF-7 human breast cancer was greater than capsaicin. RPF101 caused cell
shrinkage and pyknosis (Figure 24) in three-dimensional spheroid cultures of MCF-7 cells (deSa-Junior et al., 2013). RPF101 caused a disruption of mitochondrial membrane potential,
dysregulation of microtubule formation, and mitotic catastrophe to induce cell cycle arrest and
apoptosis in human breast cancer cells (Figure 24) (de-Sa-Junior et al., 2013). The research
group further modified RPF101 to produce an analog RPF151 (Figure 25B) with better stability
and aqueous solubility properties (Ferreira et al., 2015). In addition, RPF151 displayed lower
hyperalgesia relative to capsaicin. MTT assays showed that RPF151 decreased cell viability
better than capsaicin in MDA-MB-231 human breast cancer cells. However, RPF151 did not
differentiate between MCF-10A normal human breast epithelial cells and breast cancer cells
(Ferreira et al., 2015). The mechanism of action of RPF151 was divergent from RPF101.
RPF151 induced cell cycle arrest at S-phase with concomitant decrease in cyclin A, D1, and D3
(Figure 24). RPF151 also induced apoptosis in MDA-MB-231 cells via downregulation of p21,
reduction of mitochondrial membrane potential, and activation of the tumor necrosis factor–
related apoptosis-inducing ligand pathway (Ferreira et al., 2015). The antineoplastic activity of
RPF151 was analyzed by nude mice model of human breast cancer, where it showed higher
antitumor activity than capsaicin. Most remarkably, the growth-suppressive activity of RPF151
is independent of the TRPV1 receptor.
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Figure 24. Signaling pathways underlying the antiproliferative and proapoptotic activity of
synthetic capsaicin analogs
Lewinska et al., (2015) synthesized a constrained capsaicin analog that contained an
epoxide motif in Region C of the capsaicin (Figure 25C). The growth-suppressive activity of
capsaicin epoxide (CE) compared with capsaicin was studied in a diverse array of cell lines using
the MTT assay (Lewinska, Chochrek, Smolag, Rawska, & Wnuk, 2015). Both capsaicin and CE
did not reduce the viability of human dermal fibroblasts. However, CE decreased the viability of
NIH/3T3 murine embryonic fibroblasts better than capsaicin (Lewinska, Chochrek, et al., 2015).
The varying results in this study could be due to species and lineage differences between human
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dermal fibroblasts and the NIH/3T3 cells. Similarly, the growth-inhibitory activity of CE was
found to be better than capsaicin in prostate cancer, breast cancer, cervical cancer, and renal
cancer cell lines. The human breast cancer cell line MCF-7 was found to be most responsive to
CE-induced cell death (Lewinska, Chochrek, et al., 2015). CE was shown to trigger robust
apoptosis in these cell lines by inducing oxidative stress (Figure 24).

Figure 25. Capsaicin analogs containing a sulfonamide and epoxide motif in their structure
trigger apoptosis in human cancer cells
(A) RPF101. (B) RPF151. (C) Capsaicin epoxide.
Miscellaneous Capsaicin Analogs.
ƒe TRPV1 antagonist capsazepine (Figure 26A) displayed potent antitumor activity in
human prostate cancer and osteosarcoma cells (J. K. Huang et al., 2006; J. H. Lee et al., 2017;
Teng et al., 2004). Gonzales et al., (2014) showed that capsazepine suppressed the growth of
human oral squamous cell carcinoma in cell culture and xenograft models in athymic mice
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(Gonzales et al., 2014). The apoptotic activity of capsaicin was found to be independent of
TRPV1 (J. K. Huang et al., 2006). The apoptotic activity of capsazepine was induced by
endoplasmic reticulum stress, increase of ROS, followed by increase of intracellular calcium in a
phospholipase C–independent pathway (Figure 27). Capsazepine was also found to be an
inhibitor of Janus kinase/STAT3 signaling in prostate cancer cells (J. K. Huang et al., 2006).
Capsazepine also sensitized A549 lung cancer cells to radiation therapy (Nishino et al., 2016).
Thomas et al., (2007, 2011, 2012) synthesized the capsaicin analog nonivamide (Figure 26B),
which decreased the viability of the immortalized human lung epithelial cell line BEAS-2B
overexpressing TRPV1 (referred in this work as TRPV1-OE cells) (Thomas et al., 2011; Thomas
et al., 2012; Thomas et al., 2007). Nonivamide and its analog N-(3-4
dihydroxybenzyl)nonivamide (Figure 26C) displayed potent growth-suppressive activity in
TRPV1-OE cells, and this process was mediated by the ROS oxidative stress pathway (Thomas
et al., 2007). Damiao et al., (2014) synthesized a variety of capsaicin analogs (Figure 26 C–E)
and tested for their cytotoxicity in B16F10 (mouse melanoma), SK-MEL-28 (human melanoma),
NCI-H1299, NCI-H460 (human lung cancer), SK-BR-3, and MDA-MB-231 (human breast
cancer) cell lines (Damiao et al., 2014). The capsaicin analog N-(benzo[d] [1,3]dioxol-5ylmethyl)-4-methoxybenzamide (Figure 26D) decreased the viability of human NCI-H1299 cells
and mouse melanoma cells, comparable to capsaicin. Benzo[d][1,3]dioxol-5-ylmethyl
hexanonate (Figure 26E) showed greater growth-inhibitory activity in SK-MEL-28 cells than
capsaicin (Damiao et al., 2014), whereas its growth-suppressive effects are similar to capsaicin in
mouse melanoma cells. Furthermore, the authors performed exploratory data analysis and
molecular modeling on these both, N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-methoxybenzamide
and benzo[d][1,3]dioxol-5-ylmethyl hexanonate. These in silico experiments suggested that aryl
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amides, esters, and alkyl esters may be promising scaffolds to develop capsaicin mimetics with
improved anticancer activity (Damiao et al., 2014). The compound MRS1477 (Figure 26F), a
positive allosteric modulator of TRPV1, was found to be very robust in inducing apoptosis in
human breast cancer cells in vitro and in athymic mouse model (Naziroglu et al., 2017). The
growth-inhibitory effects of MRS1477 were observed at five-fold lower concentration relative to
capsaicin. The proapoptotic activity of MRS1477 was mediated by the TRPV1 receptor
(Naziroglu et al., 2017).

Figure 26. Miscellaneous capsaicin analogs that display growth-inhibitory activity in
human and mouse cancer cell lines
(A) Capsazepine, a TRPV1 antagonist. (B) Nonivamide. (C) N-(3-4
dihydroxybenzyl)nonivamide. (D) N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-methoxybenzamide
(N-BMB). (E) Benzo[d][1,3]dioxol-5yl-methyl hexanonate (BMH).
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Figure 27. Molecular mechanisms underlying the apoptotic activity of capsazepine and
nonivamide
CONCLUSIONS AND FUTURE DIRECTIONS
The nutritional compound capsaicin has shown potent anticancer activity in multiple
human cancers. However, the therapeutic potential of capsaicin has been limited by its
unpleasant side effects. This has led to intense research focused on the discovery and design of
natural and synthetic capsaicin-like compounds. A variety of natural capsaicinoids has been
isolated from peppers and other natural sources. Similarly, synthetic capsaicin analogs have been
designed by manipulating the pharmacophore of capsaicin. Another aim of the rational design of
capsaicin analogs has been to find compounds that will display better bioactivity and greater
therapeutic index. A promising class of synthetic non-pungent capsaicin mimetics are long-chain
unsaturated N-AVAMs. An exciting development in the field of capsaicin analogs has been the
synthesis of allosteric TRPV1 modulators for cancer therapy. However, a majority of these
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capsaicin mimetics have been tested for their analgesic activity and not their anticancer activity.
The growth-inhibitory activity of some capsaicin analogs has been predominantly analyzed in
cell culture and not in animal models. Such data underline the importance of examining the
antineoplastic of different types of synthetic capsaicin mimetics in athymic mouse and patientderived xenograft models. Capsaicin, capsiate, and EVO have been shown to display potent
antiangiogenic activity in both cell culture and mouse models. In contrast, there are no reports of
the antiangiogenic activity of other natural and synthetic capsaicin analogs. Another promising
area of research is the combinatorial anticancer activity of these capsaicin analogs with
conventional chemotherapy or radiation. The development of non-pungent second-generation
capsaicin mimetics with anticancer and antiangiogenic activity will pave the way for novel
treatment regimens in human cancers.
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CHAPTER 5: ANTI-CANCER ACTIVITY OF SYNTHETIC CAPSAICINOIDS IN
SMALL CELL LUNG CANCER
INTRODUCTION
Small cell lung cancer (SCLC) represents 15-20% of all lung cancer cases. SCLC is
characterized as being aggressive showing rapid growth and quick dissemination (Bunn et al.,
2016; Herbst, Heymach, & Lippman, 2008; Kalemkerian et al., 2013). Frequently, patients are
already in the extensive stage of disease at diagnosis, with the five-year survival rate being
almost non-existent. One of the major obstacles with SCLC treatment is its pervasiveness for
developing resistance to first line platinum-based chemotherapeutic options (Alvarado-Luna &
Morales-Espinosa, 2016; S. L. Wood et al., 2015). After resistance has developed, patients have
limited options for the next step of their treatment. Chemotherapeutic approaches typically only
extend a patient’s life by 4-8 months, emphasizing both the severity of the disease and the
continued lack of efficacious therapeutic modalities (Bunn et al., 2016; Latimer & Mott, 2015).
The lack of successful treatment options has plagued patients diagnosed with SCLC for decades.
The search for novel compounds or drugs to treat or augment chemotherapy currently used to
treat SCLC is imperative to improving response to therapy and reducing the mortality rates
associated with this disease (Alvarado-Luna & Morales-Espinosa, 2016; Bunn et al., 2016;
Koinis et al., 2016; Polley et al., 2016).
Capsaicin, the major pungent compound in chili peppers, has been studied extensively
for its analgesic properties. Along with being a potent analgesic, it has also been shown to have
anti-cancerous properties in a handful of malignancies such as lung cancer, prostate cancer and
melanoma (Basith et al., 2016; K. C. Brown et al., 2010; Lau et al., 2014; Meral et al., 2014;
Patowary, Pathak, Zaman, Raju, & Chattopadhyay, 2017). Capsaicin is an agonist of the
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transient receptor potential vanilloid (TRPV) family of receptors which can sense heat. This
receptor is why a chili pepper elicits a noxious heat sensation (Chapa-Oliver & Mejia-Teniente,
2016; Chow et al., 2007; Clark & Lee, 2016; Diaz-Laviada & Rodriguez-Henche, 2014;
Friedman et al., 2018; Lau et al., 2014; Shintaku et al., 2012). The clinical application of
capsaicin is hindered by its unpleasant side effect profile related to the heat sensation of
capsaicin (Basith et al., 2016; Patowary et al., 2017). Despite being a proven analgesic,
gastrointestinal burning, diarrhea, and abdominal discomfort are just a few of the many adverse
reactions reported by patients when being treated in clinical trials (Fuhrer et al., 2011; Hammer,
2006). The frequency of patient discontinuation of capsaicin therapy renders many trial
outcomes useless, making the proposal and implementation of capsaicin as a medicinal agent
challenging. One potential solution to this issue is to investigate the use of natural and synthetic
analogs of capsaicin (here after called capsaicinoids), both of which have also been shown to be
potent analgesics with similar anti-cancer effects of capsaicin (Appendino et al., 2002; Di Marzo
et al., 2002; X. F. Huang et al., 2013; Janusz et al., 1993). Due to the structural similarity and the
comparable analgesic activity of many of these capsaicinoids, it is plausible that these
compounds may also maintain similar, if not better, anti-cancer properties (potentially due, in
part, to therapeutic tolerability). In fact, previous studies have shown that non-pungent longchain capsaicinoids prevented invasion of lung cancer cells more effectively than capsaicin,
suggesting that further investigation to evaluate their potential clinical use is warranted (Hurley
et al., 2017).
The studies presented in this chapter evaluate the anti-cancer capabilities and mechanism
of capsaicinoids in SCLC. In order to compare the antineoplastic abilities of capsaicinoids to that
of capsaicin, a variety of assays were performed. We evaluated the cytotoxic potency of a panel
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of synthetic capsaicinoids to induce cell death in three SCLC cell lines first by MTT assay and
then by measuring caspase-3 activity, as well as a cell death ELISA. Following the evaluation of
the anti-cancer properties of multiple capsaicinoids, the most potent capsaicinoid was chosen to
further investigate the anti-cancer mechanisms of action and to compare it to that of capsaicin,
which had been established in previous studies by our laboratory (Lau et al., 2014). The selected
synthetic capsaicinoids evaluated in these studies are considered to be non-pungent, which
means they lack the adverse clinical side effects that are reported for capsaicin. The overall aim
of these studies was to determine if the synthetic capsaicinoids provide an equal, if not better
anti-cancer agent than capsaicin, and to evaluate and compare their mechanisms of action to that
of capsaicin. Identifying non-pungent capsaicinoid compounds with equivalent or greater
potency than capsaicin, in conjunction with understanding their mechanism of cytotoxicity, will
greatly benefit the search for adjuvant therapy options with potential to augment current
standard-of-care chemotherapeutic regimens and improve patient response and survival rates.
METHODS
Reagents
Capsaicin, arvanil, olvanil, BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’tetraacetic acid tetrakis(acetoxymethyl ester), Ruthenium Red (RR), AM-281, and calpeptin were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Livanil and Linvanil were synthesized by
our collaborator Dr. John Rimaldi at the University of Mississippi. All cell culture reagents,
including RPMI-1640, FBS, Trypsin-EDTA, and HEPES, were purchased from American Type
Culture Collection (ATCC; Manassas, VA, USA). Sodium pyruvate, glucose, and penicillinstreptomycin solutions were obtained from Corning (NY, USA). Alveolar Epithelial Cell
Medium was purchased from ScienCell Research Laboratory.
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A. Capsaicin [C9:1]

B. Olvanil [C18:1]

D. Linvanil [C18:3]

C. Livanil [C18:2]

E. Arvanil [C20:4]

Figure 28. The molecular structures of capsaicin, olvanil, livanil, linvanil, and arvanil
The first number following the compound names in the brackets denotes the chain length. The
number following the colon represents the number of double bonds within the chain. For
example: Capsaicin has a 9-carbon chain with one double bond and is designated [C9:1].
Cell culture
Three human SCLC cell lines were utilized: NCI-H69 (H69), NCI-H82 (H82), and DMS
114. H69 is considered a classical representative SCLC cell line, isolated from a 55-year-old
male. H82 is a variant SCLC cell line, isolated from a 40-year-old. Both cell lines were isolated
from men via pleural effusion (Broers et al., 1988; Carney et al., 1985; Gazdar, Carney, Nau, &
Minna, 1985). DMS 114 is a human SCLC cell line isolated from a 68-year-old male and
characterized by Pettengill et al., (1980). Both H69 and H82 are suspension cell lines which
grow in aggregates. DMS 114 is an adherent cell line (Pettengill et al., 1980). All three cell lines
were grown and maintained in RPMI-1650 with 2 mM glutamine, 25 mM HEPES, 1 mM sodium
pyruvate, 4.5 g/L glucose, 100 units/mL penicillin, 100 units/mL streptomycin and 10% fetal
bovine serum (Friedman et al., 2017; Lau et al., 2014). All cell lines were purchased from ATCC
and grown in accordance with their suggestions. They were maintained in an incubator at 37°C
and 5% CO2. These cell lines have been widely utilized in SCLC studies and possess
characteristics similar to human patients (Broers et al., 1988; Carney et al., 1985; Pettengill et al.,
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1980). Human pulmonary alveolar epithelial (HPAEpiC) cells were purchased from ScienCell
Research Laboratory. HPAEpiCs were used to represent “normal” lung cells. They were
maintained in Alveolar Epithelial Cell Medium (basal medium) supplemented with 10% of fetal
bovine serum, 1% epithelial cell growth supplement, and 1% penicillin/streptomycin solution in
accordance with the supplier’s suggestions. They were maintained in an incubator at 37°C and
5% CO2.
Treatment of cultured cells
Cells were grown to 70-80% confluency. Cells were then treated with each compound at
varying concentrations (10 nM, 100 nM, 1 µM, 2.5 µM, 5 µM, 10 µM, 20 µM) for 24 hours with
RPMI-1640 + 1% FBS. Vehicle controls were treated with 0.2% DMSO. When cells were
treated with BAPTA-AM (10 µM), RR (1 µM), or AM-281 (10 µM) the inhibitors were added
45 minutes before the capsaicinoid.
Preparation of lysates
Cell lysates were prepared according to a previously established protocol (Brown et al.,
2010). Cells were harvested, washed 3 times with cold PBS and added to M2 Lysis Buffer (20
mM Tris, pH 7.6, 0.5% IGEPAL CA-630, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 4 µM
DTT, 5 mM PMSF, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 25 µg/ml leupeptin, 5
µg/ml pepstatin, 5 µg/ml aprotinin and 25 µg/ml trypsin-chymotrypsin inhibitor). The lysates
were incubated on an orbital rocker at 4°C for 40 minutes, and cleared by centrifugation at
15,000 g for 15 minutes at 4°C. The supernatants were collected and stored at -80°C. Protein
concentrations were determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA).
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Cell viability assay
Cells were seeded in 96-well plates at a density of 1.0 x 104 cells per well and allowed to
incubate for 24 hours to reduce cell stress. The cells were treated in RPMI + 1% FBS in triplicate
with each compound and concentration as indicated. After 24-hour incubation the cells were
analyzed using an MTT cell viability assay. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) was added to the cells and allowed to incubate for 2-4 hours.
During this time, viable cells reduced the MTT to purple formazan. The media was removed and
DMSO was added to solubilize the formazan. Absorbance was measured at 540 nm in a
microplate reader. Each cell line was performed independently with each compound in triplicate
on the plate. Each plate was performed three times. The cell viability of the treatment groups
were compared to the vehicle controls.
Caspase-3 activity assay
The colorimetric Caspase-3 Activity Assay was purchased from EMD Millipore
(Cambridge, MA) and run in accordance with the manufacturer’s specifications, using 100-150
µg protein aliquot in a 96-well plate in duplicate. Lysates were normalized using the Bradford
protein quantification method. The Caspase-3 Activity Assay detects the chromophore pnitroaniline (pNA). Following addition of the DEVD-pNA substrate to the cell lysate, pNA is
released following cleavage of the substrate by active Caspase-3. Optical density of pNA was
detected at 405 nm using a microplate reader. This assay was performed twice on three
independent sets of cell lysates (n=6). The procedure was repeated for all cell lines.
Cell death ELISA
The Roche Cell Death Detection sandwich ELISA was purchased from Roche. The
supplied 96-wells are precoated with anti-histone antibodies. Nucleosomes associated with
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apoptosis bind to the anti-histone antibodies if they are present in the sample. A secondary
antibody (anti-DNA-POD) with a reporter peroxidase was then added. Color change following
addition of the ABTS solubilizing solution was then analyzed by measuring absorbance at 405
nm (reference wavelength approximately 490 nm) with a microplate reader to provide a
quantitative reading. Due to the specificity of the antibodies to apoptotic-associated
nucleosomes, this assay shows apoptosis but not necrosis-related cell death. The manufacturer’s
protocol was followed using the previously described cell lysates normalized by Bradford protein
quantification method. The absorbance value of untreated control cells was set as 1 and the
absorbance of the compound treated cells were reported as a fold increase in cell death relative to
the control. The protocol was identical for all cell lines.
Calpain activity assay
SCLC cells were treated with either calpeptin or BAPTA-AM (10 µM) 45 minutes prior
to adding 20 µM arvanil in RPMI media containing 1% FBS, as described above, for 24 hours.
Cells were harvested and washed twice with PBS. Lysates were made using the provided buffer
in the Sensolyte 520 Calpain Activity Assay Kit (Anaspec, Freemon, CA, USA). Two hundred
micrograms of lysates were used and incubated with 50 µL of calpain substrate for 60 minutes at
37ºC. The assay was performed according to manufacturer’s specifications. Fluorescence was
measured in a microplate reader with an excitation wavelength of 490 nm and an emission
wavelength of 520 nm.
Statistical analysis
Data were analyzed and plotted using GraphPad Prism 5 Software, Inc (La Jolla, CA,
USA), and represented as the mean ± the standard deviation. The results were compared by one-
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way analysis of variance (ANOVA) followed by a Tukey post-hoc multiple comparison test.
Data were considered significant at p£0.05.
RESULTS
Arvanil, linvanil, and livanil reduce cell viability in SCLC cell lines
Initial experiments were conducted to evaluate the effects of four capsaicinoid
compounds on cell viability in three SCLC cell lines. Previously published studies from our
laboratory found that 10 µM capsaicin has no effect on the cell viability of SCLC cell lines; thus
10 µM capsaicin was selected as the reference concentration for comparing the potency of the
capsaicinoid compounds (Hurley et al., 2017). To evaluate and compare the cytotoxic potency of
the capsaicinoid compounds relative to capsaicin, cell viability was measured by MTT assay
following a 24-hour treatment of each cell line with 10 µM capsaicinoid (arvanil, linvanil,
livanil, olvanil; Figure 28) or 10 µM capsaicin. In H69 cells there was a significant decrease in
cell viability following treatment with 10 µM of arvanil, linvanil, and livanil but not olvanil or
capsaicin (Figure 29A). Livanil decreased cell viability by about 20%, while linvanil decreased
cell viability by about 30%. These findings were consistent in H82 (Figure 29B) and DMS 114
(Figure 29C) cells as well. Arvanil demonstrated the most potent effect on cell viability in all
three cell lines, decreasing cell viability by about 50% (Figure 29 A-C). Therefore, arvanil was
selected as the representative capsaisinoid in subsequent experiments.
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Figure 29. Effect of capsaicinoids on SCLC viability
The effect of capsaicin, olvanil, livanil, linvanil, and arvanil (10µM) on cell viability over 24
hours was compared in three SCLC cell lines by MTT assay; (A) H69, (B) H82 and (C) DMS
114. * denotes statistical difference from control. Data is represented as the mean ± SD. * p
£0.05, ** p £ 0.01, *** p £ 0.001.
Arvanil induces apoptotic cell death in SCLC cells but not normal lung cells
To elucidate the mechanism of cytotoxicity, each cell line was treated for 24 hours with a
concentration range of arvanil or capsaicin (10 nM, 100 nM, 1 µM, 2.5 µM, 5 µM, 10 µM, 20
µM) and caspase-3 activity was measured. Arvanil significantly increased caspase-3 activity at
lower concentrations than the capsaicin treated cells. Capsaicin treatment failed to induce
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caspase-3 activity at all concentrations, in all cell lines. In H69 cells, arvanil significantly
induced caspase-3 activity starting at a concentration of 2.5 µM (Figure 30A). In H82 cells,
arvanil significantly induced caspase-3 activity at a concentration of 5 µM (Figure 30B). DMS
114 cells were found to be the most susceptible to arvanil, showing induced caspase-3 activity at
1 µM (Figure 30C). This showed that arvanil is more potent than capsaicin at inducing the
apoptotic pathway in human SCLC cells.
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Figure 30. Comparison of caspase-3 activity induced by arvanil and capsaicin in SCLC cell
lines
Caspase-3 Activity Assay was used to compare the ability of arvanil and capsaicin (at identical
concentrations; 10 nM, 100 nM, 1 µM, 2.5 µM, 5 µM, 10 µM, 20 µM) to induce caspase-3
activity at 24 hours in (A) H69, (B) H82 and (C) DMS 114 cells. Data is represented as the mean
± SD. * denotes statistically different from control; p£0.05.
Next, we wanted to evaluate whether arvanil-induced cell death was selective for cancer
cells by analyzing arvanil-induced cell death in normal lung cells. In order to evaluate the effects
on normal cells, normal human pulmonary alveolar epithelial cells (HPAEpiCs) were treated for
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24 hours with either 20 µM arvanil or capsaicin. Twenty micromolar was selected due to the fact
that it was statistically significant in all three SCLC cell lines. Previous data from our laboratory
also suggests that 20 µM capsaicin is ineffective at inducing significant cell death in various lung
cancer cell lines. Neither compound caused a significant increase in caspase-3 activity in
HPAEpiC cells (Figure 31A). This was further examined using the cell death ELISA to verify
the caspase-3 activity assay. Again, treatment with 20 µM arvanil or capsaicin failed to cause a
significant increase in cell death activity in HPAEpiCs (Figure 31B). This data suggests that
arvanil may be capable of selectively killing cancer cells while leaving normal lung cells
unharmed.
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Figure 31. Effect of arvanil and capsaicin on caspase-3 activity and cell death in normal
human pulmonary alveolar epithelial cells
Caspase-3 activity and cell death were evaluated in HPAEpiC cells following 24 hour treatment
with 20 µM arvanil or capsaicin. Results of the (A) caspase-3 activity assay and (B) cell death
ELISA showed that neither arvanil nor capsaicin caused a significant increase in caspase-3
activity or cell death in HPAEpiCs. Data is represented as the mean ± SD. Statistical significance
was considered at p£0.05.
Arvanil does not induce cell death via the TRPV receptor in SCLC
Next, we wanted to evaluate the signaling pathways through which arvanil may be
initiating its anti-cancerous properties. Capsaicin is considered the prototypical TRPV agonist,
and previous research in our laboratory has shown that capsaicin-induced cell death is TRPV6
receptor-dependent in SCLC (Lau et al., 2014). To evaluate whether arvanil-induced cell death is
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also TRPV receptor-dependent, we used Ruthenium Red (RR), a potent generalized TRPV
receptor antagonist, to evaluate its ability to abrogate the effects of arvanil in SCLC. If arvanilinduced cell death is TRPV receptor-dependent, RR should be able to block the effects of
arvanil. Figure 32 shows that when SCLC were pretreated with 10 µM of RR, arvanil still
induced a significant increase in caspase-3 activity in the three SCLC cell lines.
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Figure 32. Effect of TRPV receptor inhibition on arvanil-induced caspase-3 activity in
SCLC
To evaluate the role of TRPV receptor activation in arvanil-induced apoptosis, caspase-3 activity
was measured in SCLC cell lines in response to10 µm arvanil (Arv) following pretreatment with
10 µM ruthenium red (RR). (A) In H69 cells arvanil still induced a significant increase in
caspase-3 activity in the presence of RR. Similar results were found in (B) H82 and (C) DMS
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114 cells. Data is represented as the mean ± SD. Values represented by the same letter indicate
no statistical difference from each other at p£0.05.
To validate the caspase-3 activity assay, the lysates treated with RR were then used to
perform a cell death ELISA. As seen with caspase-3 activity, pretreatment with RR was unable
to inhibit arvanil-induced cell death in all SCLC cell lines, H69, H82, and DMS 114 (Figure 33).
The inability of RR to prevent arvanil from inducing caspase-3 activity or cell death suggests
that the anti-cancer effects of arvanil are TRPV receptor independent.
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Figure 33. Effect of TRPV receptor inhibition on arvanil-induced cell death in SCLC
Fold change of cell death was evaluated when arvanil (Arv) was treated with 10 µM ruthenium
red (RR) to see if it could reverse the anti-cancer activity. (A) In H69 cells arvanil was able to
induce significant increases in cell death, as well as in (B) H82 cells and (C) DMS 114 cells.
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Data is represented as the mean ± SD. Values represented by the same letter indicate no
statistical difference from each other at p£0.05.
Arvanil does not induce cell death of SCLC via the cannabinoid 1 receptor
After finding that TRPV receptor inhibition had no effect on the anti-cancer properties of
arvanil, a literature review showed that arvanil is a cannabinoid 1 receptor (CB1) agonist (Di
Marzo et al., 2002). AM 281 is a selective CB1 antagonist. To evaluate whether arvanil-induced
cytotoxicity is dependent on CB1 interaction, cells were treated with 1 µM AM 281 45 minutes
before being treated with 20 µM arvanil. Blocking the CB1 receptor had no effect on arvanilinduced caspase-3 activity in all three SCLC cell lines (Figure 34). Similar results were found
when these treatment groups were assessed by cell death ELISA. AM 281 had no effect on
arvanil-induced cell death in SCLC cells (Figure 35). The inability of AM281 to prevent arvanil
from inducing caspase-3 activity or cell death suggests that the anti-cancer effects of arvanil are
CB1 receptor independent.
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Figure 34. Effect of cannabinoid 1 receptor inhibition on arvanil-induced caspase-3 activity
in SCLC
To evaluate the role of the cannabinoid 1 receptor (CB1) in the anticancer activity of arvanil in
SCLC, caspase-3 activity was evaluated in response to arvanil (Arv) following pretreatment with
1 µM AM-281. Following treatment with AM-281 to inhibit the CB1 receptor, arvanil was still
capable of inducing a significant increase in caspase-3 activity in all three cell lines; (A) H69,
(B) H82 and (C) DMS 114. Data is represented as the mean ± SD. Values represented by the
same letter indicate no statistical difference from each other at p£0.05.
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Figure 35. Effect of cannabinoid 1 receptor inhibition on arvanil-induced cell death in
SCLC
To evaluate the effect of CB1 receptor inhibition on arvanil-induced cell death, SCLC cells were
treated with arvanil following pretreatment with 1 µM AM-281. CB1 inhibition had no effect on
inhibiting arvanil-induced cell death in SCLC. Arvanil was able to induce significant cell death
in the presence of AM-281 in all three SCLC cell lines; (A) H69, (B) H82 and (C) DMS 114.
Data is represented as the mean ± SD. Values represented by the same letter indicate no
statistical difference from each other at p£0.05.
Arvanil induces apoptosis via intracellular calcium and the calpain pathway in SCLC
Since arvanil did not appear to induce its activity via the same receptors utilized by
capsaicin, we wanted to evaluate intracellular mechanisms that may play a role in producing the
anti-cancer properties of arvanil in SCLC. Previous studies in the laboratory have demonstrated a
relationship between capsaicin and intracellular calcium signaling, which activates the calpain
pathway and leads to apoptosis (Friedman et al., 2017; Lau et al., 2014). To determine whether
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intracellular calcium also plays a role in the apoptotic signaling of arvanil, our investigations
used the chemical calcium chelator BAPTA-AM to evaluate the effect of calcium modulation on
arvanil-induced apoptosis in SCLC. When H69, H82 and DMS 114 SCLC cells were pretreated
with 10 µM BAPTA-AM, 20 µM arvanil failed to induce caspase-3 activity, which remained at
control levels (Figure 36). The results of this experiment were further verified using the cell
death ELISA. In line with the caspase-3 activity assay, BAPTA-AM was able to ablate the
induction of cell death by arvanil in all three SCLC cell lines (Figure 37).
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Figure 36. Effect of intracellular calcium chelator on arvanil-induced caspase-3 activity in
SCLC
To evaluate the role of intracellular calcium in the apoptotic activity of arvanil in SCLC,
caspase-3 activity was evaluated following treatment of three SCLC cell lines with arvanil in the
presence of 10 µM BAPTA-AM, a potent calcium chelator. Arvanil was unable to induce
caspase-3 activity in the presence of BAPTA-AM in (A) H69, (B) H82 and (C) DMS 114 cells.
Data is represented as the mean ± SD. Values represented by the same letter indicate no
statistical difference from each other at p£0.05.
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Figure 37. Effect of intracellular calcium chelation on arvanil-induced cell death in SCLC
To evaluate the role of intracellular calcium in the anti-cancer activity of arvanil in SCLC, cell
death was evaluated following treatment of three SCLC cell lines with arvanil in the presence of
10 µM BAPTA-AM, a potent calcium chelator. Arvanil was unable to induce cell death in the
presence of BAPTA-AM in (A) H69, (B) H82 and (C) DMS 114 cells. Data is represented as the
mean ± SD. Values represented by the same letter indicate no statistical difference from each
other at p£0.05.
Given that intracellular calcium appears to be involved in the apoptotic mechanism of
action of arvanil, we wanted to evaluate whether arvanil-induced modulation of intracellular
calcium also induced the calpain pathway similar to capsaicin. To evaluate the role of the calpain
pathway, SCLC cell lines were treated with arvanil in the presence of calpeptin, a calpain
pathway inhibitor. Treatment with calpeptin significantly inhibited the activity of arvanil as
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measured by caspase-3 activity assay in H69, H82, and DMS 114 SCLC cell lines (Figure 38),
which was further verified using the cell death ELISA (Figure 39).
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Figure 38. Effect of calpeptin on arvanil-induced caspase-3 activity in SCLC
To evaluate the role of the calpain pathway in arvanil-induced caspase-3 activity in SCLC,
caspase-3 activity was evaluated following treatment of three SCLC cell lines with 20 µM
arvanil in the presence of 10 µM calpeptin (Cal), a calpain pathway inhibitor. Calpeptin
effectively abrogated the anti-cancer activity of arvanil, as arvanil was unable to induce
apoptosis in the presence of calpeptin in all three cell lines; (A) H69, (B) H82 and (C) DMS 114
cells. Data is represented as the mean ± SD. Values represented by the same letter indicate no
statistical difference from each other at p£0.05.
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Figure 39. Effect of calpeptin on arvanil-induced cell death in SCLC
To evaluate the role of the calpain pathway in the anti-cancer activity of arvanil, cell death was
evaluated in all three SCLC cell lines following treatment with 20 µM arvanil in the presence of
10 µM calpeptin (Cal), a calpain pathway inhibitor. Calpeptin effectively abrogated the anticancer activity of arvanil, as arvanil was unable to induce cell death in the presence of calpeptin
in all three cell lines; (A) H69, (B) H82 and (C) DMS 114. Data is represented as the mean ± SD.
Values represented by the same letter indicate no statistical difference from each other at p£0.05.
Arvanil causes increased calpain pathway activity in SCLC
To further verify that arvanil was inducing apoptosis in the SCLC cell lines via induction
of the calpain pathway, a calpain activity assay was performed using two of the cell lines, H69
and H82. The calpain activity assay measured the amount of active calpain proteases present in
cell lysates from cells that had been treated with arvanil, with or without pretreatment with
BAPTA-AM. In both H69 (Figure 40A) and H82 (Figure 40B), calcium chelation effectively
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prevented the induction of calpain activity in response to arvanil. This suggests that calcium
plays a role in the arvanil-induced calpain pathway activation in SCLC cells. To further verify
that activation of the calpain pathway plays a role in arvanil-induced cytotoxicity, a calpain
activity assay was performed again on cells treated with arvanil in the presence of calpeptin, a
calpain pathway inhibitor. Similar to the effects of BAPTA-AM, the presence of calpeptin
brought the arvanil-induced calpain activity to control levels in both SCLC cell lines (Figure 40C
and D).
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Figure 40. Arvanil-induced calpain activity in the presence of calcium chelator (BAPTAAM) and calpain pathway inhibitor (calpeptin)
To evaluate the role of the calpain pathway in the anti-cancer activity of arvanil, a calpain
activity assay was used following treatment of SCLC cell lines with 20 µM arvanil in the
presence or absence of 10 µM BAPTA-AM (calcium chelator) or 10 µM calpeptin (Cal; calpain
pathway inhibitor). Pretreatment with BAPTA-AM abrogated arvanil-induced calpain activity in
(A) H69 and (B) H82 SCLC cell lines. Similarly, calpeptin effectively abrogated arvanil-induced
calpain activity in (C) H69 and (D) H82 SCLC cell lines. Data is represented as the mean ± SD.
Values represented by the same letter indicate no statistical difference from each other at p£0.05.
CONCLUSIONS AND DISCUSSION
Small cell lung cancer remains a malady in which there are few therapeutic options that
significantly improve patient survival (Alvarado-Luna & Morales-Espinosa, 2016). Initial
responses to the first-line platinum-based combination treatments, such as cisplatin, plus
etoposide may cause initial hope in patients, but the inevitability of relapse is rarely avoided
(Pietanza et al., 2015; S. L. Wood et al., 2015). The studies in this chapter provide evidence that
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synthetic capsaicinoids may provide unique viable options to improve clinical response in SCLC
treatment. One of the main problems with current chemotherapy options is the large incidence of
side effects and the lack of cell selectivity, given the fact that standard chemotherapy often kills
normal cells along with the cancer cells (McGowan et al., 2017; Oun et al., 2018; Willers,
Azzoli, Santivasi, & Xia, 2013). In these studies, we found arvanil to be efficacious in its ability
to kill SCLC cells while having no apparent negative effect on normal human pulmonary
alveolar epithelial cells. This suggests that arvanil may have the unique capacity to selectively
target cancerous cells while preserving normal cells in the surrounding tissue. Previous work
from our laboratory shows that in SCLC capsaicin induces apoptosis via the TRPV6 receptor
leading to increased activity of the calpain pathway (Lau et al., 2014). Despite its structural
similarity to capsaicin, arvanil’s anti-cancerous properties appear to be independent of both the
TRPV and CB1 receptors, as shown in Figures 33-36. While it remains unclear which receptors
are responsible for eliciting arvanil’s anti-cancer properties in SCLC, the fact that arvanil does
not act via the TRPV receptor suggests that arvanil should not induce a heat sensation similar to
capsaicin, and supports other studies which indicate that arvanil is non-pungent. Lacking the heat
sensation would lead to a more tolerable side effect profile, promoting patient compliance with
therapy. One similarity capsaicin and arvanil have are the induction of the calpain pathway, with
the calcium chelator BAPTA-AM and calpain inhibitor calpeptin being able to reverse the
apoptotic activity seen in SCLC.
These studies provide evidence that arvanil induces elevated intracellular calcium levels,
which leads to calpain pathway activation in SCLC cells. Calpains are a family of calciumactivated proteases. The source of intracellular calcium that activates calpain activity is thought
to be the mitochondria, the endoplasmic reticulum, or an influx of extracellular calcium
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(Harwood, Yaqoob, & Allen, 2005; Laszlo Kovacs, 2014; M. J. Lee, Kee, Suh, Lim, & Oh,
2009; Moretti et al., 2014; Ono et al., 2016; D. E. Wood & Newcomb, 1999). It is generally
accepted that calpains play a role in cellular apoptotic signaling, as well as necrotic signaling.
Due to the fact that arvanil treatment led to increased calpain activity as well as caspase-3
activity, it is logical to postulate that the calpain activity is responsible for triggering arvanilinduced apoptosis in this model. Further studies would be necessary to determine the specific
mechanism by which the calpain pathway is activating apoptosis since calpains are involved in
so many different biological pathways. Calpains have a growing list of substrates, such as
apoptosis inducing factor (AIF), p53, Bax, Bid, PARP, and cytosolic proteins/enzymes
(Lopatniuk & Witkowski, 2011; Ozaki, Yamashita, & Ishiguro, 2009; Potz et al., 2016; D. E.
Wood et al., 1998). Future studies to evaluate the role of caspase and calpain activation in
capsaicinoid-induced cytotoxicity will need to be performed in order to understand how the two
pathways may work together or independently. These studies will further our understanding of
capsaicinoid-induced apoptosis and how they can potentially be used in conjunction with other
chemotherapeutic agents to bolster their activity, reduce side effects, and improve clinical
outcomes in SCLC.
Further studies are also needed to evaluate livanil and linvanil, which also demonstrated
favorable anti-cancer activity in SCLC. If these analogs act in a similar way, they could prove
useful in other cancer types, with survival rates comparable to SCLC. Identifying the
mechanisms of action could also lead to additional modification of the capsaicin molecule to
allow it to target specific receptors/proteins. Long term ramifications of such studies could lead
to further modifications based on capsaicin as the parent compound, to be used concurrently with
current chemotherapeutic treatments in SCLC, as well as other cancer types. The possibility of
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additional interventions for cancer that could augment or deviate from the commonly used
standard-of-care treatments leads to hope for patients who have run out of options.
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CHAPTER 6: CONCLUSIONS AND DISCUSSION
Over the past several decades, researchers have demonstrated that capsaicinoids display a
wide variety of biological and physiological activities. Many of these compounds, capsaicin in
particular, demonstrate analgesic, positive cardiovascular, anti-obesity, anti-inflammatory, and
anti-tumor effects. The studies presented in this dissertation focused heavily on the anti-tumor
effects of capsaicinoids in SCLC. Our goal was to substantiate and promote the use of
capsaicinoids as a relevant chemopreventive or adjuvant chemotherapeutic option that may lead
to the development of new and advanced treatment strategies for SCLC.
Despite a decrease in smoking rates, SCLC rates remain consistent (Bunn et al., 2016;
Cronin et al., 2018; Jamal et al., 2016). Efforts to develop effective therapeutic treatments for
SCLC have been hindered by a variety of obstacles (Alvarado-Luna & Morales-Espinosa, 2016;
Bunn et al., 2016; Pietanza et al., 2015). Of considerable challenge is the fact that the majority of
SCLC patients are frequently diagnosed in later stages of the disease, after the cancer has
metastasized to distant parts of the body. SCLC treatment is further complicated by the
frequency of patients with refractory disease (relapse less than 45 days post treatment), resistant
disease (relapse 45-90 days post treatment), or the rapid acquirement of chemoresistance to first
line treatments in patients presenting with therapy sensitive disease (relapse more than 90 days
post treatment) (Pietanza et al., 2015). Regardless of the initial classification, for those with
refractory SCLC, or those who acquire chemoresistance, second line treatments rarely work,
with the median survival in patients with relapsed disease ranging from two to six months (Foy
et al., 2017; Gazdar et al., 2017; Pietanza et al., 2015). Though some advances have been made
in NSCLC treatment with the use of targeted therapies like gefitinib or erlotinib, the primary
treatment for patients with SCLC has not changed in several decades and remains limited to
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platinum-based combination therapy in conjunction with radiotherapy (Latimer & Mott, 2015; S.
L. Wood et al., 2015). The complexity of SCLC and its classification as a recalcitrant cancer
underline the need to identify new novel treatment options that will improve patient response to
chemotherapy, reduce side effects, and offer improved overall outcomes (Zeman, Brzezniak, &
Carter, 2017).
In Chapter 2, we reviewed and discussed the potential of capsaicin to be utilized as an
adjunctive treatment option in combination with several clinically relevant and widely used
chemotherapeutics. Numerous studies demonstrated that not only is capsaicin an effective
monotherapy for potentially treating various cancer types, but it also demonstrates the capacity to
effectively improve the response to chemotherapeutic agents when used in combination (Basith
et al., 2016; Chapa-Oliver & Mejia-Teniente, 2016; Friedman et al., 2018; Srinivasan, 2016).
Our published data presented in Chapter 3 further supported such findings, successfully
demonstrating that capsaicin enhanced the anti-cancer activity of camptothecin, as evidenced by
a greater induction of apoptosis at lower concentrations than camptothecin alone in three
separate human SCLC cell lines. The presence of using a quantitative method to assess drug
synergy is also a somewhat rare feature of our study. A mathematical calculation method allows
for one to see if a drug combination is synergistic quantitatively, not just by the subjective
opinion of a researcher (Chou, 2010). Using the Chou-Talaly method to analyze the data, we
were able to demonstrate that the interaction of capsaicin and camptothecin was in fact
synergistic in the SCLC cell lines and not simply additive or antagonistic. Another point
verifying the synergistic effects was the use of 10 µM capsaicin to sensitize the SCLC cell lines
when we have shown that at that concentration, capsaicin does not cause any apoptotic activity in
these cells at 24 hours. In the CAM model, H69 xenografted tumors showed a significant
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increase in caspase-3 activity, as well as a significant decrease in tumor weight. Similar to the
previous studies in our laboratory, both the in vitro and in vivo models showed evidence of a rise
in intracellular calcium levels leading to increased calpain activity. The origin of the rise in
intracellular calcium is most likely due to an influx of calcium via the TRPV6 cation channel, as
documented in other studies (Lau et al., 2014). TRPV6 was shown to be expressed in the SCLC
cell lines utilized in our studies, and its role in the anti-cancer activity of capsaicin was
recognized by using siRNA knock down of TRPV6 to reverse the effects of capsaicin. Future
studies investigating capsaicin and camptothecin could utilize TRPV6 siRNA to evaluate its role
in the ability of capsaicin to augment the effect of camptothecin in SCLC cells. It also may be
advantageous to investigate a capsaicin/camptothecin treatment option in cancers which have
already been shown to have higher levels of TRPV6 levels, for example prostate, colon, breast,
thyroid, and ovarian carcinomas (Lehen'kyi, Raphael, & Prevarskaya, 2012).
Despite its potential to sensitize human SCLC to the antineoplastic activity of
camptothecin, capsaicin’s potent and pungent side effects are a challenge to patient compliance,
compromising its efficacy. For this reason, additional studies in our laboratory were conducted to
investigate the use of non-pungent synthetic capsaicinoids which lack the characteristic heat
sensation associated with capsaicin administration. These analogs would lack the common
gastrointestinal discomfort or burning sensation side effects which typically cause
discontinuation of treatment. In Chapter 4 we discussed in detail multiple aspects of both natural
and synthetically derived capsaicin analogs. Some of the most intriguing studies were the
derivatization of unsaturated N-acylvanillamides or UN-AVAMs. These are compounds that
maintain the main pharmacophore or “head” region of the capsaicin molecule but vary in the
length and saturation of the hydrophobic fatty acid chain (Figure 23). These compounds are non-
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pungent and lack the negative side effects of capsaicin (Appendino et al., 2005; X. F. Huang et
al., 2013; Tuoya et al., 2006). While arvanil, our UN-AVAM of interest, was originally reported
to be both a CB1 and TRPV1 agonist, several anti-cancer studies have shown that arvanil
induces growth suppression independently of both CB1 and TRPV1 (Di Marzo et al., 2002;
Sancho et al., 2003). It was therefore of great interest to investigate the potential anti-cancer
activity of these capsaicinoids in SCLC.
Through our investigation discussed in Chapter 5, we found that arvanil was in fact able
to induce apoptosis in several SCLC cell lines, similar to capsaicin. To compare the efficacy and
potency of these capsaicin analogs, we chose to compare the effects of each compound to the
effects found for capsaicin at 10 µM, a concentration at which capsaicin was unable to induce
apoptosis in SCLC cell lines. Arvanil proved to be the most effective analog, inducing apoptosis
in one SCLC cell line at as low as 1 µM (Lau et al., 2014). Importantly, we also noted that
arvanil concentrations as high as 20 µM, which induced significant apoptosis and cell death in all
SCLC cell lines, had no effect on normal human lung cells in culture. If arvanil were to be
utilized in the clinic, not only would it lack capsaicin’s adverse side effect profile, but it appears
to have the highly beneficial advantage of targeting cancerous cells while leaving normal cells
intact. This finding is important given the commonly associated off target effects of conventional
chemotherapeutics (Chabner et al., 2011; Cheung-Ong et al., 2013; Dasari & Tchounwou, 2014;
McGowan et al., 2017; Oun et al., 2018; Tannock, 1989). The addition of an adjuvant therapy
such as arvanil could lower the required dose of a toxic chemotherapy and would help reduce the
side effects associated with normal tissue damage. As described in Chapter 2, the side effect
profiles of commonly used chemotherapeutic drugs are extensive and often lead to death of
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healthy tissue along with the cancerous tissue. If arvanil has little to no cytotoxic effects on
normal cells, its addition would not contribute further off targets effects.
Unlike our previous studies with capsaicin, which indicated a role for TRPV6 in the
mechanism of action, the anti-cancer activity of arvanil proved to be independent of the TRPV
receptor family, maintaining its antineoplastic activity in the presence of a general TRPV
receptor antagonist. Studies also showed that CB1 had no role in arvanil’s antineoplastic activity.
Despite these upstream differences, the anti-cancer mechanisms of arvanil did demonstrate some
similarities to capsaicin. When treating SCLC cell lines with arvanil, the membrane permeable
calcium chelator, BAPTA-AM, was able to reverse the effects, indicating a role for increased
intracellular calcium in arvanil’s anti-cancer effects. The origin of this calcium, however, is still
unclear. The rise in intracellular calcium level caused by capsaicin in SCLC cells was found to
be dependent on TRPV6 receptor activity, indicating that capsaicin most likely induced an influx
of calcium from the extracellular space via the 7TRPV6 receptor. To evaluate if increased
intracellular calcium is caused in part by a TRPV independent influx of extracellular calcium in
arvanil treated cells, further studies would be necessary, possibly by using a membrane
impermeable calcium chelator. Also similar to capsaicin, arvanil caused an increase in calpain
pathway activity. The mechanistic role of the calpain pathway in cancer is somewhat unclear;
however, calpains are known to play an important role in cell cycle regulation and in some
instances, have been shown to promote cell progression in cancer. Despite claims of calpains
being important in the development of cancer, it is also known that calpain activity is required
for a handful of chemotherapeutic agents, such as cisplatin (Leloup & Wells, 2011). If calpain
activity were inhibited, such chemotherapeutic drugs could be rendered ineffective at promoting
cell death by the inability to cleave vital signaling proteins like caspase-3. So, despite the
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knowledge of calpains’ interaction in the development of cancer, it is also a vital signaling
pathway involved in the induction of cell death when trying to treat cancer (Mandic et al., 2002;
Moretti et al., 2014). In this dissertation, increased calpain activity was implicated in causing cell
death with capsaicin and camptothecin treatments, as well as treatments with the capsaicinoid
arvanil alone. This may suggest that in SCLC, increasing calpain activity with capsaicinoids may
offer a means of intervention.
There is still much to learn about how arvanil may function as an anticancer agent. Future
studies from this research will investigate the downstream pathways involved in arvanil’s
signaling mechanism. Calpain related substrates involve many that are required for the induction
of apoptosis, like p53, PARP, BCL-2, BAX, Bid, AIF, and caspases (Harwood et al., 2005;
Leloup & Wells, 2011; Moretti et al., 2014). Identifying which substrates are cleaved/activated
in addition to caspase-3, would potentially identify additional targetable mechanisms for
capsaicinoids in SCLC. In vivo models of SCLC are also still lacking and will contribute greatly
to elucidating the effects of arvanil in SCLC. Currently, studies are being planned to utilize a
patient derived xenograft (PDX) mouse model of SCLC. These models more effectively mimic
the tumor microenvironment than other orthotopic or syngeneic mouse models. Furthermore, the
results from such studies are critical to supporting the development of much needed human trials
and applications.
I believe that the most promising research to come from continuing these studies will
ultimately be the development of clinical combination therapies with capsaicinoids such as
arvanil and chemotherapeutic agents. The ability of arvanil to show apoptotic activity equivalent
to capsaicin but at lower concentrations suggests it too might work at sensitizing human SCLC to
chemotherapeutic agents such as camptothecin. It would also be important to combine capsaicin
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and arvanil with additional chemotherapeutics, such as irinotecan, etoposide, or cisplatin, to see
if they are able to sensitize SCLC lines to a variety of agents. Irinotecan is commonly the second
line of treatment for SCLC. If combination with capsaicin or arvanil improves patient response it
would be extremely clinically relevant to patients with refractory or recurrent disease. Future
studies evaluating the efficacy of combination treatments with capsaicin or arvanil and
chemotherapy in chemoresistant cell lines will also greatly further the field and help identify new
treatment modalities for therapy resistant patients. Using cisplatin resistant cell lines to mimic
the common occurrence of SCLC relapse, would have very relevant translational implications.
Xenografts of the resistant cell lines or PDX models from patients whose tumor was resistant to
cisplatin would mimic a human patient and provide an insight to see if combination therapies
with capsaicin or arvanil would work in a clinic. If these compounds were proven effective
against resistant tumors, it would further support the development of new therapy modalities to
treat patients with resistant disease.
Unfortunately, treatment failure, harsh side effects, and chemotherapy resistance aren’t
issues limited to SCLC patients, as patients with nearly every type of cancer suffer many of the
same fates. An adjunctive treatment, such as capsaicin or arvanil, could prove helpful in treating
a multitude of cancer types. I believe that the use of capsaicin or arvanil in conjunction with an
FDA approved chemotherapeutic agent is the most viable and advantageous application of the
knowledge obtained in these studies. Arvanil has even greater possibilities due to its non-pungent
nature. The use of combination therapy with an already FDA approved drug allows for a fast
track into clinical application, which means patients could begin to use capsaicin and arvanil in
the near future. The universal use of naturally derived products as a means of medicinal
intervention supports the use of compounds like capsaicinoids in cancer intervention, and more
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importantly, analogs of natural compounds such as arvanil, may hold even more promise than
their natural parent compounds. The potential therapeutic uses of capsaicinoids and their
synthetic analogs as single drugs or combination therapies are just starting to become realized,
and is exciting for medical doctors, researchers, and patients alike.
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APPENDIX C: ABBREVIATIONS
3-MA…3-methyladenine
4-HNE…4-Hydroxynonenal
5-FU…5-fluorouracil
6-MP…6-mercaptopurine
ABC…ATP-binding cassette
AGE…advanced glycation end product
AIF…apoptosis inducing factor
ANOVA…analysis of variance
Arv…arvanil
AUC…area under the curve
Aurora A…Aurora kinase A
BAPTA-AM…(1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis
(acetoxymethyl ester)
Bcl-2…B-cell lymphoma 2
BMH…Benzo[d][1,3]dioxol-5yl-methyl hexanonate
BUN…blood urea nitrogen
Cal…calpeptin
CAM…chicken chorioallantoic membrane
CAP-NP…capsaicin-loaded folic acid nanoparticles
CAT… catalase
CB1…cannabinoid receptor 1
CCA…Human cholangiocarcinoma
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CCK-8…Cell Counting Kit-8
CDK1…cyclin B-bound cdc2
CE…capsaicin epoxide
CI…combination index
CK-MB…creatinine kinase-muscle/brain
CPT…camptothecin
CPT…Camptothecin
CPZ…capsaicin
dCCA…distal cholangiocarcinoma
DHC…dihydrocapsaicin
EAC…Ehlrich ascitis carcinoma
ED50…50% cytotoxic activity
ED75…75% cytotoxic activity
ED90… 90% cytotoxic activity
EGFR…epidermal growth factor receptor
ERK…extracellular related kinase
EVO…Evodiamine
FBS…fetal bovine serum
Gnb-CAP-NP…gefitinib-capsaicin-folic acid-based nanoparticles
Gnb-FA-NP…gefitinib-loaded nanoparticles
GSH…glutathione
H&E…hematoxylin and eosin staining
H2-DCFDA…2’ 7’ dichlorodihydrofluorescien diacetate
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HCC…hepatocellular carcinoma
HEI-OC1…mouse ear organ corti cells
HMB1…high mobility group box 1
HO-1…heme oxygenase-1
HPAEpiC…Human pulmonary alveolar epithelial cells
HSP…heat shock proteins
i.p…intraperitoneal
iCCA…intrahepatic cholangiocarcinoma
IHC…immunohistochemistry
L/P ratio…liver/plasma ratio
LAC…lung adenocarcinoma
LCC…large cell carcinoma
MDA…malonaldehyde
MMP…matrix metalloproteinase
mTOR…mechanistic target of rapamycin
MTT…3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
N-AVAM…N-acylvanillamides
N-BMB…N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-methoxybenzamide
NF-kB…nuclear factor kappa-B
NOX…NADPH oxidase family
NSCLC…non-small cell lung cancer
P-gp…p-glycoprotein
pCCA…perihilar cholangiocarcinoma
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PCNA…proliferating cell nuclear antigen
PDGF-b…platelet-derived growth factor-b
PDX…patient derived xenograft
PhAR…phenylacetylrinvanil
PI-3K…phosphoinositol-3 kinase
pNA…p-nitroaniline
Rho123…rhodamine 123
ROPA…resiniferanol-9, 13, 14 ortho-phenylacetate
ROS…reactive oxygen species
RR…Ruthenium Red
RSK…ribosomal S6 kinase
RTX…resiniferatoxin
RUT…rutaecarpine
SCC…squamous cell carcinoma
SCLC…small cell lung cancer
SD…standard deviation
SER…sensitizer enhancement ratio
SN-38G…SN-38 Glucuronide
SOD…superoxide dismutase
SPF…Specific pathogen-free
STAT…signal transducer and activator of transcription
STR…short tandem repeat
TEM…transmission electron microscopy
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TLR…toll-like receptors
TRPV… transient receptor potential vanilloid
TUNEL…Terminal deoxynucleotidyl transferase dUTP nick end labeling
TURBT…transurethral resection of bladder tumors
UN-AVAMs…unsaturated N-acylvanillamides
VEGFR…vascular endothelial growth factor receptor
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